Systemic Lupus Erythematosus

Complex MONDO:0007915 Pathograph 32 Show in embeddings browser Autoimmune Disease

An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific

Ask OpenScientist

Ask a research question about Systemic Lupus Erythematosus. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part

👪

Inheritance

Not applicable (complex/multifactorial)

SLE is a complex multifactorial disease without a simple Mendelian inheritance pattern. Orphanet classifies inheritance as "Not applicable."

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"Not applicable"

Orphanet records inheritance as not applicable for SLE, consistent with its complex multifactorial etiology.

◆

Subtypes

Discoid Lupus Erythematosus

Primarily affects the skin.

Show evidence (3 references)

PMID:30988213 SUPPORT

"The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and..."

Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin.

PMID:7763220 SUPPORT

"Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement."

This reference confirms that Discoid Lupus Erythematosus primarily affects the skin.

PMID:28941498 SUPPORT

"Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types."

This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus.

Neonatal Lupus

Affects infants, caused by transplacental transfer of maternal autoantibodies.

Show evidence (5 references)

PMID:9287379 SUPPORT

"neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies."

This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies.

PMID:24763535 SUPPORT

"Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB)."

The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement.

PMID:15744116 SUPPORT

"Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta."

This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies.

+ 2 more references

Drug-Induced Lupus

Caused by certain medications and usually reversible.

Show evidence (4 references)

PMID:1356074 SUPPORT

"The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE."

This indicates that there is a distinct subtype of SLE induced by medications.

PMID:23164669 SUPPORT

"Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal."

This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug.

PMID:1751313 SUPPORT

"All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus..."

This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement.

+ 1 more reference

◈

Mechanistic Hypotheses

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

nucleic_acid_immune_complex_interferon_tissue_injury_model CANONICAL

Evidence balance 4 support

In genetically and environmentally susceptible SLE, excess endogenous nucleic acids from apoptotic cells and neutrophil extracellular traps form immune complexes with antinuclear autoantibodies. Fc receptor-mediated uptake by plasmacytoid dendritic cells and B cells delivers RNA and DNA to endosomal TLR7/TLR9, while mitochondrial or other cytosolic self-DNA can engage cGAS-STING signaling in myeloid cells. These sensing routes ignite type I interferon production, B-cell survival and differentiation, further autoantibody production, complement activation, and organ-local immune-complex inflammation. The model treats nephritis, skin, CNS, hematologic, and vascular injury as tissue-specific downstream contexts selected by local immune-complex deposition, complement handling, resident cell sensitivity to interferon, vascular injury, and organ-specific repair capacity rather than by systemic interferon activity alone.

Pathograph links

Formation of Immune Complexes -> Nucleic Acid Immune Complex-pDC Endosomal Loop INDIRECT KNOWN INTERMEDIATES Nucleic-acid-containing immune complexes can be routed to plasmacytoid dendritic cells, where endosomal sensing produces IFN-alpha and amplifies the systemic interferon loop. Intermediates: Fc receptor and complement-dependent immune-complex handling; plasmacytoid dendritic-cell engagement; endosomal nucleic-acid sensing

Formation of Immune Complexes -> TLR7/TLR9-Mediated Nucleic Acid Sensing INDIRECT KNOWN INTERMEDIATES Nucleic-acid immune complexes can co-engage Fc receptors and endosomal TLR7/TLR9, activating B cells, plasmacytoid dendritic cells, and kidney-resident inflammatory pathways. Intermediates: Fc receptor-mediated uptake of nucleic-acid immune complexes; delivery of RNA and DNA ligands to endosomal TLR7 and TLR9

Formation of Immune Complexes -> Complement Pathway Dysregulation DIRECT Immune complexes activate complement locally while inherited or acquired defects in early complement handling impair clearance of immune complexes and apoptotic debris.

Formation of Immune Complexes -> Glomerular Immune Complex Deposition DIRECT Some nucleic-acid immune complexes localize in kidney glomeruli, making renal tissue one major downstream context for immune-complex injury.

Formation of Immune Complexes -> Cutaneous Immune Complex Deposition DIRECT Autoantibody immune complexes can contribute to skin injury, providing a tissue-specific branch parallel to nephritis.

Formation of Immune Complexes -> Synovial Immune Complex Deposition INDIRECT KNOWN INTERMEDIATES Joint inflammation is modeled as another immune-complex deposition context, while the exact tissue determinants remain less resolved than for lupus nephritis.

Glomerular Immune Complex Deposition -> Lupus Nephritis INDIRECT KNOWN INTERMEDIATES Immune complex deposition in glomeruli triggers local inflammation and tissue damage. Intermediates: complement activation; Fc receptor and Toll-like receptor amplification; renal cytokine and chemokine recruitment of inflammatory cells

Type I Interferon Pathway Activation -> Age-Associated B Cell Expansion INDIRECT UNKNOWN INTERMEDIATES Type I interferon is modeled as a systemic amplifier of autoreactive B-cell and autoantibody circuits, while the exact perpetuation mechanisms remain an open knowledge gap.

Type I Interferon Pathway Activation -> Lupus Nephritis INDIRECT KNOWN INTERMEDIATES High type I interferon identifies a subgroup with more active disease and greater nephritis propensity. Intermediates: immune-cell activation; inflammatory mediator induction

TLR7/TLR9-Mediated Nucleic Acid Sensing -> Type I Interferon Pathway Activation DIRECT Nucleic-acid immune-complex sensing by plasmacytoid dendritic cells is modeled as a proximate ignition route for IFN-alpha/type I interferon production.

TLR7/TLR9-Mediated Nucleic Acid Sensing -> Glomerular Immune Complex Deposition INDIRECT KNOWN INTERMEDIATES In renal tissue, immune-complex Fc receptor and TLR co-signaling amplifies local inflammation after glomerular immune-complex formation.

Nucleic Acid Immune Complex-pDC Endosomal Loop -> Type I Interferon Pathway Activation DIRECT pDC engagement by nucleic-acid immune complexes produces IFN-alpha, feeding the systemic type I interferon signature.

Cytosolic cGAS-STING DNA Sensing -> Type I Interferon Pathway Activation INDIRECT KNOWN INTERMEDIATES Cytosolic self-DNA sensing can produce type I interferon and therefore acts as a non-endosomal ignition route for the interferon signature. Intermediates: oxidized mitochondrial DNA release; cGAS activation or STING-dependent DNA sensing; myeloid type I interferon production

NETosis and Neutrophil Extracellular Trap Formation -> Type I Interferon Pathway Activation INDIRECT KNOWN INTERMEDIATES NET material provides nucleic-acid antigen and can directly activate plasmacytoid dendritic cells, promoting type I interferon production. Intermediates: NET-derived DNA, histones, and neutrophil proteins; pDC activation by NET-associated cathelicidin

NETosis and Neutrophil Extracellular Trap Formation -> Cytosolic cGAS-STING DNA Sensing INDIRECT KNOWN INTERMEDIATES Oxidized mitochondrial DNA released during lupus-relevant NET biology can feed cytosolic DNA sensing and STING-dependent interferon signaling. Intermediates: mitochondrial ROS-dependent NETosis; extracellular oxidized mitochondrial DNA release; STING-dependent type I interferon signaling

NETosis and Neutrophil Extracellular Trap Formation -> Glomerular Immune Complex Deposition INDIRECT KNOWN INTERMEDIATES Impaired NET dismantling increases persistent DNA/histone/neutrophil-protein antigenic material and is associated with renal involvement.

Age-Associated B Cell Expansion -> Formation of Immune Complexes INDIRECT KNOWN INTERMEDIATES Expanded autoreactive B-cell and plasma-cell programs produce antinuclear and anti-dsDNA antibodies that feed immune-complex formation. Intermediates: autoreactive plasma-cell differentiation; anti-dsDNA and other antinuclear antibody production

Impaired Apoptotic Cell Clearance -> Formation of Immune Complexes INDIRECT KNOWN INTERMEDIATES Defective apoptotic-cell clearance increases the self-antigen substrate available for autoreactive antibody binding and immune-complex formation.

Complement Pathway Dysregulation -> Type I Interferon Pathway Activation INDIRECT KNOWN INTERMEDIATES Defective C1q-mediated immune-complex handling can redirect immune complexes toward plasmacytoid dendritic cells and IFN-alpha production.

Complement Pathway Dysregulation -> Inflammation And Tissue Damage INDIRECT KNOWN INTERMEDIATES Complement activation downstream of immune-complex deposition amplifies local inflammatory injury, particularly in lupus nephritis. Intermediates: C3/C5 activation fragments; membrane attack complex formation; renal inflammatory cell recruitment

Non-Coding RNA Dysregulation -> Age-Associated B Cell Expansion INDIRECT UNKNOWN INTERMEDIATES Non-coding RNA dysregulation is proposed to converge with EBV infection in autoreactive B cells, contributing to expansion of the autoreactive B cell compartment and loss of B cell tolerance.

Epstein-Barr Virus-Mediated Persistent Immune Activation -> Formation of Immune Complexes INDIRECT KNOWN INTERMEDIATES EBV-driven B cell activation and proliferation produces autoreactive antibodies that form immune complexes. Intermediates: EBV latency antigen (EBNA) -specific B cell activation; molecular mimicry between viral and nuclear epitopes; persistent B cell proliferation and antibody class switching

Epstein-Barr Virus-Mediated Persistent Immune Activation -> Non-Coding RNA Dysregulation INDIRECT UNKNOWN INTERMEDIATES EBV modulates host non-coding RNA pathways, linking persistent infection to the ncRNA dysregulation arm of SLE pathogenesis.

Show evidence (4 references)

PMID:36792346 SUPPORT Other

"Research elucidating the pathogenesis of systemic lupus erythematosus (SLE) has defined two critical families of mediators, type I interferon (IFN-I) and autoantibodies targeting nucleic acids and nucleic acid-binding proteins, as fundamental contributors to the disease."

This review anchors the canonical model around type I interferon and nucleic-acid-directed autoantibodies.

PMID:39343084 SUPPORT Other

"Abnormalities in B cell development and activation lead to the production of autoreactive antibodies, forming immune complexes that cause tissue damage."

The review connects B-cell dysregulation to autoreactive antibody production, immune-complex formation, and tissue damage.

PMID:22999705 SUPPORT Other

"Together, these findings provide both direct and indirect links between two key pathways implicated in lupus pathogenesis: complement and IFN."

This supports modeling complement handling and type I interferon as connected rather than independent SLE mechanisms.

+ 1 more reference

Discussions and Knowledge Gaps

Which upstream nucleic-acid trigger first ignites type I interferon in SLE, which immune-complex, pDC, B-cell, NET, cGAS-STING, and complement loops maintain it, and which tissue-local variables determine nephritis versus cutaneous, CNS, hematologic, vascular, or serosal injury?

KNOWLEDGE GAP OPEN gap_sle_interferon_trigger_persistence_tissue_specificity

Attached to

mechanistic_hypotheses#nucleic_acid_immune_complex_interferon_tissue_injury_model pathophysiology#Type I Interferon Pathway Activation pathophysiology#TLR7/TLR9-Mediated Nucleic Acid Sensing pathophysiology#Nucleic Acid Immune Complex-pDC Endosomal Loop pathophysiology#Cytosolic cGAS-STING DNA Sensing pathophysiology#NETosis and Neutrophil Extracellular Trap Formation pathophysiology#Complement Pathway Dysregulation pathophysiology#Glomerular Immune Complex Deposition phenotypes#Lupus Nephritis

The entry now models a canonical loop in which nucleic-acid immune complexes, NET-derived self-antigens, plasmacytoid dendritic-cell TLR signaling, B-cell autoantibody production, and complement handling converge on sustained type I interferon and immune-complex inflammation. The unresolved curation problem is not whether this loop exists, but how to assign patient- and organ-specific causal priority: high IFN can precede disease and associate with nephritis, pDC endosomal sensing and cytosolic cGAS-STING sensing can both produce interferon, but immune-complex deposition alone is insufficient for proliferative renal disease, and the same systemic autoantibody/IFN background can present as skin, CNS, hematologic, vascular, serosal, or kidney-predominant SLE.

Proposed experiments

Longitudinal flare and paired-tissue interferon-loop cohort

longitudinal multimodal cohort study

exp_sle_longitudinal_flare_paired_tissue_ifn_loop

Enroll autoantibody-positive at-risk individuals and established SLE patients before, during, and after flares, with oversampling of nephritis, cutaneous, CNS, hematologic, and serosal presentations. Combine serial serum immune-complex/NET/complement measurements, pDC and B-cell single-cell profiles, IFN-stimulated gene scores, autoantibody repertoires, and paired renal, skin, blood, urine, and CSF readouts where clinically available. The design should test whether the first measurable IFN rise follows a specific nucleic-acid source, whether B-cell and complement states maintain the loop after onset, and whether tissue-local programs explain organ selection.

Assays

peripheral blood single-cell RNA sequencing interferon-stimulated gene expression profiling autoantibody repertoire profiling serum complement biomarker profiling neutrophil extracellular trap quantification cGAS-STING pathway activation profiling paired kidney and skin biopsy transcriptomics

Readouts

Interferon ignition temporal precedence

pathophysiology#Type I Interferon Pathway Activation

Time-resolved IFN-stimulated gene scores, serum IFN-alpha/protein markers, pDC activation state, and preceding infection, UV, NET, apoptotic debris, or immune-complex measurements.

Direction: POSITIVE

Interpretation: IFN elevation after a specific nucleic-acid or immune-complex signal would support that trigger as upstream; IFN elevation before measurable immune-complex/NET changes would require a separate initiating mechanism.

Autoreactive B-cell and immune-complex persistence

pathophysiology#Formation of Immune Complexes

Longitudinal autoreactive B-cell clones, plasma-cell signatures, autoantibody titers, immune-complex burden, and complement consumption modeled relative to IFN activity and flare resolution.

Direction: POSITIVE

Interpretation: Persistent B-cell/immune-complex activity after IFN normalization would support a self-maintaining adaptive loop; collapse after IFNAR blockade or IFN-score decline would support IFN-dependent maintenance.

Organ-specific injury selection

phenotypes#Lupus Nephritis

Tissue and biofluid readouts comparing nephritis with skin, CNS, hematologic, vascular, and serosal-predominant disease for local complement activation, Fc receptor/TLR signaling, endothelial injury, resident-cell IFN response, chemokine recruitment, and repair/fibrosis programs.

Direction: POSITIVE

Interpretation: Organ-restricted signatures that predict nephritis independently of systemic IFN and autoantibody burden would support separate downstream tissue-injury modules.

Controls

Autoantibody-positive non-SLE controls

Individuals with antinuclear or anti-Ro/La antibodies but no classified SLE.

IFN-low SLE controls

Established SLE patients without a high interferon-stimulated gene signature.

Decision criterion

Revise the pathophysiology graph according to which signal reproducibly precedes IFN onset, which loop persists after clinical flare resolution, and which tissue-local readouts predict nephritis or other organ injury after controlling for systemic IFN score and autoantibody burden.

Show evidence (3 references)

PMID:33246136 SUPPORT Other

"the specific triggers of type I IFN production, the mechanisms by which IFNs help perpetuate the cycle of autoreactive cells and autoantibody production are not completely clear."

This directly supports the trigger and persistence portion of the SLE interferon knowledge gap.

PMID:22192660 SUPPORT Other

"Deposition of ICs, however, is not sufficient for disease expression"

This supports keeping organ-specific downstream injury as an open modeling problem rather than a simple immune-complex-deposition edge.

PMID:35872103 SUPPORT Other

"the underlying mechanisms of autoantibody-induced tissue damage and systemic inflammation are still not fully understood."

This supports the broader unresolved mechanism of autoantibody-linked systemic and tissue damage.

Is canonical cuproptosis - copper-dependent, FDX1-lipoylation-driven regulated cell death - an actual causal mechanism in lupus lesions and lupus immune cells, or is the reported copper signal only a correlative transcriptomic and metabolic-stress marker that should stay out of the SLE pathograph until the canonical criteria are demonstrated in vivo?

KNOWLEDGE GAP OPEN gap_sle_cuproptosis_evidence_hierarchy

Attached to

pathophysiology#Epigenetic Dysregulation and T Cell Metabolic Reprogramming pathophysiology#Impaired Apoptotic Cell Clearance

SLE is one of the two systemic autoimmune diseases named in the cuproptosis-in-autoimmunity literature, and copper dysregulation, mitochondrial stress, and immunometabolic remodeling are all reported in lupus. This entry deliberately does NOT model cuproptosis as a mechanism node, because the published SLE evidence is transcriptomic association and public-dataset mining rather than demonstration of the canonical criteria (copper dependence, FDX1-lipoylation involvement, lipoylated-protein aggregation, Fe-S cluster destabilization, and functional rescue). The gap matters for two existing nodes: T cell metabolic reprogramming already carries an immunometabolic claim that a copper-dependent mitochondrial mechanism would either extend or compete with, and impaired apoptotic-cell clearance is the entry's autoantigen-supply node, which a distinct copper-dependent regulated-cell-death route would add to rather than replace. The entry's other regulated-cell-death node, NETosis and neutrophil extracellular trap formation, is the closest structural analog for a cuproptosis claim but is deliberately NOT attached: the source's immune-cell analysis covers macrophages, dendritic cells and T cells and does not extend to neutrophils, so attaching the gap there would assert a cell-type scope the evidence does not carry. Recording this as an open gap keeps the mechanism visible to curators without asserting a cell-death pathway the source itself declines to confirm.

Proposed experiments

Canonical-cuproptosis criteria applied to lupus nephritis biopsies and matched immune cells

mechanism validation study with biochemical and in vivo arms

exp_sle_canonical_cuproptosis_criteria_in_lesional_tissue

Apply the five canonical cuproptosis criteria directly to disease-relevant human lupus material rather than to transcriptomic surrogates: measure tissue and intracellular copper in lupus nephritis biopsies and matched peripheral immune subsets, assay FDX1 protein and lipoylated DLAT/DLST aggregation in situ, quantify Fe-S cluster protein destabilization, and test copper-chelation and copper-ionophore rescue in a lupus-prone mouse model with the same biochemical panel read out in kidney. Stratify by interferon score and disease activity so that any copper signal can be separated from a generic inflammatory or metabolic-stress correlate.

Assays

tissue and intracellular copper quantification FDX1 immunoblot and in situ protein detection lipoylated protein aggregation assay Fe-S cluster protein stability assay copper chelator and ionophore rescue in lupus-prone mice

Readouts

Copper dependence of lesional cell death

pathophysiology#Impaired Apoptotic Cell Clearance

Copper content in lesional kidney and immune subsets paired with cell-death burden, and the change in that burden under chelation.

Direction: INCREASED

Interpretation: A copper burden that tracks lesional cell death and falls with chelation would satisfy the copper-dependence criterion; an unchanged death burden would place the copper signal downstream or incidental.

FDX1-lipoylation axis engagement in situ

pathophysiology#Epigenetic Dysregulation and T Cell Metabolic Reprogramming

FDX1 protein level, lipoylated DLAT/DLST aggregate formation, and Fe-S cluster protein destabilization measured in the same lesional and immune-cell material.

Direction: ALTERED

Interpretation: Concordant FDX1-dependent lipoylated-protein aggregation with Fe-S destabilization would support canonical cuproptosis; transcript-level change without protein aggregation would confirm the correlative reading and close the gap negatively.

Controls

Non-lupus inflammatory nephropathy controls

Biopsy-proven inflammatory kidney disease without SLE, to test whether any copper signal is lupus-specific or a generic inflammation correlate.

Interferon-high SLE without nephritis

Systemically active SLE lacking renal involvement, separating tissue-local copper biology from systemic disease activity.

Decision criterion

Add a cuproptosis pathophysiology node to this entry only if copper dependence, FDX1-lipoylation axis involvement, lipoylated-protein aggregation, Fe-S cluster destabilization, and functional rescue are all demonstrated in lupus-relevant tissue; otherwise record the copper signal as a susceptibility or metabolic-stress marker and leave the graph unchanged.

Would support

pathophysiology#Impaired Apoptotic Cell Clearance pathophysiology#Epigenetic Dysregulation and T Cell Metabolic Reprogramming

Posed 2026-08-11T00:00:00Z

Filed from monarch-initiative/dismech#6381. The parallel gap is recorded on Rheumatoid_Arthritis and Ankylosing_Spondylitis, the other dismech entries named in the source review.

Show evidence (4 references)

PMID:42435071 SUPPORT Other

"direct in vivo evidence of canonical cuproptosis in autoimmune lesions remains scarce, and most relevant studies rely on transcriptomic associations, public dataset mining, or model-dependent experiments"

States the evidence-hierarchy gap directly - the reason this entry records cuproptosis as an open question rather than as a pathophysiology node.

PMID:42435071 SUPPORT Other

"systemic AIDs (e.g., systemic lupus erythematosus, rheumatoid arthritis) and organ-specific AIDs (e.g., inflammatory bowel disease, ankylosing spondylitis) were summarized. Findings mostly reflected copper-associated metabolic stress or susceptibility markers rather than definitive functional activation."

Names systemic lupus erythematosus specifically, and characterizes what the lupus-relevant findings actually show - metabolic stress or susceptibility markers, not demonstrated functional activation.

PMID:42435071 SUPPORT Other

"immunometabolic regulatory roles of cuproptosis in immune cells-including macrophages, dendritic cells, and T cells-were analyzed, highlighting that their effects are cell-type and context dependent"

Supports attaching the gap to the T cell metabolic reprogramming node while warning that any resolution will be cell-type specific rather than a single disease-level edge.

+ 1 more reference

⚙

Pathophysiology

Formation of Immune Complexes

Antinuclear, anti-dsDNA, anti-Sm, and related autoantibodies bind nucleic acids, nucleosomes, and nucleic-acid-binding proteins to form immune complexes that can deposit in tissues or induce cytokine production.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

B cell CL:0000236 plasma cell CL:0000786 macrophage CL:0000235

Immunoglobulin production GO:0002377 Complement activation, classical pathway GO:0006958 B cell mediated immunity GO:0019724

Downstream

Nucleic Acid Immune Complex-pDC Endosomal Loop Nucleic-acid-containing immune complexes can be routed to plasmacytoid dendritic cells, where endosomal sensing produces IFN-alpha and amplifies the systemic interferon loop.

TLR7/TLR9-Mediated Nucleic Acid Sensing Nucleic-acid immune complexes can co-engage Fc receptors and endosomal TLR7/TLR9, activating B cells, plasmacytoid dendritic cells, and kidney-resident inflammatory pathways.

Complement Pathway Dysregulation Immune complexes activate complement locally while inherited or acquired defects in early complement handling impair clearance of immune complexes and apoptotic debris.

Glomerular Immune Complex Deposition Some nucleic-acid immune complexes localize in kidney glomeruli, making renal tissue one major downstream context for immune-complex injury.

Cutaneous Immune Complex Deposition Autoantibody immune complexes can contribute to skin injury, providing a tissue-specific branch parallel to nephritis.

Synovial Immune Complex Deposition Joint inflammation is modeled as another immune-complex deposition context, while the exact tissue determinants remain less resolved than for lupus nephritis.

Show evidence (6 references)

PMID:32884126 SUPPORT Other

"antinuclear antibodies (ANAs) that form immune complexes"

This directly supports immune-complex formation by antinuclear antibodies in SLE.

PMID:35872103 SUPPORT Other

"participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS)."

This supports the link between SLE autoantibodies, immune-complex formation, and multi-organ inflammatory injury.

PMID:27709413 SUPPORT

"Here, we review what is known on the altered metabolic patterns of CD4(+) T cells, B cells, and myeloid cells in lupus patients and lupus-prone mice and how they contribute to lupus pathogenesis."

The reference discusses the altered metabolic patterns of B cells, CD4(+) T cells, and myeloid cells (which include macrophages) and their contribution to lupus, which indirectly supports the involvement of these cell types in lupus mechanisms, but it does not specifically address immune complex formation directly.

+ 3 more references

Glomerular Immune Complex Deposition

Circulating immune complexes containing anti-dsDNA and anti-Sm antibodies lodge in kidney glomeruli, activating complement and recruiting inflammatory cells.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

complement activation GO:0006956

Kidney UBERON:0002113

Downstream

Lupus Nephritis Immune complex deposition in glomeruli triggers local inflammation and tissue damage.

Show evidence (3 references)

PMID:22192660 SUPPORT Other

"Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney."

This directly supports kidney immune-complex deposition in SLE.

PMID:33841392 SUPPORT

"Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges. Deposition of immune complexes in kidneys glomeruli are associated with lupus nephritis, determining SLE diagnosis."

The literature supports the deposition of immune complexes in kidney glomeruli but does not cover skeletal joints, skin, heart, or lung in this context.

PMID:30009962 SUPPORT

"LN is characterized by glomerular kidney injury, essentially due to deposition of immune complexes involving autoantibodies against cellular components and circulating proteins."

This confirms immune complex deposition in kidneys.

Cutaneous Immune Complex Deposition

Immune complexes deposit at the dermal-epidermal junction and in vessel walls of the skin, leading to cutaneous manifestations of lupus.

inflammatory response GO:0006954

Skin UBERON:0002097

Show evidence (2 references)

PMID:35872103 SUPPORT

"The autoantibodies, especially anti-dsDNA and anti-Sm autoantibodies are highly specific to SLE, and participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS)."

This paper directly establishes that autoantibodies form immune complexes which cause inflammatory damage to multiple organs in SLE.

PMID:16572034 SUPPORT

"Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune..."

The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.

Synovial Immune Complex Deposition

Immune complexes accumulate in synovial fluid and tissue of joints, activating complement and triggering inflammatory arthritis.

complement activation GO:0006956

Skeletal Joint UBERON:0000982

Show evidence (1 reference)

PMID:16572034 SUPPORT

Confirms deposition of aberrant immune complexes into tissues including the joints, supporting synovial immune-complex deposition as the mechanism of lupus arthritis.

Inflammation And Tissue Damage

Show evidence (5 references)

PMID:22192660 SUPPORT

"Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage."

The article describes inflammation and immune complex deposition as mechanisms leading to tissue damage in SLE.

PMID:36555640 SUPPORT

"The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues."

The literature explains that inflammation and tissue damage are core mechanisms in the pathology of SLE due to immune system disturbances.

PMID:28623084 SUPPORT

"Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. A complex interaction of genetics, environment, and hormones leads to immune dysregulation and breakdown of tolerance to self-antigens, resulting in autoantibody production, inflammation, and..."

This article outlines inflammation as part of the immune dysregulation in SLE, leading to tissue damage in multiple organs.

+ 2 more references

Chronic Inflammation

Show evidence (5 references)

PMID:16572034 SUPPORT

"Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues..."

The abstract confirms that inflammation is a key aspect of systemic lupus erythematosus pathogenesis.

PMID:26330673 SUPPORT

"Systemic lupus erythematosus, the prototype systemic autoimmune disease, is characterized by extensive self-reactivity, inflammation, and organ system damage."

The abstract clearly mentions inflammation as a characteristic feature of SLE.

PMID:32237942 SUPPORT

"Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is potentially life-threatening and can affect any organ."

The literature describes SLE as a chronic autoimmune disease affecting various organs, implying sustained inflammation over time.

+ 2 more references

Flare-Ups

The symptoms of lupus can worsen suddenly in episodes known as flares, which can be triggered by factors like stress, sunlight, and infections.

Show evidence (3 references)

PMID:26951252 SUPPORT

"These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms."

This reference mentions the potential triggers for lupus flares, which include UV light (sunlight) and infections.

PMID:26494589 SUPPORT

"Some triggers for these exacerbations have been identified, including infections, vaccines, pregnancy, environmental factors such as weather, stress and drugs."

This reference specifically states that stress and infections can trigger lupus flares.

PMID:22385883 SUPPORT

"Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus."

This reference confirms that sunlight exposure can trigger lupus flares.

Type I Interferon Pathway Activation

Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

plasmacytoid dendritic cell CL:0000784 B cell CL:0000236 T cell CL:0000084

IRF5 hgnc:6120

type I interferon signaling pathway GO:0060337

Downstream

Age-Associated B Cell Expansion Type I interferon is modeled as a systemic amplifier of autoreactive B-cell and autoantibody circuits, while the exact perpetuation mechanisms remain an open knowledge gap.

Lupus Nephritis High type I interferon identifies a subgroup with more active disease and greater nephritis propensity.

Show evidence (2 references)

PMID:33246136 SUPPORT Other

"Type I interferon (IFN) is a primary pathogenic factor in systemic lupus erythematosus (SLE)."

This review directly supports the central pathogenic role of type I interferon in SLE.

PMID:24834763 SUPPORT

"An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE."

This review describes the type I interferon gene signature in SLE, supporting chronic activation of the type I interferon pathway.

TLR7/TLR9-Mediated Nucleic Acid Sensing

B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

B cell CL:0000236 plasmacytoid dendritic cell CL:0000784

TLR7 hgnc:15631 TLR9 hgnc:15633 MYD88 hgnc:7562 CYBB hgnc:2578 UNC93B1 hgnc:13481

toll-like receptor signaling pathway GO:0002224 toll-like receptor 7 signaling pathway GO:0034154 toll-like receptor 9 signaling pathway GO:0034162

Downstream

Type I Interferon Pathway Activation Nucleic-acid immune-complex sensing by plasmacytoid dendritic cells is modeled as a proximate ignition route for IFN-alpha/type I interferon production.

Glomerular Immune Complex Deposition In renal tissue, immune-complex Fc receptor and TLR co-signaling amplifies local inflammation after glomerular immune-complex formation.

Show evidence (1 reference)

PMID:22192660 SUPPORT Other

"This type of two-step activation is known to activate B cells by ICs containing either TLR9 or TLR7 activators such as dsDNA or single-stranded RNA"

This supports the TLR7/TLR9 nucleic-acid sensing node in immune-complex-driven SLE mechanisms.

Nucleic Acid Immune Complex-pDC Endosomal Loop

Nucleic-acid-containing immune complexes are routed to plasmacytoid dendritic cells and endosomal nucleic-acid sensors, generating IFN-alpha and reinforcing the autoantibody, immune-complex, and interferon circuit. Complement handling, especially C1q-dependent clearance, modulates whether immune complexes are cleared or preferentially engage pDCs.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

plasmacytoid dendritic cell CL:0000784

immune-complex endosomal nucleic-acid sensing GO:0002224 type I interferon production GO:0032606

Downstream

Type I Interferon Pathway Activation pDC engagement by nucleic-acid immune complexes produces IFN-alpha, feeding the systemic type I interferon signature.

Show evidence (1 reference)

PMID:22999705 SUPPORT Other

"in the absence of C1q, instead of ICs binding to monocytes, they preferentially engage plasmacytoid dendritic cells (pDC) so generating interferon (IFN) alpha"

This supports immune-complex routing to pDCs as part of the interferon loop.

Cytosolic cGAS-STING DNA Sensing

Cytosolic DNA sensing provides a parallel route to type I interferon activation outside the endosomal TLR7/TLR9 loop. In SLE, interferogenic mitochondrial DNA from NET biology and mitochondria-retaining erythroid cells can engage STING- or cGAS-dependent pathways in myeloid cells.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

macrophage CL:0000235 neutrophil CL:0000775

cGAS-STING-mediated type I interferon production GO:0032606

Downstream

Type I Interferon Pathway Activation Cytosolic self-DNA sensing can produce type I interferon and therefore acts as a non-endosomal ignition route for the interferon signature.

Show evidence (2 references)

PMID:26779811 SUPPORT Model Organism

"Extracellular release of oxidized mitochondrial DNA is proinflammatory in vitro, and when this DNA is injected into mice, it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING."

This supports oxidized mitochondrial DNA as a STING-dependent type I interferon trigger in lupus-relevant experimental systems.

PMID:34384544 SUPPORT Human Clinical

"SLE patients carrying both Mito+ RBCs and opsonizing antibodies display the highest levels of blood IFN-stimulated gene (ISG) signatures, a distinctive feature of SLE."

This supports a human SLE association between mitochondria-containing erythroid material, antibodies, and high interferon signatures.

NETosis and Neutrophil Extracellular Trap Formation

Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

neutrophil CL:0000775

DNASE1 hgnc:2956

neutrophil degranulation GO:0043312 neutrophil extracellular trap formation GO:0140645

Downstream

Type I Interferon Pathway Activation NET material provides nucleic-acid antigen and can directly activate plasmacytoid dendritic cells, promoting type I interferon production.

Cytosolic cGAS-STING DNA Sensing Oxidized mitochondrial DNA released during lupus-relevant NET biology can feed cytosolic DNA sensing and STING-dependent interferon signaling.

Glomerular Immune Complex Deposition Impaired NET dismantling increases persistent DNA/histone/neutrophil-protein antigenic material and is associated with renal involvement.

Show evidence (1 reference)

PMID:20439745 SUPPORT Human Clinical

"Neutrophils respond to infections and release extracellular traps (NETs), which are antimicrobial and are made of DNA, histones, and neutrophil proteins."

This supports the NET composition and infection-responsive release described in the node.

Age-Associated B Cell Expansion

Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

B cell CL:0000236

TNFSF13B hgnc:11929

B cell activation GO:0042113 B cell differentiation GO:0030183

Downstream

Formation of Immune Complexes Expanded autoreactive B-cell and plasma-cell programs produce antinuclear and anti-dsDNA antibodies that feed immune-complex formation.

T Follicular Helper Cell Dysregulation

T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.

T follicular helper cell CL:0002038 T cell CL:0000084

IL21 hgnc:6005

T cell activation GO:0042110 germinal center formation GO:0002467

Impaired Apoptotic Cell Clearance

Defective clearance of apoptotic cells and impaired efferocytosis lead to increased exposure to nuclear antigens, propagating immune complex formation and autoantibody production.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

apoptotic cell clearance GO:0043277 efferocytosis GO:0043277

Downstream

Formation of Immune Complexes Defective apoptotic-cell clearance increases the self-antigen substrate available for autoreactive antibody binding and immune-complex formation.

Complement Pathway Dysregulation

Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

complement activation, classical pathway GO:0006958

Kidney UBERON:0002113 Glomerulus UBERON:0000074

Downstream

Type I Interferon Pathway Activation Defective C1q-mediated immune-complex handling can redirect immune complexes toward plasmacytoid dendritic cells and IFN-alpha production.

Inflammation And Tissue Damage Complement activation downstream of immune-complex deposition amplifies local inflammatory injury, particularly in lupus nephritis.

Show evidence (2 references)

PMID:22999705 SUPPORT Other

"promoting the clearance of immune complexes (ICs) and apoptotic cells."

This supports the clearance arm of complement dysregulation in the SLE mechanism.

PMID:22192660 SUPPORT Other

"Deposition of complement proteins in glomeruli is a key feature of lupus nephritis."

This supports complement involvement at the renal tissue-injury site.

Epigenetic Dysregulation and T Cell Metabolic Reprogramming

Aberrant DNA methylation, histone modifications, and metabolic reprogramming in T cells contribute to lupus pathogenesis. Hypomethylation of immune gene loci activates autoreactive T cells, while metabolic shifts including altered mTOR signaling and glutaminolysis support inflammatory T cell programs.

CD4-positive helper T cell CL:0000492

Epigenetic Regulation of Gene Expression GO:0040029 T Cell Differentiation GO:0030217

Downstream

Autoantibody Production Dysregulated T cell programs promote autoreactive B cell help and autoantibody production

Non-Coding RNA Dysregulation

Non-coding RNAs (microRNAs, long non-coding RNAs, and circular RNAs) regulate immune responses, epigenetic modifications, and cytokine signaling in SLE. Their dysregulation is associated with altered autoimmune activation, impaired tolerance, disease activity, and specific clinical phenotypes.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

miRNA-mediated gene silencing GO:0035195 epigenetic regulation of gene expression GO:0040029

Downstream

Age-Associated B Cell Expansion Non-coding RNA dysregulation is proposed to converge with EBV infection in autoreactive B cells, contributing to expansion of the autoreactive B cell compartment and loss of B cell tolerance.

Show evidence (1 reference)

PMID:42439858 SUPPORT Other

"Increasing evidence suggests that non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, are involved in the fine regulation of immune responses, epigenetic changes, and cytokine signaling in SLE."

Narrative review asserting ncRNA involvement in SLE immune regulation. The hedged framing ("Increasing evidence suggests") supports the existence of the mechanism rather than a settled causal role, so this is recorded as partial support.

Epstein-Barr Virus-Mediated Persistent Immune Activation

Persistent EBV infection contributes to SLE pathogenesis through multiple mechanisms: sustained immune activation by viral antigens, molecular mimicry of host autoantigens, and modulation of host ncRNA pathways. EBV can drive autoreactive B cell activation and maintain chronic autoimmune responses through EBV-encoded latency-associated antigens.

Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model

memory B cell CL:0000787 B cell CL:0000236 T cell CL:0000084

B cell mediated immunity GO:0019724 EBV latency in the memory B cell reservoir GO:0019042

Downstream

Formation of Immune Complexes EBV-driven B cell activation and proliferation produces autoreactive antibodies that form immune complexes.

Non-Coding RNA Dysregulation EBV modulates host non-coding RNA pathways, linking persistent infection to the ncRNA dysregulation arm of SLE pathogenesis.

Show evidence (2 references)

PMID:42439858 SUPPORT Other

"Epstein-Barr virus (EBV), a long-suspected contributor to SLE, may further shape disease through persistent immune activation, molecular mimicry, and modulation of host ncRNA pathways. In this review, we examine how EBV and ncRNA dysregulation may converge in autoreactive B cells and other..."

Narrative review framing EBV as a persistent contributor to SLE through immune activation, molecular mimicry, and ncRNA modulation. The claims are hedged throughout ("long-suspected", "may"), so this is recorded as partial support.

PMID:38146370 SUPPORT Human Clinical

"The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated."

Primary human case-control study supporting persistent/reactivated EBV infection as a real feature of SLE, while explicitly noting that the mechanism of EBV influence is still unresolved.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

Referential integrity issues (1):

Target 'Autoantibody Production' (from 'Epigenetic Dysregulation and T Cell Metabolic Reprogramming') not found in named elements

●

Phenotypes

Blood 3

Leukopenia FREQUENT Decreased total leukocyte count HP:0001882

Low white blood cell count

Show evidence (5 references)

ORPHA:536 SUPPORT Other

"HP:0001882 | Leukopenia | Frequent (79-30%)"

Orphanet phenotype table classifies leukopenia (decreased total leukocyte count) as frequent in SLE.

PMID:26170228 SUPPORT

"The prevalence of leukopenia is reported in 22-41.8% of cases."

The study reports that leukopenia is prevalent in 22-41.8% of SLE cases, indicating that leukopenia is a frequent hematologic abnormality in SLE patients.

PMID:27590999 SUPPORT

"TCP was the most prevalent hematological abnormality evident in 15%, more than leucopenia (14%) and anemia (2%)."

Although thrombocytopenia was the most prevalent, leukopenia was still present in 14% of the cases, supporting the statement that leukopenia is a frequent hematologic abnormality in SLE patients.

+ 2 more references

Thrombocytopenia OCCASIONAL HP:0001873

Low platelet count

Show evidence (5 references)

ORPHA:536 SUPPORT Other

"HP:0001873 | Thrombocytopenia | Occasional (29-5%)"

Orphanet phenotype table classifies thrombocytopenia as occasional in SLE.

PMID:14530779 SUPPORT Human Clinical

"134 (13.4%) thrombocytopenia"

Euro-Lupus cohort found thrombocytopenia in 13.4% of 1,000 SLE patients over 10 years.

PMID:32896257 SUPPORT

"Thrombocytopenia was classified as mild (100-149x109/L), moderate (31-99x109/L) or severe (</=30x109/L platelets)."

The study shows that thrombocytopenia is a common occurrence in SLE patients, with a significant portion experiencing various degrees of thrombocytopenia.

+ 2 more references

Hemolytic Anemia OCCASIONAL HP:0001878

Destruction of red blood cells

Show evidence (5 references)

ORPHA:536 SUPPORT Other

"HP:0001878 | Hemolytic anemia | Occasional (29-5%)"

Orphanet phenotype table classifies hemolytic anemia as occasional in SLE.

PMID:12481500 SUPPORT

"Anaemia is the most common hematological abnormality in SLE, it is multifactorial. The most common form of anaemia is that of chronic disease, and it is relate with inflammatory cytokines. Other tips of anaemia are: iron deficiency anaemia, autoimmune haemolytic anaemia, pure red cell aplasia."

The abstract lists autoimmune hemolytic anemia among the anemias occurring in SLE, supporting the disease-phenotype association; it does not quantify its frequency.

PMID:36469203 SUPPORT

"Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that would potentiate many pathological complications, including hemolytic anemia."

This reference confirms that hemolytic anemia is one of the complications of SLE.

+ 2 more references

Cardiovascular 4

Pericarditis OCCASIONAL HP:0001701

Inflammation of the pericardium (lining around the heart)

Show evidence (3 references)

PMID:16218467 SUPPORT

"Pericarditis is the most common cardiac abnormality in systemic lupus erythematosus (SLE) patients..."

Confirms pericarditis as the most common cardiac abnormality in SLE, supporting it as a recognized cardiac manifestation (the "most common cardiac" ranking is compatible with an overall occasional per-patient frequency).

PMID:31507126 SUPPORT

"Several diseases are frequently associated with such manifestations. They include systemic lupus erythematosus..."

Lists systemic lupus erythematosus among diseases frequently associated with pericarditis, supporting the SLE-pericarditis association.

PMID:33216192 SUPPORT

"Pericarditis can be present in the context of systemic inflammatory rheumatic diseases..."

The literature suggests that pericarditis can commonly be present in systemic inflammatory rheumatic diseases, including SLE.

Raynaud Phenomenon FREQUENT HP:0030880

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0030880 | Raynaud phenomenon | Frequent (79-30%)"

Orphanet phenotype table classifies Raynaud phenomenon as frequent in SLE.

PMID:14530779 SUPPORT Human Clinical

"163 (16.3%) Raynaud phenomenon"

Euro-Lupus cohort found Raynaud phenomenon in 16.3%, below the Frequent (30-79%) band; supports association but not the frequency classification.

Hypertension FREQUENT HP:0000822

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0000822 | Hypertension | Frequent (79-30%)"

Orphanet phenotype table classifies hypertension as frequent in SLE.

PMID:14530779 SUPPORT Human Clinical

"169 (16.9%) hypertension"

Euro-Lupus cohort found hypertension in 16.9%, below the Frequent (30-79%) band; supports association but not the frequency classification.

Lymphadenopathy OCCASIONAL HP:0002716

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0002716 | Lymphadenopathy | Occasional (29-5%)"

Orphanet phenotype table classifies lymphadenopathy as occasional in SLE.

Digestive 1

Anorexia VERY_FREQUENT HP:0002039

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0002039 | Anorexia | Very frequent (99-80%)"

Orphanet phenotype table classifies anorexia (decreased appetite) as very frequent in SLE.

Eye 1

Retinopathy VERY_RARE HP:0000488

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0000488 | Retinopathy | Very rare (<4-1%)"

Orphanet phenotype table classifies retinopathy as very rare in SLE.

Genitourinary 4

Lupus Nephritis FREQUENT HP:0033726

Inflammation of the kidneys, can lead to renal failure

Show evidence (6 references)

ORPHA:536 SUPPORT Other

"HP:0033726 | Lupus nephritis | Frequent (79-30%)"

Orphanet phenotype table classifies lupus nephritis as frequent in SLE.

PMID:14530779 SUPPORT Human Clinical

"279 (27.9%) active nephropathy"

Euro-Lupus cohort found active nephropathy in 27.9% of 1,000 SLE patients over 10 years.

PMID:16530602 SUPPORT

"Lupus nephritis is one of the more serious manifestations of the systemic autoimmune disease, systemic lupus erythematosus, and is associated with considerable morbidity and even mortality."

The reference confirms that lupus nephritis is a serious and frequent manifestation of systemic lupus erythematosus (SLE).

+ 3 more references

Proteinuria VERY_FREQUENT HP:0000093

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0000093 | Proteinuria | Very frequent (99-80%)"

Orphanet phenotype table classifies proteinuria as very frequent in SLE.

Hematuria FREQUENT HP:0000790

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0000790 | Hematuria | Frequent (79-30%)"

Orphanet phenotype table classifies hematuria as frequent in SLE.

Pyuria FREQUENT HP:0012085

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0012085 | Pyuria | Frequent (79-30%)"

Orphanet phenotype table classifies pyuria as frequent in SLE.

Head and Neck 2

Oral Ulcers OCCASIONAL HP:0000155

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0000155 | Oral ulcer | Occasional (29-5%)"

Orphanet phenotype table classifies oral ulcers as occasional in SLE.

PMID:23846232 SUPPORT Human Clinical

"oral ulcers (51%)"

Malaysian cohort reports oral ulcers in 51%, which exceeds the Occasional (5-29%) band; supports association but not the frequency classification.

Cheilitis OCCASIONAL HP:0100825

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0100825 | Cheilitis | Occasional (29-5%)"

Orphanet phenotype table classifies cheilitis as occasional in SLE.

Immune 3

Malar Rash FREQUENT HP:0025300

Show evidence (3 references)

ORPHA:536 SUPPORT Other

"HP:0025300 | Malar rash | Frequent (79-30%)"

Orphanet phenotype table classifies malar rash as frequent in SLE.

PMID:14530779 SUPPORT Human Clinical

"311 (31.1%) patients had malar rash"

Euro-Lupus cohort of 1,000 patients found malar rash in 31.1% over 10 years.

PMID:23846232 SUPPORT Human Clinical

"The most common clinical manifestations were malar rash (61.3%)..."

Malaysian multi-ethnic cohort reports malar rash in 61.3% of SLE patients.

Discoid Lupus Rash OCCASIONAL HP:0007417

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0007417 | Discoid lupus rash | Occasional (29-5%)"

Orphanet phenotype table classifies discoid lupus rash as occasional in SLE.

PMID:30488801 SUPPORT Human Clinical

"discoid lupus 17.63%"

Oman cohort reports discoid lupus at initial presentation in 17.63% of SLE patients.

Serositis OCCASIONAL HP:0045073

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0045073 | Serositis | Occasional (29-5%)"

Orphanet phenotype table classifies serositis as occasional in SLE.

PMID:14530779 SUPPORT Human Clinical

"160 (16.0%) serositis (pleuritis and/or pericarditis)"

Euro-Lupus cohort found serositis in 16.0% of patients over 10-year follow-up.

Integument 2

Photosensitivity OCCASIONAL Cutaneous photosensitivity HP:0000992

Show evidence (3 references)

ORPHA:536 SUPPORT Other

"HP:0000992 | Cutaneous photosensitivity | Occasional (29-5%)"

Orphanet phenotype table classifies cutaneous photosensitivity as occasional in SLE.

PMID:15379880 SUPPORT Human Clinical

"Photosensitivity is one the most common manifestations of lupus erythematosus."

Photosensitivity is recognized as a common manifestation in lupus erythematosus.

PMID:30488801 SUPPORT Human Clinical

"photosensitivity 35.10%"

Oman cohort reports photosensitivity at initial presentation in 35.1%, which exceeds the Occasional (5-29%) band; supports association but not the frequency classification.

Alopecia FREQUENT HP:0001596

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0001596 | Alopecia | Frequent (79-30%)"

Orphanet phenotype table classifies alopecia as frequent in SLE.

PMID:30488801 SUPPORT Human Clinical

"hair loss 39.29%"

Oman cohort reports hair loss at initial presentation in 39.29% of SLE patients.

Metabolism 1

Fever VERY_FREQUENT HP:0001945

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0001945 | Fever | Very frequent (99-80%)"

Orphanet phenotype table classifies fever as very frequent in SLE.

PMID:14530779 SUPPORT Human Clinical

"166 (16.6%) fever"

Euro-Lupus cohort found fever in 16.6% over 10-year follow-up, well below the Very Frequent (80-99%) band; supports association but not the frequency classification.

Musculoskeletal 1

Arthritis FREQUENT HP:0001369

Show evidence (6 references)

ORPHA:536 SUPPORT Other

"HP:0001369 | Arthritis | Frequent (79-30%)"

Orphanet phenotype table classifies arthritis as frequent in SLE.

PMID:14530779 SUPPORT Human Clinical

"481 (48.1%) patients presented 1 or more episodes of arthritis at any time during the 10 years"

Euro-Lupus cohort found arthritis in 48.1% of 1,000 SLE patients over 10 years.

PMID:19591780 SUPPORT Human Clinical

"Arthritis in systemic lupus erythematosus (SLE) is one of the most common disease manifestations. Nearly all joints can be affected by SLE, but hand and knee involvement are the most typical."

This reference explicitly states that arthritis is one of the most common disease manifestations in patients with SLE.

+ 3 more references

Nervous System 4

Seizures OCCASIONAL HP:0001250

Show evidence (3 references)

ORPHA:536 SUPPORT Other

"HP:0001250 | Seizure | Occasional (29-5%)"

Orphanet phenotype table classifies seizures as occasional in SLE.

PMID:33626435 SUPPORT

"The prevalence of explicit episodes of seizures among SLE patients, varies from 2 to 8%."

The prevalence range of 2 to 8% suggests that seizures are not very common but occur at a noticeable rate, which could be interpreted as occasional.

PMID:12136236 SUPPORT

"Seizures and psychosis are neuropsychiatric (NP) manifestations of a large number of systemic lupus erythematosus (SLE) patients."

This reference supports the idea that seizures are a recognized neuropsychiatric manifestation of SLE, implying they occur with some regularity.

Psychosis OCCASIONAL HP:0000709

Show evidence (2 references)

PMID:30375754 SUPPORT

"Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has a significant negative impact on health status."

The study indicates that psychosis is an infrequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), which suggests it is not common but does occur occasionally. This partially supports the statement that psychosis is an 'occasional' manifestation.

PMID:37771217 SUPPORT

"Psychosis is a rare NPSLE manifestation that can occur at any phase of the illness; 21% of SLE-related psychosis cases occur at the onset of SLE."

This case report describes psychosis as a rare manifestation of NPSLE, occurring in 21% of cases at the onset of SLE. While 'rare' and 'occasional' are not identical, they both imply infrequency, partially supporting the statement.

Depression OCCASIONAL HP:0000716

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0000716 | Depression | Occasional (29-5%)"

Orphanet phenotype table classifies depression as occasional in SLE.

Chorea VERY_RARE HP:0002072

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0002072 | Chorea | Very rare (<4-1%)"

Orphanet phenotype table classifies chorea as very rare in SLE.

Respiratory 1

Pleuritis OCCASIONAL HP:0002102

Inflammation of the pleura (lining around the lungs)

Show evidence (3 references)

PMID:8153398 SUPPORT

"The pleuropulmonary manifestation of systemic lupus erythematous (SLE) are pleuritis, acute lupus pneumonitis, chronic interstitial lung disease with fibrosis, alveolar hemorrhage, respiratory muscle and diaphragmatic dysfunction, atelectasis, bronchiolitis obliterans, pulmonary vascular disease..."

The article explicitly lists pleuritis as one of the pleuropulmonary manifestations of SLE.

PMID:25318967 SUPPORT

"We investigated the clinical characteristics of pleural effusion in systemic lupus erythematosus (SLE). A prospective analysis of 17 SLE patients with pleural effusion (seven lupus pleuritis, eight transudative effusions and two parapneumonic effusions) was performed."

The prospective analysis found lupus pleuritis in SLE patients, supporting the statement.

PMID:12055395 SUPPORT

"Fortunately, pleuritis in systemic lupus erythematosus is not usually as life threatening as may be the renal or central nervous system complications. Nevertheless, pleuritis does occur in systemic lupus erythematosus and may be a significant cause of morbidity."

The article confirms that pleuritis occurs in SLE patients.

Constitutional 2

Fatigue VERY_FREQUENT HP:0012378

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0012378 | Fatigue | Very frequent (99-80%)"

Orphanet phenotype table classifies fatigue as very frequent in SLE.

PMID:30488801 SUPPORT Human Clinical

"Constitutional symptoms were found in 48.68 of SLE population including fatigue in 35.22%"

Oman cohort reports fatigue at initial presentation in 35.22%, below the Very Frequent (80-99%) band; supports association but not the frequency classification.

Malaise VERY_FREQUENT HP:0033834

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"HP:0033834 | Malaise | Very frequent (99-80%)"

Orphanet phenotype table classifies malaise as very frequent in SLE.

Growth 1

Weight Loss VERY_FREQUENT HP:0001824

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"HP:0001824 | Weight loss | Very frequent (99-80%)"

Orphanet phenotype table classifies weight loss as very frequent in SLE.

PMID:30488801 SUPPORT Human Clinical

"weight changes in 13.43%"

Oman cohort reports weight changes at 13.43%, well below the Very Frequent (80-99%) band, and the term is imprecise (weight changes vs weight loss); supports association but not the frequency classification.

Other 1

Kidney Involvement

Show evidence (3 references)

PMID:36251502 SUPPORT

"Among 365 patients with SLE, 36% had LN."

The study indicates that a significant portion of patients with Systemic Lupus Erythematosus (SLE) exhibit kidney involvement in the form of lupus nephritis (LN).

PMID:330103 SUPPORT

"The pathologic abnormalities present in patients with SLE have been classified as follows: minimal lupus nephritis, mild (focal) proliferative lupus nephritis, severe (diffuse) proliferative lupus nephritis, and membranous lupus nephritis."

The classification of pathologic abnormalities in SLE patients includes various forms of lupus nephritis, which confirms kidney involvement.

PMID:30454753 SUPPORT

"Patients with early onset SLE tend to have a greater genetic component to their disease cause, more multisystemic involvement, and a more severe disease course, which includes greater risks for developing nephritis and end-stage kidney disease."

This study highlights that childhood-onset SLE has a high risk of developing nephritis, underlining kidney involvement as a significant phenotype.

🧬

Genetic Associations

HLA-DR2

Show evidence (1 reference)

PMID:37801591 SUPPORT

"HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis)"

The study indicates that HLA-DR2 is associated with an increased susceptibility to SLE in the Taiwanese population.

HLA-DR3

Show evidence (2 references)

PMID:17910142 SUPPORT

"A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01)."

The study finds a significant association between HLA-DR3 and the presence of anti-Ro/La antibodies in SLE patients, though it does not establish that HLA-DR3 alone is a genetic risk factor for SLE.

PMID:6103441 NO_EVIDENCE

"It was also noted that the distribution of DR antigens in the hydralazine-SLE patients was significantly different from that in the group with idiopathic SLE."

This study highlights differences in HLA-DR distribution between drug-induced SLE and idiopathic SLE, but it does not specifically address the genetic contribution of HLA-DR3 to idiopathic SLE.

PTPN22 (Associated)

Gene: PTPN22 hgnc:9652

Show evidence (1 reference)

PMID:31232672 SUPPORT

"We found that the PTPN22 polymorphisms rs1310182 A allele (p = 0.01, OR = 1.92 95% CI = 1.16-3.18), and rs1310182 AA genotype with (p < 0.001) and rs12760457 TT (p = 0.046) were associated with PSLE."

The study indicates that certain polymorphisms in the PTPN22 gene are associated with pediatric systemic lupus erythematosus (PSLE), supporting the genetic association between PTPN22 and SLE.

STAT4 (Associated)

Gene: STAT4 hgnc:11365

Show evidence (3 references)

PMID:23912645 SUPPORT

"Our results showed a significant association between rs7574865 T allele (odds ratio (OR) = 1.50, 95 % CI = 1.18-1.92, P = 0.002) and susceptibility to SLE."

The study found a significant association between the STAT4 gene (specifically rs7574865) and susceptibility to SLE.

PMID:31082500 SUPPORT

"Analysis of existing transcriptomes and GWAS data identified eight up-regulated candidate genes with more than four relationships among the different pathways associated with SNPs to pinpoint the relevant loci linked to SLE... STAT4..."

This study identified STAT4 as one of the candidate genes associated with SLE through transcriptomic data analysis and pathway analysis of GWAS data.

PMID:34525002 NO_EVIDENCE

"The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. METHODS: Patients were selected from a cohort of individuals with SLE followed at 2 rheumatology reference centers in..."

The study aimed to evaluate the association between STAT4 polymorphisms and the presence of Jaccoud Arthropathy in individuals with SLE, implying an association between STAT4 and SLE.

IRF5 (Associated)

Gene: IRF5 hgnc:6120

Show evidence (5 references)

PMID:20962850 SUPPORT

"Our results replicate previously reported associations to alleles of interferon regulatory factor 5 (IRF5)... This study confirms the existence of multiple genetic risk factors for SLE..."

The study clearly identifies IRF5 as one of the genetic risk factors associated with SLE.

PMID:26233721 SUPPORT

"This meta-analysis demonstrated the IRF5 rs2070197 polymorphism conferred susceptibility to SLE in all subjects... The IRF5 rs2070197 polymorphism was identified as risk factors for SLE..."

The meta-analysis confirms the association of IRF5 polymorphism with SLE in multiple populations.

PMID:23251221 SUPPORT

"Interferon regulatory factor 5 (IRF5) is a transcription factor which... genetic variants of IRF5 have been strongly linked to SLE pathogenesis."

The paper discusses the role of IRF5 in SLE pathogenesis and confirms its genetic association with the disease.

+ 2 more references

TLR7 (Associated)

Gene: TLR7 hgnc:15631

TLR9 (Associated)

Gene: TLR9 hgnc:15633

MYD88 (Associated)

Gene: MYD88 hgnc:7562

CYBB (Associated)

Gene: CYBB hgnc:2578

TNFSF13B (Associated)

Gene: TNFSF13B hgnc:11929

IL21 (Associated)

Gene: IL21 hgnc:6005

BACH2 (GWAS)

Gene: BACH2 hgnc:14078

TNFAIP3 (GWAS)

Gene: TNFAIP3 hgnc:11896

STAT3 (GWAS)

Gene: STAT3 hgnc:11364

IL10 (GWAS)

Gene: IL10 hgnc:5962

EGR2 (GWAS)

Gene: EGR2 hgnc:3239

ETS1 (GWAS)

Gene: ETS1 hgnc:3488

IRF4 (GWAS)

Gene: IRF4 hgnc:6119

IRF8 (GWAS)

Gene: IRF8 hgnc:5358

IKZF1 (GWAS)

Gene: IKZF1 hgnc:13176

SMAD3 (GWAS)

Gene: SMAD3 hgnc:6769

REL (GWAS)

Gene: REL hgnc:9954

PRDM1 (GWAS)

Gene: PRDM1 hgnc:9346

DNASE1 (Pathogenic Variants)

Gene: DNASE1 hgnc:2956

Show evidence (1 reference)

CGGV:assertion_b71d9246-5a7e-4e81-8fc6-925181d124cd-2024-06-14T190000.000Z SUPPORT Other

ClinGen classifies the DNASE1-systemic lupus erythematosus gene-disease relationship as limited with autosomal dominant inheritance.

PRKCD (Pathogenic Variants)

Gene: PRKCD hgnc:9399

Show evidence (1 reference)

CGGV:assertion_842fc2a6-9c37-47f1-8c38-bacb3880d31a-2024-10-11T190000.000Z SUPPORT Other

ClinGen classifies the PRKCD-systemic lupus erythematosus gene-disease relationship as definitive with autosomal recessive inheritance.

UNC93B1 (Pathogenic Variants)

Gene: UNC93B1 hgnc:13481

Show evidence (1 reference)

CGGV:assertion_5cd5e1c8-5047-4ea1-9045-cb5bf978613b-2025-04-09T190000.000Z SUPPORT Other

ClinGen classifies the UNC93B1-systemic lupus erythematosus gene-disease relationship as moderate with semidominant inheritance.

💊

Medical Actions

Type I Interferon Receptor Antagonist

Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: anifrolumab NCIT:C166658

Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.

Show evidence (1 reference)

PMID:28130918 SUPPORT

"Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE"

This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures.

B Cell Depletion Therapy

Action: Pharmacotherapy NCIT:C15986

Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.

BAFF Pathway Inhibition

Action: Pharmacotherapy NCIT:C15986

Agent: belimumab NCIT:C91385

Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.

Show evidence (1 reference)

PMID:22127708 SUPPORT

"Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE"

This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo.

Immunosuppressive Therapy

Action: immunosuppressive therapy Ontology label: Immunosuppressive Therapy NCIT:C15261

Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.

Show evidence (2 references)

PMID:37827694 SUPPORT Other

"Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation."

The 2023 EULAR recommendations advise prompt use of immunosuppressive drugs (methotrexate, azathioprine, mycophenolate) and biologics to control disease and enable glucocorticoid tapering.

PMID:37827694 SUPPORT Other

"For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered."

The 2023 EULAR recommendations name glucocorticoids plus mycophenolate or low-dose cyclophosphamide as anchor drugs for active lupus nephritis, with belimumab or a calcineurin inhibitor as add-on therapy.

Supportive Care

Action: Supportive Care NCIT:C15747

Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.

🌍

Environmental Factors

UV Exposure

Exacerbates disease activity.

Show evidence (2 references)

PMID:24763542 SUPPORT

"While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE."

The literature clearly states that UV radiation exposure may exacerbate pre-existing lupus, which supports the statement.

PMID:22385883 SUPPORT

"Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus."

The study investigates the seasonal variation in lupus flares and correlates increased flares with increased temperature and sunshine, supporting the statement that UV exposure exacerbates disease activity.

Mechanism Target:

EXACERBATES Flare-Ups — The source is unusually explicit that these are two different claims: ultraviolet light worsens established disease, while whether it causes disease in the first place is unresolved. EXACERBATES records the supported half and declines the unsupported one.

Show evidence (1 reference)

PMID:24763542 SUPPORT Human Clinical

"While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE."

States that ultraviolet exposure may exacerbate pre-existing lupus while noting it remains unclear whether it is a risk factor for developing the disease, which is exactly the distinction this effect value encodes.

Infection

Can trigger or worsen disease symptoms.

Show evidence (3 references)

PMID:36332998 SUPPORT

"This review focuses on SLE risk potentially associated with environmental factors including infections."

The paper identifies infections as one of the environmental factors potentially associated with the risk of SLE, thereby supporting the statement that infections can trigger or worsen disease symptoms in SLE.

PMID:25022358 SUPPORT

"New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described."

This review mentions infections, specifically Epstein-Barr virus, as triggers for autoimmunity, which supports the notion that infections can influence SLE disease activity.

PMID:38146370 SUPPORT

This study supports the connection between infections (specifically EBV) and SLE, further establishing that infections can trigger or worsen SLE symptoms.

Mechanism Target:

EXACERBATES Flare-Ups — Graded alongside the stress link and below the existing ultraviolet one for the same reason: no cited sentence follows infection to a node. The onset arm of this exposure is deliberately not drawn separately, even though the entry models nucleic-acid sensing and interferon activation that a viral trigger would plausibly enter, because the one item that addresses the question says the mechanism remains to be elucidated. That item is carried here rather than left out, so the open question travels with the claim.

Show evidence (3 references)

PMID:25022358 SUPPORT Other

"New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described."

Reports that new mechanisms for autoimmunity triggered by Epstein-Barr virus and commensal microbiota have been described. It records that mechanisms exist without stating one.

PMID:38146370 SUPPORT Human Clinical

States that the relationship has been suggested for decades but the underlying mechanism remains to be elucidated. Carried because it is the reason the intermediates here are recorded as unknown.

PMID:36332998 SUPPORT Other

"This review focuses on SLE risk potentially associated with environmental factors including infections."

A review of environmental risk that names infections among the factors it covers. Category-level, and the weakest of the three.

Stress

Psychological stress can trigger flares.

Show evidence (3 references)

PMID:25216337 SUPPORT

"It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individuals"

This reference discusses various environmental factors that can trigger SLE flares, which supports the notion that stress, as an environmental factor, can do so as well.

PMID:36537191 SUPPORT

"In a racially diverse sample of individuals with SLE, those who experienced an increase in stress had significantly worse disease activity and greater symptom burden at follow-up compared to those with stress levels that remained stable or declined."

This reference directly supports the statement that psychological stress can trigger and worsen SLE flares.

PMID:36535611 SUPPORT

"Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disorder characterized by unpredictable disease flares.... suggesting that stress-related disorders alter the susceptibility to SLE."

This reference indicates a link between stress-related disorders and the development or worsening of SLE.

Mechanism Target:

EXACERBATES Flare-Ups — Points at the same flare node as this entry's existing ultraviolet link and is graded just below it: ultraviolet exposure is recorded with known intermediates because this entry models the apoptotic and nucleic-acid-sensing route it acts through, whereas nothing here follows psychological stress to any node. The evidence is nonetheless the strongest of the three items, because one is a longitudinal cohort measuring the outcome this node holds rather than asserting that environmental factors matter in general.

Show evidence (3 references)

PMID:36537191 SUPPORT Human Clinical

Cohort finding that patients whose stress increased had significantly worse disease activity and symptom burden at follow-up than those whose stress was stable or fell. Disease activity is this node.

PMID:25216337 SUPPORT Other

"It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individuals"

States that onset and flares are triggered by various environmental factors in susceptible individuals. It supports the category and does not name this exposure.

PMID:36535611 SUPPORT Other

Suggests that stress-related disorders alter susceptibility. Susceptibility to the disease rather than the flare this node holds.

🔬

Biochemical Markers

Anti-Nuclear Antibodies (ANA) (Positive)

Show evidence (4 references)

PMID:32884126 SUPPORT

"Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction."

While ANAs are indeed characteristic of SLE, the specific frequency (98%) mentioned in the statement is not detailed in the provided literature.

PMID:34996081 SUPPORT

"The 2019 classification criteria for systemic lupus erythematosus (SLE) includes an initial criterion requiring the presence of an antinuclear antibody (ANA), positive at a titer of at least 1:80 on HEp-2 cells, or equivalent."

The criteria confirm the importance of ANA for SLE diagnosis, but do not explicitly confirm a 98% frequency rate.

PMID:23456415 SUPPORT

"Antinuclear antibody was present in 79.6%."

This report lists a frequency different from 98%, but supports the general relevance of ANA in SLE.

+ 1 more reference

Anti-dsDNA Antibodies (Positive)

Show evidence (4 references)

PMID:29224677 SUPPORT

"Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens."

This supports the presence of anti-dsDNA antibodies in patients with SLE.

PMID:20414746 SUPPORT

"Lupus nephritis (LN) remains the most common severe manifestation of systemic lupus erythematosus (SLE) characterized by the presence of autoantibodies (Abs) that are believed to play a central role in the pathogenesis of LN."

This confirms the involvement of autoantibodies, including anti-dsDNA, in SLE and specifically lupus nephritis.

PMID:35049409 SUPPORT

"Anti-double-stranded DNA (anti-dsDNA) autoantibodies are archetypal biomarkers found in systemic lupus erythematosus (SLE)."

This directly supports the presence and diagnostic role of anti-dsDNA antibodies in SLE.

+ 1 more reference

Anti-Smith Antibodies (Positive)

Show evidence (1 reference)

PMID:29503043 SUPPORT

"One unique SLE target is the Smith antigen (Sm), a nuclear ribonucleoprotein complex. Sm response occurs in 25% of patients with SLE."

The Smith antigen is a specific target in SLE, and the presence of anti-Smith antibodies (Sm) is marked, indicating high specificity.

Anti-Histone Antibodies (Positive)

Show evidence (2 references)

PMID:35383534 SUPPORT

"Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE)."

The literature specifically mentions the presence of anti-histone antibodies in systemic lupus erythematosus and drug-induced lupus erythematosus.

PMID:35383534 SUPPORT

"AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs."

While anti-histone antibodies are present in drug-induced lupus, their prevalence is reducing with the use of modern biological agents.

📈

Progression

Age of onset

Age: Adolescent to adult, with childhood and infant onset also described

SLE most commonly presents in women of childbearing age (15-45 years). Orphanet records onset across infancy, childhood, adolescent, and adult stages. Incidence peaks in middle adulthood.

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"Age of onset: Adolescent"

Orphanet records adolescent as one of the onset ages for SLE.

PMID:28968809 SUPPORT Human Clinical

"Incidence peaked in middle adulthood and occurred later for men"

Systematic review confirms SLE incidence peaks in middle adulthood.

📊

Prevalence

Worldwide

Point Prevalence 10.0–50.0 per 100,000 1–9 per 10,000

Global prevalence estimated at 43.7 per 100,000 persons (3.41 million people). Women are disproportionately affected with prevalence of 78.73 per 100,000 vs 9.26 per 100,000 in men. Prevalence varies by region and ethnicity.

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"1-5 / 10 000 | Worldwide | Point prevalence | PMID:36241363"

Orphanet epidemiology table reports worldwide point prevalence of 1-5 per 10,000.

PMID:36241363 SUPPORT Human Clinical

"the global SLE prevalence and affected population were estimated to be 43.7 (15.87 to 108.92) per 100 000 persons and 3.41 million people, respectively"

Comprehensive global epidemiological modeling estimates SLE prevalence at approximately 43.7 per 100,000 persons worldwide.

Worldwide annual incidence

Annual Incidence 1.0–9.0 per 100,000 1–9 per 100,000 per year

Global incidence estimated at 5.14 per 100,000 person-years. In women, 8.82 per 100,000 person-years; in men, 1.53 per 100,000.

Show evidence (2 references)

ORPHA:536 SUPPORT Other

"1-9 / 100 000 | Worldwide | Annual incidence | PMID:36241363"

Orphanet epidemiology table reports worldwide annual incidence of 1-9 per 100,000.

PMID:36241363 SUPPORT Human Clinical

"The global SLE incidence and newly diagnosed population were estimated to be 5.14 (1.4 to 15.13) per 100 000 person-years and 0.40 million people annually, respectively"

Global SLE incidence modeling estimates 5.14 per 100,000 person-years.

Europe

Point Prevalence 10.0–50.0 per 100,000 1–9 per 10,000

Show evidence (1 reference)

ORPHA:536 SUPPORT Other

"1-5 / 10 000 | Europe | Point prevalence | ORPHANET"

Orphanet reports European point prevalence of 1-5 per 10,000.

North America

Point Prevalence 241.0 per 100,000 >1 in 1,000

Highest regional point-prevalence estimate.

Show evidence (1 reference)

PMID:28968809 SUPPORT Human Clinical

"The highest estimates of incidence and prevalence of SLE were in North America [23.2/100 000 person-years (95% CI: 23.4, 24.0) and 241/100 000 people (95% CI: 130, 352), respectively]"

Systematic review identifies North America as having the highest regional SLE point prevalence (241/100,000).

North America

Annual Incidence 23.2 per 100,000 1–9 per 10,000 per year

Highest regional annual-incidence estimate.

Show evidence (1 reference)

PMID:28968809 SUPPORT Human Clinical

"The highest estimates of incidence and prevalence of SLE were in North America [23.2/100 000 person-years (95% CI: 23.4, 24.0) and 241/100 000 people (95% CI: 130, 352), respectively]"

Systematic review identifies North America as having the highest regional SLE incidence (23.2/100,000 person-years).

📊

Related Datasets

STK25 m6A modification regulates CD4+ T cell glycolysis mediated immune imbalance in systemic lupus erythematosus geo:GSE334206

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with an incompletely understood pathogenesis. N6-methyladenosine (m6A) has been implicated in immune regulation and disease progression, yet its role in disrupting immune homeostasis in SLE, particularly in CD4+ T-cell differentiation, remains poorly understood. In the present study, m6A-modified RNA immunoprecipitation sequencing (m6A-seq) and RNA sequencing (RNA-seq) of peripheral blood mononuclear cells from patients with SLE identified serine/threonine protein kinase 25 (STK25) as a candidate gene exhibiting abnormal m6A modification, and its expression was subsequently validated using reverse transcription-quantitative (...

human n=20

Identified by GEO DataSets index search for Systemic Lupus Erythematosus (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Profiling and Functional Analysis of Urinary Exosomal MicroRNAs in Pregnant Women with Systemic Lupus Erythematosus geo:GSE298542

Background: Pregnancy in Systemic Lupus Erythematosus (pSLE) is high-risk, necessitating non-invasive biomarkers for monitoring and predicting complications. Urinary exosomes, containing miRNAs, offer a promising source reflecting systemic and renal states, yet their profile in late gestation pSLE is less studied. Objective: This study aimed to investigate the profile of urinary exosomal miRNAs in pregnant women with SLE during late gestation compared to healthy pregnant controls and to explore their potential biological roles and pathways. Methods: Urinary exosomes were isolated from 6 pSLE patients and 5 controls. Exosomes were characterized, and miRNAs were sequenced.

human BULK RNA SEQ n=11

Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing ega:EGAS00001000962

We performed a high-resolution analysis of the biological characteristics of plasma DNA in systemic lupus erythematosus (SLE) patients using massively parallel genomic and methylomic sequencing. A number of plasma DNA abnormalities were found. First, aberrations in measured genomic representations (MGRs) were identified in the plasma DNA of SLE patients. The extent of the aberrations in MGRs correlated with anti-double–stranded DNA (anti-dsDNA) antibody level. Second, the plasma DNA of active SLE patients exhibited skewed molecular size-distribution profiles with a significantly increased proportion of short DNA fragments.

human

PMID:25427797

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Systemic Lupus Erythematosus"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Combined genetic and transcriptome analysis of patients with Systemic Lupus Erythematosus (SLE) ega:EGAS00001003662

A comprehensive profiling of the genomic architecture of Systemic Lupus Erythematosus (SLE) by combining genetic and transscriptomic analysis by RNA-seq.

human

Single-cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus ega:EGAS00001006798

Rituximab, a CD20+ B cell depletion therapy, is frequently used in the treatment of systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation. In this study, we conducted longitudinal single-cell profiling of nine SLE patients treated with rituximab from pretreatment to up to 15 months post-treatment. These were compared to eight healthy controls. We profiled PBMCs via 10X Genomics single-cell RNA, surface protein (CITE-seq), B cell receptor (BCR), and T cell receptor (TCR) sequencing and sequenced bulk BCR repertoires in parallel.

human

Systemic Lupus Erythematosus Subtypes in a Multi-Ethnic Cohort dbgap:phs001850

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple organ systems and varies in severity across different populations. To examine the clinical heterogeneity of SLE, we sought to identify different lupus subtypes within our multi-ethnic cohort using a clustering approach. Additionally, with genome-wide methylation and genotype data generated for our cohort, we applied integrative methods to investigate genetic and epigenetic risk factors. This integrative and computational approach revealed molecular differences associated with phenotypic clusters.

Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Systemic Lupus Erythematosus"). Retrieved 2026-08-02.

🐁

Animal Models

MRL/lpr

genetically prone to develop lupus-like symptoms and APS

Species

Mouse

Genotype

MRL/lpr strain

Alleles

FAS lpr

Genes

FAS hgnc:11920

Show evidence (4 references)

PMID:25183233 SUPPORT

"Mouse models of autoimmunity, such as (NZB×NZW)F1, MRL/MpJ-Fas(lpr) (MRL-lpr) and BXSB mice, spontaneously develop systemic lupus erythematosus (SLE)-like syndromes with heterogeneity and complexity that characterize human SLE"

This excerpt supports the statement by confirming that MRL/MpJ-Fas(lpr) (MRL-lpr) mice develop SLE-like syndromes.

PMID:38113962 SUPPORT

"Sle1 and Faslpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus"

The snippet confirms that Fas(lpr) is a lupus susceptibility locus leading to SLE manifestations.

PMID:28078597 SUPPORT

"This is characterized by the development of arthritis and immune complex glomerulonephrosis making this strain a useful model for studying systemic lupus erythematosus."

This excerpt supports the statement by describing the MRL-lpr strain as a useful model for studying SLE, noting the development of relevant symptoms.

+ 1 more reference

NZB/W F1

Species

Mouse

Background

(NZB/BlNJ x NZW/LacJ)F1/J

Show evidence (2 references)

PMID:36211391 SUPPORT

"The (NZW×BXSB) F1 lupus-prone male mouse model of this disease is potentially useful to study mechanism and treatment modalities, but there is a lack of information about this model's characterization and disease progression"

The reference discusses the (NZWxBXSB) F1 model rather than the (NZB/BlNJ x NZW/LacJ) F1/J model.

PMID:31943822 SUPPORT

"METHODS: Lupus-prone (NZB × NZW)F1 mice that had been DNA-vaccinated with plasmids encoding Hsp70 and controls were monitored for lupus disease parameters including anti-double stranded DNA (anti-dsDNA) autoantibodies and cytokines using enzyme-linked immunosorbent assay, and for kidney function..."

This reference supports the use of (NZB x NZW)F1 mice as a model for SLE.

{ }

Source YAML

click to show

name: Systemic Lupus Erythematosus
creation_date: '2025-12-04T16:57:31Z'
description: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific
category: Complex
parents:
- Autoimmune Disease
has_subtypes:
- name: Discoid Lupus Erythematosus
  description: Primarily affects the skin.
  evidence:
  - reference: PMID:30988213
    reference_title: "[Systemic Lupus Erythematosus]."
    supports: SUPPORT
    snippet: The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and acute LE eruptions mainly appear in SLE.
    explanation: Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin.
  - reference: PMID:7763220
    reference_title: "Discoid lupus erythematosus."
    supports: SUPPORT
    snippet: Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement.
    explanation: This reference confirms that Discoid Lupus Erythematosus primarily affects the skin.
  - reference: PMID:28941498
    reference_title: "Not Just Skin Deep: Systemic Disease Involvement in Patients With Cutaneous Lupus."
    supports: SUPPORT
    snippet: Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types.
    explanation: This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus.
- name: Neonatal Lupus
  description: Affects infants, caused by transplacental transfer of maternal autoantibodies.
  evidence:
  - reference: PMID:9287379
    reference_title: "Neonatal lupus erythematosus."
    supports: SUPPORT
    snippet: neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies.
    explanation: This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies.
  - reference: PMID:24763535
    reference_title: "The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes."
    supports: SUPPORT
    snippet: Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB).
    explanation: The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement.
  - reference: PMID:15744116
    reference_title: "[Neonatal lupus syndrome]."
    supports: SUPPORT
    snippet: Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta.
    explanation: This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies.
  - reference: PMID:3521977
    reference_title: "Lupus erythematosus in childhood."
    supports: SUPPORT
    snippet: 'Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus...'
    explanation: This supports the classification of neonatal lupus erythematosus as a subtype affecting children due to maternal factors.
  - reference: PMID:22832822
    reference_title: "Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease."
    supports: SUPPORT
    snippet: Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy.
    explanation: This reference implies that neonatal lupus caused by maternal autoantibodies affects the heart but doesn't explicitly say it's a systemic lupus erythematosus subtype.
- name: Drug-Induced Lupus
  description: Caused by certain medications and usually reversible.
  evidence:
  - reference: PMID:1356074
    reference_title: "Medication-induced systemic lupus erythematosus."
    supports: SUPPORT
    snippet: The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE.
    explanation: This indicates that there is a distinct subtype of SLE induced by medications.
  - reference: PMID:23164669
    reference_title: "Drug-induced lupus erythematosus."
    supports: SUPPORT
    snippet: Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal.
    explanation: This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug.
  - reference: PMID:1751313
    reference_title: "Drug-related lupus."
    supports: SUPPORT
    snippet: All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus erythematosus itself.
    explanation: This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement.
  - reference: PMID:25037258
    reference_title: "Severe drug-induced dermatoses."
    supports: SUPPORT
    snippet: This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus...
    explanation: This article covers drug-induced lupus, affirming the existence of this subtype linked to medications.
inheritance:
- name: Not applicable (complex/multifactorial)
  description: >-
    SLE is a complex multifactorial disease without a simple Mendelian inheritance pattern.
    Orphanet classifies inheritance as "Not applicable."
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Not applicable"
    explanation: Orphanet records inheritance as not applicable for SLE, consistent with its complex multifactorial etiology.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: "1-5 / 10 000 point prevalence"
  notes: >-
    Global prevalence estimated at 43.7 per 100,000 persons (3.41 million people).
    Women are disproportionately affected with prevalence of 78.73 per 100,000 vs
    9.26 per 100,000 in men. Prevalence varies by region and ethnicity.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Worldwide | Point prevalence | PMID:36241363"
    explanation: Orphanet epidemiology table reports worldwide point prevalence of 1-5 per 10,000.
  - reference: PMID:36241363
    reference_title: "Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the global SLE prevalence and affected population were estimated to be 43.7 (15.87 to 108.92) per 100 000 persons and 3.41 million people, respectively"
    explanation: Comprehensive global epidemiological modeling estimates SLE prevalence at approximately 43.7 per 100,000 persons worldwide.
- population: Worldwide annual incidence
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: "1-9 / 100 000 annual incidence"
  notes: >-
    Global incidence estimated at 5.14 per 100,000 person-years. In women, 8.82
    per 100,000 person-years; in men, 1.53 per 100,000.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Annual incidence | PMID:36241363"
    explanation: Orphanet epidemiology table reports worldwide annual incidence of 1-9 per 100,000.
  - reference: PMID:36241363
    reference_title: "Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The global SLE incidence and newly diagnosed population were estimated to be 5.14 (1.4 to 15.13) per 100 000 person-years and 0.40 million people annually, respectively"
    explanation: Global SLE incidence modeling estimates 5.14 per 100,000 person-years.
- population: Europe
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: "1-5 / 10 000 point prevalence"
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Europe | Point prevalence | ORPHANET"
    explanation: Orphanet reports European point prevalence of 1-5 per 10,000.
- population: North America
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 241.0
  percentage: "241 per 100,000 prevalence"
  notes: Highest regional point-prevalence estimate.
  evidence:
  - reference: PMID:28968809
    reference_title: "The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The highest estimates of incidence and prevalence of SLE were in North America [23.2/100 000 person-years (95% CI: 23.4, 24.0) and 241/100 000 people (95% CI: 130, 352), respectively]"
    explanation: Systematic review identifies North America as having the highest regional SLE point prevalence (241/100,000).
- population: North America
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 23.2
  percentage: "23.2 per 100,000 person-years incidence"
  notes: Highest regional annual-incidence estimate.
  evidence:
  - reference: PMID:28968809
    reference_title: "The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The highest estimates of incidence and prevalence of SLE were in North America [23.2/100 000 person-years (95% CI: 23.4, 24.0) and 241/100 000 people (95% CI: 130, 352), respectively]"
    explanation: Systematic review identifies North America as having the highest regional SLE incidence (23.2/100,000 person-years).
progression:
- phase: Age of onset
  age_range: Adolescent to adult, with childhood and infant onset also described
  notes: >-
    SLE most commonly presents in women of childbearing age (15-45 years).
    Orphanet records onset across infancy, childhood, adolescent, and adult stages.
    Incidence peaks in middle adulthood.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adolescent"
    explanation: Orphanet records adolescent as one of the onset ages for SLE.
  - reference: PMID:28968809
    reference_title: "The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Incidence peaked in middle adulthood and occurred later for men"
    explanation: Systematic review confirms SLE incidence peaks in middle adulthood.
mechanistic_hypotheses:
- hypothesis_group_id: nucleic_acid_immune_complex_interferon_tissue_injury_model
  hypothesis_label: Nucleic-Acid Immune Complex, Interferon, and Tissue-Injury Model
  status: CANONICAL
  description: >
    In genetically and environmentally susceptible SLE, excess endogenous nucleic
    acids from apoptotic cells and neutrophil extracellular traps form immune
    complexes with antinuclear autoantibodies. Fc receptor-mediated uptake by
    plasmacytoid dendritic cells and B cells delivers RNA and DNA to endosomal
    TLR7/TLR9, while mitochondrial or other cytosolic self-DNA can engage
    cGAS-STING signaling in myeloid cells. These sensing routes ignite type I
    interferon production, B-cell survival and differentiation, further
    autoantibody production, complement activation, and organ-local
    immune-complex inflammation. The model treats nephritis, skin, CNS,
    hematologic, and vascular injury as tissue-specific downstream contexts
    selected by local immune-complex deposition, complement handling, resident
    cell sensitivity to interferon, vascular injury, and organ-specific repair
    capacity rather than by systemic interferon activity alone.
  evidence:
  - reference: PMID:36792346
    reference_title: "Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Research elucidating the pathogenesis of systemic lupus erythematosus (SLE) has defined two critical families of mediators, type I interferon (IFN-I) and autoantibodies targeting nucleic acids and nucleic acid-binding proteins, as fundamental contributors to the disease."
    explanation: This review anchors the canonical model around type I interferon and nucleic-acid-directed autoantibodies.
  - reference: PMID:39343084
    reference_title: "Immunopathogenesis of systemic lupus erythematosus: An update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Abnormalities in B cell development and activation lead to the production of autoreactive antibodies, forming immune complexes that cause tissue damage."
    explanation: The review connects B-cell dysregulation to autoreactive antibody production, immune-complex formation, and tissue damage.
  - reference: PMID:22999705
    reference_title: "Complement, interferon and lupus."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Together, these findings provide both direct and indirect links between two key pathways implicated in lupus pathogenesis: complement and IFN."
    explanation: This supports modeling complement handling and type I interferon as connected rather than independent SLE mechanisms.
  - reference: PMID:34384544
    reference_title: "Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Antibody-mediated internalization of Mito+ RBCs induces type I interferon (IFN) production through activation of cGAS in macrophages."
    explanation: This supports a human SLE cytosolic cGAS route to type I interferon production.
pathophysiology:
- name: Formation of Immune Complexes
  description: >
    Antinuclear, anti-dsDNA, anti-Sm, and related autoantibodies bind nucleic
    acids, nucleosomes, and nucleic-acid-binding proteins to form immune
    complexes that can deposit in tissues or induce cytokine production.
  biological_processes:
  - preferred_term: Immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
  - preferred_term: Complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  - preferred_term: B cell mediated immunity
    term:
      id: GO:0019724
      label: B cell mediated immunity
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Nucleic Acid Immune Complex-pDC Endosomal Loop
    description: Nucleic-acid-containing immune complexes can be routed to plasmacytoid dendritic cells, where endosomal sensing produces IFN-alpha and amplifies the systemic interferon loop.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Fc receptor and complement-dependent immune-complex handling
    - plasmacytoid dendritic-cell engagement
    - endosomal nucleic-acid sensing
    evidence:
    - reference: PMID:22999705
      reference_title: "Complement, interferon and lupus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "in the absence of C1q, instead of ICs binding to monocytes, they preferentially engage plasmacytoid dendritic cells (pDC) so generating interferon (IFN) alpha"
      explanation: This supports an immune-complex to pDC interferon route in the SLE mechanism.
  - target: TLR7/TLR9-Mediated Nucleic Acid Sensing
    description: Nucleic-acid immune complexes can co-engage Fc receptors and endosomal TLR7/TLR9, activating B cells, plasmacytoid dendritic cells, and kidney-resident inflammatory pathways.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Fc receptor-mediated uptake of nucleic-acid immune complexes
    - delivery of RNA and DNA ligands to endosomal TLR7 and TLR9
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "These complexes can then lead to further activation of immune pathways by co-stimulation of FcγRs and endosomal Toll-like receptors (TLRs) and/or by activating the complement cascade"
      explanation: The lupus-nephritis review describes immune complexes as upstream of Fc receptor/TLR co-signaling and complement activation.
  - target: Complement Pathway Dysregulation
    description: Immune complexes activate complement locally while inherited or acquired defects in early complement handling impair clearance of immune complexes and apoptotic debris.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22999705
      reference_title: "Complement, interferon and lupus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "early complement component (C1q, C2 and C4) deficiencies predispose to lupus has been explained by the beneficial roles of these proteins in promoting the clearance of immune complexes (ICs) and apoptotic cells."
      explanation: This supports connecting immune-complex burden with complement clearance and dysregulation.
  - target: Glomerular Immune Complex Deposition
    description: Some nucleic-acid immune complexes localize in kidney glomeruli, making renal tissue one major downstream context for immune-complex injury.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "autoantibody production and immune complex formation/deposition in target organs such as the kidney."
      explanation: This supports connecting immune-complex formation to kidney-local deposition.
  - target: Cutaneous Immune Complex Deposition
    description: Autoantibody immune complexes can contribute to skin injury, providing a tissue-specific branch parallel to nephritis.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35872103
      reference_title: "Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS)."
      explanation: This supports skin as an immune-complex injury context in SLE.
  - target: Synovial Immune Complex Deposition
    description: Joint inflammation is modeled as another immune-complex deposition context, while the exact tissue determinants remain less resolved than for lupus nephritis.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:16572034
      reference_title: "The pathogenesis of systemic lupus erythematosus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues."
      explanation: This supports joints as one of the tissue contexts included in multisystem immune-complex deposition.
  evidence:
  - reference: PMID:32884126
    reference_title: "New insights into the role of antinuclear antibodies in systemic lupus erythematosus."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "antinuclear antibodies (ANAs) that form immune complexes"
    explanation: This directly supports immune-complex formation by antinuclear antibodies in SLE.
  - reference: PMID:35872103
    reference_title: "Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS)."
    explanation: This supports the link between SLE autoantibodies, immune-complex formation, and multi-organ inflammatory injury.
  - reference: PMID:27709413
    reference_title: "Immune Cell Metabolism in Systemic Lupus Erythematosus."
    supports: SUPPORT
    snippet: Here, we review what is known on the altered metabolic patterns of CD4(+) T cells, B cells, and myeloid cells in lupus patients and lupus-prone mice and how they contribute to lupus pathogenesis.
    explanation: The reference discusses the altered metabolic patterns of B cells, CD4(+) T cells, and myeloid cells (which include macrophages) and their contribution to lupus, which indirectly supports the involvement of these cell types in lupus mechanisms, but it does not specifically address immune complex formation directly.
  - reference: PMID:29925508
    reference_title: "TLR4(+)CXCR4(+) plasma cells drive nephritis development in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: TLR4(+)CXCR4(+) plasma cells drive nephritis development in systemic lupus erythematosus.
    explanation: This reference demonstrates the role of specific plasma cells in the development of lupus nephritis, implying their role in immune complex-related pathology, but does not detail the direct involvement of B cells or macrophages in immune complex formation.
  - reference: PMID:34402453
    reference_title: "Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: B-lymphocytes are crucial in the pathogenesis of systemic lupus erythematosus (SLE), including autoantibody production, antigen presentation, co-stimulation, and cytokine secretion.
    explanation: The reference highlights the crucial role of B cells in the pathogenesis of SLE through mechanisms such as autoantibody production, which is critical for immune complex formation. However, it does not explicitly discuss the role of plasma cells or macrophages in the context given.
  - reference: PMID:22999705
    reference_title: "Complement, interferon and lupus."
    supports: SUPPORT
    snippet: C1q opsonized apoptotic cells also exert an immunosuppressive effect through cytokine regulation and the stimulation of additional opsonins by macrophages.
    explanation: This suggests that macrophages have a role in immune complex-mediated processes through cytokine regulation and opsonin stimulation, contributing to the immune system’s activity in lupus but does not detail the involvement of B cells or plasma cells in immune complex formation.
- name: Glomerular Immune Complex Deposition
  description: >
    Circulating immune complexes containing anti-dsDNA and anti-Sm antibodies
    lodge in kidney glomeruli, activating complement and recruiting inflammatory
    cells.
  locations:
  - preferred_term: Kidney
    term:
      id: UBERON:0002113
      label: kidney
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  downstream:
  - target: Lupus Nephritis
    description: Immune complex deposition in glomeruli triggers local inflammation and tissue damage.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - complement activation
    - Fc receptor and Toll-like receptor amplification
    - renal cytokine and chemokine recruitment of inflammatory cells
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Following the formation and/or deposition of ICs in the kidney, interactions between resident renal cells and infiltrating inflammatory cells promote tissue injury."
      explanation: This supports treating nephritis as an organ-local downstream consequence of immune-complex deposition plus renal inflammatory amplification.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney."
    explanation: This directly supports kidney immune-complex deposition in SLE.
  - reference: PMID:33841392
    reference_title: "Deposition of Immune Complexes in Gingival Tissues in the Presence of Periodontitis and Systemic Lupus Erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges. Deposition of immune complexes in kidneys glomeruli are associated with lupus nephritis, determining SLE diagnosis.
    explanation: The literature supports the deposition of immune complexes in kidney glomeruli but does not cover skeletal joints, skin, heart, or lung in this context.
  - reference: PMID:30009962
    reference_title: "Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers."
    supports: SUPPORT
    snippet: LN is characterized by glomerular kidney injury, essentially due to deposition of immune complexes involving autoantibodies against cellular components and circulating proteins.
    explanation: This confirms immune complex deposition in kidneys.
- name: Cutaneous Immune Complex Deposition
  description: >
    Immune complexes deposit at the dermal-epidermal junction and in vessel
    walls of the skin, leading to cutaneous manifestations of lupus.
  locations:
  - preferred_term: Skin
    term:
      id: UBERON:0002097
      label: skin of body
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:35872103
    reference_title: "Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target."
    supports: SUPPORT
    snippet: The autoantibodies, especially anti-dsDNA and anti-Sm autoantibodies are highly specific to SLE, and participate in the immune complex formation and inflammatory damage on multiple end-organs such as kidney, skin, and central nervous system (CNS).
    explanation: This paper directly establishes that autoantibodies form immune complexes which cause inflammatory damage to multiple organs in SLE.
  - reference: PMID:16572034
    reference_title: "The pathogenesis of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues.
    explanation: The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.
- name: Synovial Immune Complex Deposition
  description: >
    Immune complexes accumulate in synovial fluid and tissue of joints,
    activating complement and triggering inflammatory arthritis.
  locations:
  - preferred_term: Skeletal Joint
    term:
      id: UBERON:0000982
      label: skeletal joint
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:16572034
    reference_title: "The pathogenesis of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues.
    explanation: Confirms deposition of aberrant immune complexes into tissues including the joints, supporting synovial immune-complex deposition as the mechanism of lupus arthritis.
- name: Inflammation And Tissue Damage
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage.
    explanation: The article describes inflammation and immune complex deposition as mechanisms leading to tissue damage in SLE.
  - reference: PMID:36555640
    reference_title: "Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies."
    supports: SUPPORT
    snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
    explanation: The literature explains that inflammation and tissue damage are core mechanisms in the pathology of SLE due to immune system disturbances.
  - reference: PMID:28623084
    reference_title: "Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. A complex interaction of genetics, environment, and hormones leads to immune dysregulation and breakdown of tolerance to self-antigens, resulting in autoantibody production, inflammation, and destruction of end-organs.
    explanation: This article outlines inflammation as part of the immune dysregulation in SLE, leading to tissue damage in multiple organs.
  - reference: PMID:33841392
    reference_title: "Deposition of Immune Complexes in Gingival Tissues in the Presence of Periodontitis and Systemic Lupus Erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges.
    explanation: The study identifies widespread inflammation and tissue damage as defining characteristics of SLE.
  - reference: PMID:37712757
    reference_title: "Biomarkers for systemic lupus erythematosus - a focus on organ damage."
    supports: SUPPORT
    snippet: In the current review, we focus on the commonly affected organs (skin, kidney, and nervous system) in SLE to summarize the emerging biomarkers that show promise in disease diagnosis, monitoring and treatment response assessment.
    explanation: The review supports that inflammation and tissue damage are significant mechanisms in SLE affecting organs such as the skin, kidneys, and nervous system.
- name: Chronic Inflammation
  evidence:
  - reference: PMID:16572034
    reference_title: "The pathogenesis of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues...
    explanation: The abstract confirms that inflammation is a key aspect of systemic lupus erythematosus pathogenesis.
  - reference: PMID:26330673
    reference_title: "Identification of Candidate Predictors of Lupus Flare."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus, the prototype systemic autoimmune disease, is characterized by extensive self-reactivity, inflammation, and organ system damage.
    explanation: The abstract clearly mentions inflammation as a characteristic feature of SLE.
  - reference: PMID:32237942
    reference_title: "Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is potentially life-threatening and can affect any organ.
    explanation: The literature describes SLE as a chronic autoimmune disease affecting various organs, implying sustained inflammation over time.
  - reference: PMID:24992143
    reference_title: "The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis?"
    supports: SUPPORT
    snippet: Recent evidence suggests that the inflammasome machinery is dysregulated in SLE, plays an important role in promotion of organ damage, and may mediate cross-talk between environmental triggers and the development of lupus.
    explanation: The abstract discusses the role of inflammasome and inflammation in organ damage associated with SLE, supporting the chronic inflammation mechanism.
  - reference: PMID:36555640
    reference_title: "Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies."
    supports: SUPPORT
    snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
    explanation: The literature describes inflammation and tissue damage due to immune complexes, which supports chronic inflammation as a mechanism of SLE.
- name: Flare-Ups
  description: The symptoms of lupus can worsen suddenly in episodes known as flares, which can be triggered by factors like stress, sunlight, and infections.
  evidence:
  - reference: PMID:26951252
    reference_title: "What Causes Lupus Flares?"
    supports: SUPPORT
    snippet: These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms.
    explanation: This reference mentions the potential triggers for lupus flares, which include UV light (sunlight) and infections.
  - reference: PMID:26494589
    reference_title: "Systemic lupus erythematosus flare triggered by a spider bite."
    supports: SUPPORT
    snippet: Some triggers for these exacerbations have been identified, including infections, vaccines, pregnancy, environmental factors such as weather, stress and drugs.
    explanation: This reference specifically states that stress and infections can trigger lupus flares.
  - reference: PMID:22385883
    reference_title: "Seasonal variations of systemic lupus erythematosus flares in southern France."
    supports: SUPPORT
    snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
    explanation: This reference confirms that sunlight exposure can trigger lupus flares.
- name: Type I Interferon Pathway Activation
  description: Chronic activation of the type I interferon signaling pathway is a central pathophysiological mechanism in SLE, shaping dysregulation across immune cell lineages and correlating with disease activity and therapy response.
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: type I interferon signaling pathway
    term:
      id: GO:0060337
      label: type I interferon-mediated signaling pathway
  genes:
  - preferred_term: IRF5
    term:
      id: hgnc:6120
      label: IRF5
  downstream:
  - target: Age-Associated B Cell Expansion
    description: Type I interferon is modeled as a systemic amplifier of autoreactive B-cell and autoantibody circuits, while the exact perpetuation mechanisms remain an open knowledge gap.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33246136
      reference_title: "Type I interferon in the pathogenesis of systemic lupus erythematosus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "the mechanisms by which IFNs help perpetuate the cycle of autoreactive cells and autoantibody production are not completely clear."
      explanation: This supports the relevance of an IFN-to-autoreactive-cell cycle but marks the specific causal intermediates as unresolved.
  - target: Lupus Nephritis
    description: High type I interferon identifies a subgroup with more active disease and greater nephritis propensity.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - immune-cell activation
    - inflammatory mediator induction
    evidence:
    - reference: PMID:33246136
      reference_title: "Type I interferon in the pathogenesis of systemic lupus erythematosus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Patients with SLE and evidence of high type I IFN have more active disease and a greater propensity to nephritis and other severe manifestations."
      explanation: This supports linking high type I interferon activity to nephritis and other severe manifestations.
  evidence:
  - reference: PMID:33246136
    reference_title: "Type I interferon in the pathogenesis of systemic lupus erythematosus."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Type I interferon (IFN) is a primary pathogenic factor in systemic lupus erythematosus (SLE)."
    explanation: This review directly supports the central pathogenic role of type I interferon in SLE.
  - reference: PMID:24834763
    reference_title: "Type I interferon signature in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE.
    explanation: This review describes the type I interferon gene signature in SLE, supporting chronic activation of the type I interferon pathway.
- name: TLR7/TLR9-Mediated Nucleic Acid Sensing
  description: B cell-intrinsic TLR7 signaling drives severe lupus through recognition of RNA-associated autoantigens, while TLR9 can exert counter-regulatory effects. TLR7/9 activation in plasmacytoid dendritic cells triggers type I interferon production.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  biological_processes:
  - preferred_term: toll-like receptor signaling pathway
    term:
      id: GO:0002224
      label: toll-like receptor signaling pathway
  - preferred_term: toll-like receptor 7 signaling pathway
    term:
      id: GO:0034154
      label: toll-like receptor 7 signaling pathway
  - preferred_term: toll-like receptor 9 signaling pathway
    term:
      id: GO:0034162
      label: toll-like receptor 9 signaling pathway
  genes:
  - preferred_term: TLR7
    term:
      id: hgnc:15631
      label: TLR7
  - preferred_term: TLR9
    term:
      id: hgnc:15633
      label: TLR9
  - preferred_term: MYD88
    term:
      id: hgnc:7562
      label: MYD88
  - preferred_term: CYBB
    term:
      id: hgnc:2578
      label: CYBB
  - preferred_term: UNC93B1
    term:
      id: hgnc:13481
      label: UNC93B1
  downstream:
  - target: Type I Interferon Pathway Activation
    description: Nucleic-acid immune-complex sensing by plasmacytoid dendritic cells is modeled as a proximate ignition route for IFN-alpha/type I interferon production.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22999705
      reference_title: "Complement, interferon and lupus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "they preferentially engage plasmacytoid dendritic cells (pDC) so generating interferon (IFN) alpha"
      explanation: In the context of immune-complex handling without C1q, this supports pDC engagement as an interferon-alpha-generating route.
  - target: Glomerular Immune Complex Deposition
    description: In renal tissue, immune-complex Fc receptor and TLR co-signaling amplifies local inflammation after glomerular immune-complex formation.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "FcγR may be important in association with TLRs in mediating IC-induced inflammation in the kidney"
      explanation: This supports modeling Fc receptor/TLR co-signaling as a renal immune-complex inflammatory amplifier.
  evidence:
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This type of two-step activation is known to activate B cells by ICs containing either TLR9 or TLR7 activators such as dsDNA or single-stranded RNA"
    explanation: This supports the TLR7/TLR9 nucleic-acid sensing node in immune-complex-driven SLE mechanisms.
- name: Nucleic Acid Immune Complex-pDC Endosomal Loop
  description: >
    Nucleic-acid-containing immune complexes are routed to plasmacytoid
    dendritic cells and endosomal nucleic-acid sensors, generating IFN-alpha and
    reinforcing the autoantibody, immune-complex, and interferon circuit.
    Complement handling, especially C1q-dependent clearance, modulates whether
    immune complexes are cleared or preferentially engage pDCs.
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  biological_processes:
  - preferred_term: immune-complex endosomal nucleic-acid sensing
    term:
      id: GO:0002224
      label: toll-like receptor signaling pathway
  - preferred_term: type I interferon production
    term:
      id: GO:0032606
      label: type I interferon production
  downstream:
  - target: Type I Interferon Pathway Activation
    description: pDC engagement by nucleic-acid immune complexes produces IFN-alpha, feeding the systemic type I interferon signature.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22999705
      reference_title: "Complement, interferon and lupus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "they preferentially engage plasmacytoid dendritic cells (pDC) so generating interferon (IFN) alpha"
      explanation: This supports the pDC immune-complex loop as a proximate interferon-producing mechanism.
  evidence:
  - reference: PMID:22999705
    reference_title: "Complement, interferon and lupus."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in the absence of C1q, instead of ICs binding to monocytes, they preferentially engage plasmacytoid dendritic cells (pDC) so generating interferon (IFN) alpha"
    explanation: This supports immune-complex routing to pDCs as part of the interferon loop.
- name: Cytosolic cGAS-STING DNA Sensing
  description: >
    Cytosolic DNA sensing provides a parallel route to type I interferon
    activation outside the endosomal TLR7/TLR9 loop. In SLE, interferogenic
    mitochondrial DNA from NET biology and mitochondria-retaining erythroid
    cells can engage STING- or cGAS-dependent pathways in myeloid cells.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: cGAS-STING-mediated type I interferon production
    term:
      id: GO:0032606
      label: type I interferon production
  downstream:
  - target: Type I Interferon Pathway Activation
    description: Cytosolic self-DNA sensing can produce type I interferon and therefore acts as a non-endosomal ignition route for the interferon signature.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - oxidized mitochondrial DNA release
    - cGAS activation or STING-dependent DNA sensing
    - myeloid type I interferon production
    evidence:
    - reference: PMID:34384544
      reference_title: "Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Antibody-mediated internalization of Mito+ RBCs induces type I interferon (IFN) production through activation of cGAS in macrophages."
      explanation: This supports cytosolic cGAS activation in macrophages as a human SLE interferon-producing mechanism.
    - reference: PMID:26779811
      reference_title: "Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING."
      explanation: This supports STING-dependent type I interferon signaling from oxidized mitochondrial DNA in lupus-relevant experimental systems.
  evidence:
  - reference: PMID:26779811
    reference_title: "Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Extracellular release of oxidized mitochondrial DNA is proinflammatory in vitro, and when this DNA is injected into mice, it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING."
    explanation: This supports oxidized mitochondrial DNA as a STING-dependent type I interferon trigger in lupus-relevant experimental systems.
  - reference: PMID:34384544
    reference_title: "Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SLE patients carrying both Mito+ RBCs and opsonizing antibodies display the highest levels of blood IFN-stimulated gene (ISG) signatures, a distinctive feature of SLE."
    explanation: This supports a human SLE association between mitochondria-containing erythroid material, antibodies, and high interferon signatures.
- name: NETosis and Neutrophil Extracellular Trap Formation
  description: Neutrophils undergo enhanced NETosis, releasing extracellular traps (NETs) composed of DNA, histones, and granule proteins. Impaired NET degradation due to deficient serum DNase1 amplifies the pDC-TLR9-IFN-alpha loop and provides modified autoantigens. NETs are associated with lupus nephritis.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
  - preferred_term: neutrophil extracellular trap formation
    term:
      id: GO:0140645
      label: neutrophil extracellular trap formation
  genes:
  - preferred_term: DNASE1
    term:
      id: hgnc:2956
      label: DNASE1
  downstream:
  - target: Type I Interferon Pathway Activation
    description: NET material provides nucleic-acid antigen and can directly activate plasmacytoid dendritic cells, promoting type I interferon production.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - NET-derived DNA, histones, and neutrophil proteins
    - pDC activation by NET-associated cathelicidin
    evidence:
    - reference: PMID:22999705
      reference_title: "Complement, interferon and lupus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "NETs are known to promote type I IFN production in SLE by providing a source of antigen for the formation of ICs as well as through direct pDC activation by cathelicidin (LL37)."
      explanation: This supports NETs as an upstream source and activator for the type I interferon loop.
  - target: Cytosolic cGAS-STING DNA Sensing
    description: Oxidized mitochondrial DNA released during lupus-relevant NET biology can feed cytosolic DNA sensing and STING-dependent interferon signaling.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mitochondrial ROS-dependent NETosis
    - extracellular oxidized mitochondrial DNA release
    - STING-dependent type I interferon signaling
    evidence:
    - reference: PMID:26779811
      reference_title: "Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Extracellular release of oxidized mitochondrial DNA is proinflammatory in vitro, and when this DNA is injected into mice, it stimulates type I interferon (IFN) signaling through a pathway dependent on the DNA sensor STING."
      explanation: This supports NET-associated mitochondrial DNA as an upstream input to STING-dependent interferon signaling.
  - target: Glomerular Immune Complex Deposition
    description: Impaired NET dismantling increases persistent DNA/histone/neutrophil-protein antigenic material and is associated with renal involvement.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20439745
      reference_title: "Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Impairment of DNase1 function and failure to dismantle NETs correlated with kidney involvement."
      explanation: This supports NET persistence as a renal-involvement-associated upstream mechanism.
  evidence:
  - reference: PMID:20439745
    reference_title: "Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neutrophils respond to infections and release extracellular traps (NETs), which are antimicrobial and are made of DNA, histones, and neutrophil proteins."
    explanation: This supports the NET composition and infection-responsive release described in the node.
- name: Age-Associated B Cell Expansion
  description: Age-associated B cells (ABCs) are enriched in SLE, characterized by T-bet and CD11c expression. They correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: B cell activation
    term:
      id: GO:0042113
      label: B cell activation
  - preferred_term: B cell differentiation
    term:
      id: GO:0030183
      label: B cell differentiation
  genes:
  - preferred_term: TNFSF13B
    term:
      id: hgnc:11929
      label: TNFSF13B
  downstream:
  - target: Formation of Immune Complexes
    description: Expanded autoreactive B-cell and plasma-cell programs produce antinuclear and anti-dsDNA antibodies that feed immune-complex formation.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - autoreactive plasma-cell differentiation
    - anti-dsDNA and other antinuclear antibody production
    evidence:
    - reference: PMID:39343084
      reference_title: "Immunopathogenesis of systemic lupus erythematosus: An update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Abnormalities in B cell development and activation lead to the production of autoreactive antibodies, forming immune complexes that cause tissue damage."
      explanation: This supports the B-cell to autoreactive-antibody to immune-complex segment of the model.
- name: T Follicular Helper Cell Dysregulation
  description: T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in SLE, characterized by ICOS, PD-1, and IL-21 expression. They drive autoreactive B cell differentiation through both extrafollicular and germinal center pathways.
  cell_types:
  - preferred_term: T follicular helper cell
    term:
      id: CL:0002038
      label: T follicular helper cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: T cell activation
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: germinal center formation
    term:
      id: GO:0002467
      label: germinal center formation
  genes:
  - preferred_term: IL21
    term:
      id: hgnc:6005
      label: IL21
- name: Impaired Apoptotic Cell Clearance
  description: Defective clearance of apoptotic cells and impaired efferocytosis lead to increased exposure to nuclear antigens, propagating immune complex formation and autoantibody production.
  biological_processes:
  - preferred_term: apoptotic cell clearance
    term:
      id: GO:0043277
      label: apoptotic cell clearance
  - preferred_term: efferocytosis
    term:
      id: GO:0043277
      label: apoptotic cell clearance
  downstream:
  - target: Formation of Immune Complexes
    description: Defective apoptotic-cell clearance increases the self-antigen substrate available for autoreactive antibody binding and immune-complex formation.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39343084
      reference_title: "Immunopathogenesis of systemic lupus erythematosus: An update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "defective clearance of apoptotic cells due to defective phagocytosis and complement activation leads to accumulation of self-antigens."
      explanation: This supports impaired apoptotic-cell clearance as an upstream source of self-antigens.
- name: Complement Pathway Dysregulation
  description: Early component complement deficiencies (C1q, C3, C4) and complement consumption occur alongside immune complex deposition. Classical pathway activation by immune complexes contributes to tissue injury, particularly in lupus nephritis.
  biological_processes:
  - preferred_term: complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  locations:
  - preferred_term: Kidney
    term:
      id: UBERON:0002113
      label: kidney
  - preferred_term: Glomerulus
    term:
      id: UBERON:0000074
      label: renal glomerulus
  downstream:
  - target: Type I Interferon Pathway Activation
    description: Defective C1q-mediated immune-complex handling can redirect immune complexes toward plasmacytoid dendritic cells and IFN-alpha production.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:22999705
      reference_title: "Complement, interferon and lupus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "in the absence of C1q, instead of ICs binding to monocytes, they preferentially engage plasmacytoid dendritic cells (pDC) so generating interferon (IFN) alpha"
      explanation: This supports complement handling as a determinant of whether immune complexes drive pDC interferon production.
  - target: Inflammation And Tissue Damage
    description: Complement activation downstream of immune-complex deposition amplifies local inflammatory injury, particularly in lupus nephritis.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - C3/C5 activation fragments
    - membrane attack complex formation
    - renal inflammatory cell recruitment
    evidence:
    - reference: PMID:22192660
      reference_title: "Mechanisms of tissue injury in lupus nephritis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "There is strong evidence that complement activation is deleterious in lupus nephritis"
      explanation: This supports complement activation as an inflammatory tissue-injury amplifier in lupus nephritis.
  evidence:
  - reference: PMID:22999705
    reference_title: "Complement, interferon and lupus."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "promoting the clearance of immune complexes (ICs) and apoptotic cells."
    explanation: This supports the clearance arm of complement dysregulation in the SLE mechanism.
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Deposition of complement proteins in glomeruli is a key feature of lupus nephritis."
    explanation: This supports complement involvement at the renal tissue-injury site.
- name: Epigenetic Dysregulation and T Cell Metabolic Reprogramming
  description: >
    Aberrant DNA methylation, histone modifications, and metabolic reprogramming
    in T cells contribute to lupus pathogenesis. Hypomethylation of immune gene
    loci activates autoreactive T cells, while metabolic shifts including altered
    mTOR signaling and glutaminolysis support inflammatory T cell programs.
  cell_types:
  - preferred_term: CD4-positive helper T cell
    term:
      id: CL:0000492
      label: CD4-positive helper T cell
  biological_processes:
  - preferred_term: Epigenetic Regulation of Gene Expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
  - preferred_term: T Cell Differentiation
    term:
      id: GO:0030217
      label: T cell differentiation
  downstream:
  - target: Autoantibody Production
    description: Dysregulated T cell programs promote autoreactive B cell help and autoantibody production
  notes: >
    Cluster 100 (ATF4, GLS, CBLB) from Zhu/Dann Perturb-seq shows OR=3.7 for SLE, the
    strongest signal for this metabolic/stress response regulatory program. DNA methylation
    changes are well-established in lupus T cells.
- name: Non-Coding RNA Dysregulation
  biological_scale: MOLECULAR
  description: >-
    Non-coding RNAs (microRNAs, long non-coding RNAs, and circular RNAs) regulate
    immune responses, epigenetic modifications, and cytokine signaling in SLE. Their
    dysregulation is associated with altered autoimmune activation, impaired tolerance,
    disease activity, and specific clinical phenotypes.
  biological_processes:
  - preferred_term: miRNA-mediated gene silencing
    term:
      id: GO:0035195
      label: miRNA-mediated post-transcriptional gene silencing
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
  downstream:
  - target: Age-Associated B Cell Expansion
    description: >-
      Non-coding RNA dysregulation is proposed to converge with EBV infection in
      autoreactive B cells, contributing to expansion of the autoreactive B cell
      compartment and loss of B cell tolerance.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42439858
      reference_title: "The silent regulators: non-coding RNAs and Epstein-Barr virus at the crossroads of lupus pathogenesis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "EBV and ncRNA dysregulation may converge in autoreactive B cells and other immune compartments to promote the loss of tolerance and the development of clinically distinct forms of SLE."
      explanation: >-
        The review proposes convergence of ncRNA dysregulation and EBV in autoreactive B
        cells, but frames it as a hypothesis ("may converge") and does not identify the
        intermediate steps, so this edge is recorded as partial support only.
  evidence:
  - reference: PMID:42439858
    reference_title: "The silent regulators: non-coding RNAs and Epstein-Barr virus at the crossroads of lupus pathogenesis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Increasing evidence suggests that non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, are involved in the fine regulation of immune responses, epigenetic changes, and cytokine signaling in SLE."
    explanation: >-
      Narrative review asserting ncRNA involvement in SLE immune regulation. The hedged
      framing ("Increasing evidence suggests") supports the existence of the mechanism
      rather than a settled causal role, so this is recorded as partial support.
  notes: >-
    This node currently rests on a single narrative review (PMID:42439858) and has no
    primary experimental citation. The specific miRNA/lncRNA/circRNA species, their
    target genes, and the direction of change in SLE remain to be curated from primary
    studies before any stronger causal claim is made here. An earlier version of this
    node also asserted a direct ncRNA to type I interferon edge; it was removed because
    the cited review discusses ncRNAs as biomarkers and does not report an IFNAR/IRF
    mechanism.
- name: Epstein-Barr Virus-Mediated Persistent Immune Activation
  description: >-
    Persistent EBV infection contributes to SLE pathogenesis through multiple mechanisms:
    sustained immune activation by viral antigens, molecular mimicry of host autoantigens,
    and modulation of host ncRNA pathways. EBV can drive autoreactive B cell activation
    and maintain chronic autoimmune responses through EBV-encoded latency-associated antigens.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: memory B cell
    term:
      id: CL:0000787
      label: memory B cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: B cell mediated immunity
    term:
      id: GO:0019724
      label: B cell mediated immunity
  - preferred_term: EBV latency in the memory B cell reservoir
    term:
      id: GO:0019042
      label: viral latency
  downstream:
  - target: Formation of Immune Complexes
    description: EBV-driven B cell activation and proliferation produces autoreactive antibodies that form immune complexes.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - EBV latency antigen (EBNA) -specific B cell activation
    - molecular mimicry between viral and nuclear epitopes
    - persistent B cell proliferation and antibody class switching
    evidence:
    - reference: PMID:42439858
      reference_title: "The silent regulators: non-coding RNAs and Epstein-Barr virus at the crossroads of lupus pathogenesis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Epstein-Barr virus (EBV), a long-suspected contributor to SLE, may further shape disease through persistent immune activation, molecular mimicry, and modulation of host ncRNA pathways."
      explanation: >-
        The review names persistent immune activation and molecular mimicry as candidate
        EBV mechanisms in SLE, but hedges the causal claim ("may further shape disease")
        and does not itself demonstrate immune complex formation, so this is partial support.
    - reference: PMID:38146370
      reference_title: Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "24 times higher possibility of having SLE if there is the presence of anti-EBV-EA(D) (early antigen) IgG antibodies"
      explanation: >-
        Primary case-control study (103 SLE patients, 99 controls) showing that serological
        evidence of EBV reactivation is strongly associated with SLE. It substantiates the
        EBV-SLE link in humans but is an association, not a demonstration of this causal edge.
  - target: Non-Coding RNA Dysregulation
    description: >-
      EBV modulates host non-coding RNA pathways, linking persistent infection to the
      ncRNA dysregulation arm of SLE pathogenesis.
    hypothesis_groups:
    - nucleic_acid_immune_complex_interferon_tissue_injury_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42439858
      reference_title: "The silent regulators: non-coding RNAs and Epstein-Barr virus at the crossroads of lupus pathogenesis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Epstein-Barr virus (EBV), a long-suspected contributor to SLE, may further shape disease through persistent immune activation, molecular mimicry, and modulation of host ncRNA pathways."
      explanation: >-
        The review states that EBV modulates host ncRNA pathways, supporting this edge in
        direction, but hedges the disease-level claim, so it is recorded as partial support.
  evidence:
  - reference: PMID:42439858
    reference_title: "The silent regulators: non-coding RNAs and Epstein-Barr virus at the crossroads of lupus pathogenesis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Epstein-Barr virus (EBV), a long-suspected contributor to SLE, may further shape disease through persistent immune activation, molecular mimicry, and modulation of host ncRNA pathways. In this review, we examine how EBV and ncRNA dysregulation may converge in autoreactive B cells and other immune compartments to promote the loss of tolerance and the development of clinically distinct forms of SLE."
    explanation: >-
      Narrative review framing EBV as a persistent contributor to SLE through immune
      activation, molecular mimicry, and ncRNA modulation. The claims are hedged
      throughout ("long-suspected", "may"), so this is recorded as partial support.
  - reference: PMID:38146370
    reference_title: Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated."
    explanation: >-
      Primary human case-control study supporting persistent/reactivated EBV infection as a
      real feature of SLE, while explicitly noting that the mechanism of EBV influence is
      still unresolved.
  notes: >-
    The mechanistic detail of this node (molecular mimicry, ncRNA modulation, tolerance
    loss) currently derives from a narrative review; the primary human evidence
    (PMID:38146370) establishes the EBV-SLE association and its clinical correlates but
    not the mechanism. Treat the causal chain as provisional.
phenotypes:
- category: Cutaneous
  name: Malar Rash
  frequency: FREQUENT
  diagnostic: true
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0025300 | Malar rash | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies malar rash as frequent in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "311 (31.1%) patients had malar rash"
    explanation: Euro-Lupus cohort of 1,000 patients found malar rash in 31.1% over 10 years.
  - reference: PMID:23846232
    reference_title: "Systemic lupus erythematosus in the multiethnic Malaysian population: disease expression and ethnic differences revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common clinical manifestations were malar rash (61.3%)...
    explanation: Malaysian multi-ethnic cohort reports malar rash in 61.3% of SLE patients.
  phenotype_term:
    preferred_term: Malar Rash
    term:
      id: HP:0025300
      label: Malar rash
- category: Cutaneous
  name: Photosensitivity
  frequency: OCCASIONAL
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000992 | Cutaneous photosensitivity | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies cutaneous photosensitivity as occasional in SLE.
  - reference: PMID:15379880
    reference_title: "Photosensitivity in lupus erythematosus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Photosensitivity is one the most common manifestations of lupus erythematosus.
    explanation: Photosensitivity is recognized as a common manifestation in lupus erythematosus.
  - reference: PMID:30488801
    reference_title: "Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "photosensitivity 35.10%"
    explanation: Oman cohort reports photosensitivity at initial presentation in 35.1%, which exceeds the Occasional (5-29%) band; supports association but not the frequency classification.
  phenotype_term:
    preferred_term: Photosensitivity
    term:
      id: HP:0000992
      label: Cutaneous photosensitivity
- category: Musculoskeletal
  name: Arthritis
  frequency: FREQUENT
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001369 | Arthritis | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies arthritis as frequent in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "481 (48.1%) patients presented 1 or more episodes of arthritis at any time during the 10 years"
    explanation: Euro-Lupus cohort found arthritis in 48.1% of 1,000 SLE patients over 10 years.
  - reference: PMID:19591780
    reference_title: "Lupus arthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arthritis in systemic lupus erythematosus (SLE) is one of the most common disease manifestations. Nearly all joints can be affected by SLE, but hand and knee involvement are the most typical.
    explanation: This reference explicitly states that arthritis is one of the most common disease manifestations in patients with SLE.
  - reference: PMID:27742023
    reference_title: "Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis."
    supports: SUPPORT
    snippet: The precise nature of the disorder can be obscure and different disorders can present with similar symptoms, such as joint pain.
    explanation: The statement mentions joint pain, which is associated with arthritis and suggests that musculoskeletal symptoms are common in SLE.
  - reference: PMID:19013374
    reference_title: "Deforming arthropathy in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus is an autoimmune and inflammatory disease characterized by a variety of symptoms, including arthropathy. The clinical presentation of joint involvement varies, ranging from arthralgia without erosions or deformity to an erosive arthropathy and severe functional disability.
    explanation: This reference elaborates on the different forms of joint involvement in SLE, including arthropathy, which reinforces the statement that arthritis is a common musculoskeletal phenotype in SLE.
  - reference: PMID:32956154
    reference_title: "Frequency of Polyautoimmunity in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus."
    supports: SUPPORT
    snippet: Polyautoimmunity was recorded in 15 patients with RA (13.8%), 43 with SLE (41%), and 2 controls (2.2%). ... In SLE, joint damage (OR, 2.282; p = 0.038) and anti-RNP antibodies (OR, 5.095; p = 0.028) were risk factors for polyautoimmunity...
    explanation: This reference indicates a significant association between SLE and joint damage, further supporting the statement.
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
- category: Renal
  name: Kidney Involvement
  phenotype_term:
    preferred_term: Kidney Involvement
  evidence:
  - reference: PMID:36251502
    reference_title: "Prevalence and Patterns of Renal Involvement Among Patients With Systemic Lupus Erythematous at a Tertiary Center."
    supports: SUPPORT
    snippet: Among 365 patients with SLE, 36% had LN.
    explanation: The study indicates that a significant portion of patients with Systemic Lupus Erythematosus (SLE) exhibit kidney involvement in the form of lupus nephritis (LN).
  - reference: PMID:330103
    reference_title: "Kidney in lupus erythematosus."
    supports: SUPPORT
    snippet: 'The pathologic abnormalities present in patients with SLE have been classified as follows: minimal lupus nephritis, mild (focal) proliferative lupus nephritis, severe (diffuse) proliferative lupus nephritis, and membranous lupus nephritis.'
    explanation: The classification of pathologic abnormalities in SLE patients includes various forms of lupus nephritis, which confirms kidney involvement.
  - reference: PMID:30454753
    reference_title: "Lupus Nephritis."
    supports: SUPPORT
    snippet: Patients with early onset SLE tend to have a greater genetic component to their disease cause, more multisystemic involvement, and a more severe disease course, which includes greater risks for developing nephritis and end-stage kidney disease.
    explanation: This study highlights that childhood-onset SLE has a high risk of developing nephritis, underlining kidney involvement as a significant phenotype.
- category: Renal
  frequency: FREQUENT
  name: Lupus Nephritis
  notes: Inflammation of the kidneys, can lead to renal failure
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0033726 | Lupus nephritis | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies lupus nephritis as frequent in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "279 (27.9%) active nephropathy"
    explanation: Euro-Lupus cohort found active nephropathy in 27.9% of 1,000 SLE patients over 10 years.
  - reference: PMID:16530602
    reference_title: "Lupus nephritis."
    supports: SUPPORT
    snippet: Lupus nephritis is one of the more serious manifestations of the systemic autoimmune disease, systemic lupus erythematosus, and is associated with considerable morbidity and even mortality.
    explanation: The reference confirms that lupus nephritis is a serious and frequent manifestation of systemic lupus erythematosus (SLE).
  - reference: PMID:32295853
    reference_title: "Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis."
    supports: SUPPORT
    snippet: The frequency of endstage renal disease (ESRD) from systemic lupus erythematosus (SLE) in the United States has not improved over the last few decades in large population datasets.
    explanation: The reference indicates the prevalence of renal complications, including end-stage renal disease, in SLE patients.
  - reference: PMID:35775489
    reference_title: "Lymphocytes in the neighborhood: good or bad for the kidney?"
    supports: SUPPORT
    snippet: Lupus nephritis (LN) is common in people with systemic lupus erythematosus (SLE) and advances, almost invariably, to end-stage renal disease (ESRD).
    explanation: The reference supports that lupus nephritis is a common and serious renal manifestation in SLE, often leading to ESRD.
  - reference: PMID:22192934
    reference_title: "[Renal involvement in systemic lupus erythematosus]."
    supports: SUPPORT
    snippet: Renal involvement is frequent (20 to 50% of cases) during the course of systemic lupus erythematosus (SLE).
    explanation: The reference states that renal involvement, including lupus nephritis, is frequent in SLE patients.
  phenotype_term:
    preferred_term: Lupus Nephritis
    term:
      id: HP:0033726
      label: Lupus nephritis
- category: Hematologic
  frequency: FREQUENT
  name: Leukopenia
  notes: Low white blood cell count
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001882 | Leukopenia | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies leukopenia (decreased total leukocyte count) as frequent in SLE.
  - reference: PMID:26170228
    reference_title: "Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact--A systematic literature review."
    supports: SUPPORT
    snippet: The prevalence of leukopenia is reported in 22-41.8% of cases.
    explanation: The study reports that leukopenia is prevalent in 22-41.8% of SLE cases, indicating that leukopenia is a frequent hematologic abnormality in SLE patients.
  - reference: PMID:27590999
    reference_title: "Prognostic significance of platelet count in SLE patients."
    supports: SUPPORT
    snippet: TCP was the most prevalent hematological abnormality evident in 15%, more than leucopenia (14%) and anemia (2%).
    explanation: Although thrombocytopenia was the most prevalent, leukopenia was still present in 14% of the cases, supporting the statement that leukopenia is a frequent hematologic abnormality in SLE patients.
  - reference: PMID:8130682
    reference_title: "Haematological manifestations of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: The increased risk of infection in patients with SLE is due in part to changes in the white blood cells though treatments do not yet aim to modify these.
    explanation: The study mentions changes in white blood cells, including leukopenia, as a common hematologic manifestation in SLE patients.
  - reference: PMID:15580984
    reference_title: "Review of ACR hematologic criteria in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: 'In the updated 1982 ACR criteria, the presence of one or more of the four elements: 1) hemolytic anemia (with reticulocytosis); 2) leukopenia (<4000/microL on two or more occasions)... is now considered as a single hematologic disorder.'
    explanation: The ACR criteria include leukopenia as a significant hematologic disorder in the diagnosis of SLE, supporting its frequent occurrence.
  phenotype_term:
    preferred_term: Leukopenia
    term:
      id: HP:0001882
      label: Decreased total leukocyte count
- category: Hematologic
  frequency: OCCASIONAL
  name: Thrombocytopenia
  notes: Low platelet count
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001873 | Thrombocytopenia | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies thrombocytopenia as occasional in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "134 (13.4%) thrombocytopenia"
    explanation: Euro-Lupus cohort found thrombocytopenia in 13.4% of 1,000 SLE patients over 10 years.
  - reference: PMID:32896257
    reference_title: "Prevalence and outcome of thrombocytopenia in systemic lupus erythematous: single-centre cohort analysis."
    supports: SUPPORT
    snippet: Thrombocytopenia was classified as mild (100-149x109/L), moderate (31-99x109/L) or severe (</=30x109/L platelets).
    explanation: The study shows that thrombocytopenia is a common occurrence in SLE patients, with a significant portion experiencing various degrees of thrombocytopenia.
  - reference: PMID:12481500
    reference_title: "[Hematological abnormalities in patients with systemic lupus erythematosus]."
    supports: SUPPORT
    snippet: Thrombocytopenia is common, autoimmune and associated with a decreased survival.
    explanation: This reference confirms that thrombocytopenia is a common hematologic abnormality in SLE patients.
  - reference: PMID:15580984
    reference_title: "Review of ACR hematologic criteria in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Thrombocytopenia (< 100,000/microL in the absence of offending drugs) is now considered as a single hematologic disorder.
    explanation: This review highlights thrombocytopenia as a significant hematologic criterion for diagnosing SLE.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Hematologic
  frequency: OCCASIONAL
  name: Hemolytic Anemia
  notes: Destruction of red blood cells
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001878 | Hemolytic anemia | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies hemolytic anemia as occasional in SLE.
  - reference: PMID:12481500
    reference_title: "[Hematological abnormalities in patients with systemic lupus erythematosus]."
    supports: SUPPORT
    snippet: 'Anaemia is the most common hematological abnormality in SLE, it is multifactorial. The most common form of anaemia is that of chronic disease, and it is relate with inflammatory cytokines. Other tips of anaemia are: iron deficiency anaemia, autoimmune haemolytic anaemia, pure red cell aplasia.'
    explanation: The abstract lists autoimmune hemolytic anemia among the anemias occurring in SLE, supporting the disease-phenotype association; it does not quantify its frequency.
  - reference: PMID:36469203
    reference_title: "Circulating Levels of Hypoxia-regulating MicroRNAs in Systemic Lupus Erythematosus Patients with Hemolytic Anemia."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that would potentiate many pathological complications, including hemolytic anemia.
    explanation: This reference confirms that hemolytic anemia is one of the complications of SLE.
  - reference: PMID:15580984
    reference_title: "Review of ACR hematologic criteria in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: 'In the updated 1982 ACR criteria, the presence of one or more of the four elements: 1) hemolytic anemia (with reticulocytosis)... is now considered as a single hematologic disorder.'
    explanation: The ACR criteria for diagnosing SLE includes hemolytic anemia as one of the hematologic disorders.
  - reference: PMID:30631001
    reference_title: "Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus."
    supports: SUPPORT
    snippet: One month prior, she had been diagnosed with Evans syndrome (haemolytic anemia with positive Coombs test and thrombocytopenia)... Further examination revealed positive for ANA, anti-SSA, and diagnosis of SLE was established.
    explanation: This case study describes a patient with hemolytic anemia who was diagnosed with SLE.
  phenotype_term:
    preferred_term: Hemolytic Anemia
    term:
      id: HP:0001878
      label: Hemolytic anemia
- category: Cardiac
  frequency: OCCASIONAL
  name: Pericarditis
  notes: Inflammation of the pericardium (lining around the heart)
  evidence:
  - reference: PMID:16218467
    reference_title: "Cardiac involvement in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Pericarditis is the most common cardiac abnormality in systemic lupus erythematosus (SLE) patients...
    explanation: Confirms pericarditis as the most common cardiac abnormality in SLE, supporting it as a recognized cardiac manifestation (the "most common cardiac" ranking is compatible with an overall occasional per-patient frequency).
  - reference: PMID:31507126
    reference_title: "The Heart Matters: Contribution of Genetic Factors in Recurrent Pericarditis."
    supports: SUPPORT
    snippet: Several diseases are frequently associated with such manifestations. They include systemic lupus erythematosus...
    explanation: Lists systemic lupus erythematosus among diseases frequently associated with pericarditis, supporting the SLE-pericarditis association.
  - reference: PMID:33216192
    reference_title: "[Pericarditis is inflammation of the pericardium, which rheumatologists should know]."
    supports: SUPPORT
    snippet: Pericarditis can be present in the context of systemic inflammatory rheumatic diseases...
    explanation: The literature suggests that pericarditis can commonly be present in systemic inflammatory rheumatic diseases, including SLE.
  phenotype_term:
    preferred_term: Pericarditis
    term:
      id: HP:0001701
      label: Pericarditis
- category: Pulmonary
  frequency: OCCASIONAL
  name: Pleuritis
  notes: Inflammation of the pleura (lining around the lungs)
  evidence:
  - reference: PMID:8153398
    reference_title: "Pleuropulmonary manifestations of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: The pleuropulmonary manifestation of systemic lupus erythematous (SLE) are pleuritis, acute lupus pneumonitis, chronic interstitial lung disease with fibrosis, alveolar hemorrhage, respiratory muscle and diaphragmatic dysfunction, atelectasis, bronchiolitis obliterans, pulmonary vascular disease with pulmonary hypertension, and pulmonary embolism.
    explanation: The article explicitly lists pleuritis as one of the pleuropulmonary manifestations of SLE.
  - reference: PMID:25318967
    reference_title: "Characteristics of pleural effusions in systemic lupus erythematosus: differential diagnosis of lupus pleuritis."
    supports: SUPPORT
    snippet: We investigated the clinical characteristics of pleural effusion in systemic lupus erythematosus (SLE). A prospective analysis of 17 SLE patients with pleural effusion (seven lupus pleuritis, eight transudative effusions and two parapneumonic effusions) was performed.
    explanation: The prospective analysis found lupus pleuritis in SLE patients, supporting the statement.
  - reference: PMID:12055395
    reference_title: "Diagnosis and management of lupus pleuritis."
    supports: SUPPORT
    snippet: Fortunately, pleuritis in systemic lupus erythematosus is not usually as life threatening as may be the renal or central nervous system complications. Nevertheless, pleuritis does occur in systemic lupus erythematosus and may be a significant cause of morbidity.
    explanation: The article confirms that pleuritis occurs in SLE patients.
  phenotype_term:
    preferred_term: Pleuritis
    term:
      id: HP:0002102
      label: Pleuritis
- category: Neuropsychiatric
  frequency: OCCASIONAL
  name: Seizures
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies seizures as occasional in SLE.
  - reference: PMID:33626435
    reference_title: "Seizures in systemic lupus erythematosus: A scoping review."
    supports: SUPPORT
    snippet: The prevalence of explicit episodes of seizures among SLE patients, varies from 2 to 8%.
    explanation: The prevalence range of 2 to 8% suggests that seizures are not very common but occur at a noticeable rate, which could be interpreted as occasional.
  - reference: PMID:12136236
    reference_title: "SLEB3 in systemic lupus erythematosus (SLE) is strongly related to SLE families ascertained through neuropsychiatric manifestations."
    supports: SUPPORT
    snippet: Seizures and psychosis are neuropsychiatric (NP) manifestations of a large number of systemic lupus erythematosus (SLE) patients.
    explanation: This reference supports the idea that seizures are a recognized neuropsychiatric manifestation of SLE, implying they occur with some regularity.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
- category: Neuropsychiatric
  frequency: OCCASIONAL
  name: Psychosis
  evidence:
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    snippet: Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has a significant negative impact on health status.
    explanation: The study indicates that psychosis is an infrequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), which suggests it is not common but does occur occasionally. This partially supports the statement that psychosis is an 'occasional' manifestation.
  - reference: PMID:37771217
    reference_title: "Psychosis Unmasking a Diagnosis of Systemic Lupus Erythematosus: a Case Report."
    supports: SUPPORT
    snippet: Psychosis is a rare NPSLE manifestation that can occur at any phase of the illness; 21% of SLE-related psychosis cases occur at the onset of SLE.
    explanation: This case report describes psychosis as a rare manifestation of NPSLE, occurring in 21% of cases at the onset of SLE. While 'rare' and 'occasional' are not identical, they both imply infrequency, partially supporting the statement.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
- category: Neuropsychiatric
  frequency: OCCASIONAL
  name: Depression
  description: Depression is a common neuropsychiatric manifestation in SLE patients.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000716 | Depression | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies depression as occasional in SLE.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
- category: Neuropsychiatric
  frequency: VERY_RARE
  name: Chorea
  description: Rare movement disorder in SLE, associated with antiphospholipid antibodies.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002072 | Chorea | Very rare (<4-1%)"
    explanation: Orphanet phenotype table classifies chorea as very rare in SLE.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
- category: Constitutional
  frequency: VERY_FREQUENT
  name: Fatigue
  description: >-
    Fatigue is one of the most prevalent and debilitating symptoms of SLE,
    reported by the vast majority of patients and often persisting even during
    disease remission.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012378 | Fatigue | Very frequent (99-80%)"
    explanation: Orphanet phenotype table classifies fatigue as very frequent in SLE.
  - reference: PMID:30488801
    reference_title: "Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Constitutional symptoms were found in 48.68 of SLE population including fatigue in 35.22%"
    explanation: Oman cohort reports fatigue at initial presentation in 35.22%, below the Very Frequent (80-99%) band; supports association but not the frequency classification.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Constitutional
  frequency: VERY_FREQUENT
  name: Fever
  description: Fever is common in SLE, occurring both as a disease manifestation and during flares.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001945 | Fever | Very frequent (99-80%)"
    explanation: Orphanet phenotype table classifies fever as very frequent in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "166 (16.6%) fever"
    explanation: Euro-Lupus cohort found fever in 16.6% over 10-year follow-up, well below the Very Frequent (80-99%) band; supports association but not the frequency classification.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Constitutional
  frequency: VERY_FREQUENT
  name: Weight Loss
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001824 | Weight loss | Very frequent (99-80%)"
    explanation: Orphanet phenotype table classifies weight loss as very frequent in SLE.
  - reference: PMID:30488801
    reference_title: "Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "weight changes in 13.43%"
    explanation: Oman cohort reports weight changes at 13.43%, well below the Very Frequent (80-99%) band, and the term is imprecise (weight changes vs weight loss); supports association but not the frequency classification.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Constitutional
  frequency: VERY_FREQUENT
  name: Malaise
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0033834 | Malaise | Very frequent (99-80%)"
    explanation: Orphanet phenotype table classifies malaise as very frequent in SLE.
  phenotype_term:
    preferred_term: Malaise
    term:
      id: HP:0033834
      label: Malaise
- category: Constitutional
  frequency: VERY_FREQUENT
  name: Anorexia
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002039 | Anorexia | Very frequent (99-80%)"
    explanation: Orphanet phenotype table classifies anorexia (decreased appetite) as very frequent in SLE.
  phenotype_term:
    preferred_term: Anorexia
    term:
      id: HP:0002039
      label: Anorexia
- category: Cutaneous
  frequency: FREQUENT
  name: Alopecia
  description: Non-scarring hair loss is common in SLE. Scarring alopecia occurs in discoid lupus.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001596 | Alopecia | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies alopecia as frequent in SLE.
  - reference: PMID:30488801
    reference_title: "Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hair loss 39.29%"
    explanation: Oman cohort reports hair loss at initial presentation in 39.29% of SLE patients.
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
- category: Cutaneous
  frequency: OCCASIONAL
  name: Discoid Lupus Rash
  description: Chronic cutaneous lupus with disc-shaped erythematous patches that may cause scarring.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007417 | Discoid lupus rash | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies discoid lupus rash as occasional in SLE.
  - reference: PMID:30488801
    reference_title: "Systemic Lupus Erythematosus: Symptoms and Signs at Initial Presentations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "discoid lupus 17.63%"
    explanation: Oman cohort reports discoid lupus at initial presentation in 17.63% of SLE patients.
  phenotype_term:
    preferred_term: Discoid lupus rash
    term:
      id: HP:0007417
      label: Discoid lupus rash
- category: Vascular
  frequency: FREQUENT
  name: Raynaud Phenomenon
  description: Episodic vasospasm of digital arteries causing color changes (white-blue-red) in fingers and toes.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0030880 | Raynaud phenomenon | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies Raynaud phenomenon as frequent in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "163 (16.3%) Raynaud phenomenon"
    explanation: Euro-Lupus cohort found Raynaud phenomenon in 16.3%, below the Frequent (30-79%) band; supports association but not the frequency classification.
  phenotype_term:
    preferred_term: Raynaud phenomenon
    term:
      id: HP:0030880
      label: Raynaud phenomenon
- category: Oral
  frequency: OCCASIONAL
  name: Oral Ulcers
  description: Painless or painful ulcers of the oral mucosa, one of the ACR/EULAR classification criteria.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000155 | Oral ulcer | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies oral ulcers as occasional in SLE.
  - reference: PMID:23846232
    reference_title: "Systemic lupus erythematosus in the multiethnic Malaysian population: disease expression and ethnic differences revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "oral ulcers (51%)"
    explanation: Malaysian cohort reports oral ulcers in 51%, which exceeds the Occasional (5-29%) band; supports association but not the frequency classification.
  phenotype_term:
    preferred_term: Oral ulcer
    term:
      id: HP:0000155
      label: Oral ulcer
- category: Oral
  frequency: OCCASIONAL
  name: Cheilitis
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100825 | Cheilitis | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies cheilitis as occasional in SLE.
  phenotype_term:
    preferred_term: Cheilitis
    term:
      id: HP:0100825
      label: Cheilitis
- category: Renal
  frequency: VERY_FREQUENT
  name: Proteinuria
  description: A hallmark of renal involvement in SLE, indicating glomerular damage.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000093 | Proteinuria | Very frequent (99-80%)"
    explanation: Orphanet phenotype table classifies proteinuria as very frequent in SLE.
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
- category: Renal
  frequency: FREQUENT
  name: Hematuria
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000790 | Hematuria | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies hematuria as frequent in SLE.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
- category: Renal
  frequency: FREQUENT
  name: Pyuria
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012085 | Pyuria | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies pyuria as frequent in SLE.
  phenotype_term:
    preferred_term: Pyuria
    term:
      id: HP:0012085
      label: Pyuria
- category: Cardiovascular
  frequency: FREQUENT
  name: Hypertension
  description: Common in SLE, especially in patients with lupus nephritis.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000822 | Hypertension | Frequent (79-30%)"
    explanation: Orphanet phenotype table classifies hypertension as frequent in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "169 (16.9%) hypertension"
    explanation: Euro-Lupus cohort found hypertension in 16.9%, below the Frequent (30-79%) band; supports association but not the frequency classification.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
- category: Serosal
  frequency: OCCASIONAL
  name: Serositis
  description: Inflammation of serous membranes (pleura, pericardium, peritoneum).
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0045073 | Serositis | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies serositis as occasional in SLE.
  - reference: PMID:14530779
    reference_title: "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "160 (16.0%) serositis (pleuritis and/or pericarditis)"
    explanation: Euro-Lupus cohort found serositis in 16.0% of patients over 10-year follow-up.
  phenotype_term:
    preferred_term: Serositis
    term:
      id: HP:0045073
      label: Serositis
- category: Lymphatic
  frequency: OCCASIONAL
  name: Lymphadenopathy
  description: Generalized or regional lymph node enlargement, common during active disease.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002716 | Lymphadenopathy | Occasional (29-5%)"
    explanation: Orphanet phenotype table classifies lymphadenopathy as occasional in SLE.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
- category: Ophthalmologic
  frequency: VERY_RARE
  name: Retinopathy
  description: Lupus retinopathy involving retinal vasculitis or vaso-occlusive changes.
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000488 | Retinopathy | Very rare (<4-1%)"
    explanation: Orphanet phenotype table classifies retinopathy as very rare in SLE.
  phenotype_term:
    preferred_term: Retinopathy
    term:
      id: HP:0000488
      label: Retinopathy
biochemical:
- name: Anti-Nuclear Antibodies (ANA)
  specificity: High
  frequency: 98%
  presence: Positive
  evidence:
  - reference: PMID:32884126
    reference_title: "New insights into the role of antinuclear antibodies in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction.
    explanation: While ANAs are indeed characteristic of SLE, the specific frequency (98%) mentioned in the statement is not detailed in the provided literature.
  - reference: PMID:34996081
    reference_title: "Anti-Nuclear Antibody Quantitation: Calibration and Harmonization Adjustment via Population Interrogation."
    supports: SUPPORT
    snippet: The 2019 classification criteria for systemic lupus erythematosus (SLE) includes an initial criterion requiring the presence of an antinuclear antibody (ANA), positive at a titer of at least 1:80 on HEp-2 cells, or equivalent.
    explanation: The criteria confirm the importance of ANA for SLE diagnosis, but do not explicitly confirm a 98% frequency rate.
  - reference: PMID:23456415
    reference_title: "Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital."
    supports: SUPPORT
    snippet: Antinuclear antibody was present in 79.6%.
    explanation: This report lists a frequency different from 98%, but supports the general relevance of ANA in SLE.
  - reference: PMID:22301032
    reference_title: "Pediatric systemic lupus erythematosus: more than a positive antinuclear antibody."
    supports: SUPPORT
    snippet: Based on some research evidence and consensus, the diagnosis of pSLE is unlikely if the ANA is negative, and most patients with SLE have a positive ANA at a titer ≥1:160
    explanation: While the statement indicates the common presence of ANA in SLE, it does not confirm the 98% figure.
- name: Anti-dsDNA Antibodies
  specificity: High
  presence: Positive
  evidence:
  - reference: PMID:29224677
    reference_title: "Diagnostic and prognostic tests in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens.
    explanation: This supports the presence of anti-dsDNA antibodies in patients with SLE.
  - reference: PMID:20414746
    reference_title: "Glomerular antibodies in lupus nephritis."
    supports: SUPPORT
    snippet: Lupus nephritis (LN) remains the most common severe manifestation of systemic lupus erythematosus (SLE) characterized by the presence of autoantibodies (Abs) that are believed to play a central role in the pathogenesis of LN.
    explanation: This confirms the involvement of autoantibodies, including anti-dsDNA, in SLE and specifically lupus nephritis.
  - reference: PMID:35049409
    reference_title: "IgA anti-dsDNA antibodies: A neglected serological parameter in systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Anti-double-stranded DNA (anti-dsDNA) autoantibodies are archetypal biomarkers found in systemic lupus erythematosus (SLE).
    explanation: This directly supports the presence and diagnostic role of anti-dsDNA antibodies in SLE.
  - reference: PMID:2203596
    reference_title: "Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: The prevalence of anti-dsDNA antibodies was strongly influenced by the selection criteria of the patient.
    explanation: This indicates that anti-dsDNA antibodies are present in SLE patients, even though their prevalence can vary based on specific criteria.
- name: Anti-Smith Antibodies
  specificity: High
  presence: Positive
  evidence:
  - reference: PMID:29503043
    reference_title: "Origins and specificity of auto-antibodies in Sm+ SLE patients."
    supports: SUPPORT
    snippet: One unique SLE target is the Smith antigen (Sm), a nuclear ribonucleoprotein complex. Sm response occurs in 25% of patients with SLE.
    explanation: The Smith antigen is a specific target in SLE, and the presence of anti-Smith antibodies (Sm) is marked, indicating high specificity.
- name: Anti-Histone Antibodies
  notes: Common in drug-induced lupus.
  presence: Positive
  evidence:
  - reference: PMID:35383534
    reference_title: "Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus."
    supports: SUPPORT
    snippet: Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE).
    explanation: The literature specifically mentions the presence of anti-histone antibodies in systemic lupus erythematosus and drug-induced lupus erythematosus.
  - reference: PMID:35383534
    reference_title: "Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus."
    supports: SUPPORT
    snippet: AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs.
    explanation: While anti-histone antibodies are present in drug-induced lupus, their prevalence is reducing with the use of modern biological agents.
genetic:
- name: HLA-DR2
  presence: Positive
  evidence:
  - reference: PMID:37801591
    reference_title: "HLA-DR genotypes in patients with systemic lupus erythematosus in Taiwan."
    supports: SUPPORT
    snippet: HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis)
    explanation: The study indicates that HLA-DR2 is associated with an increased susceptibility to SLE in the Taiwanese population.
- name: HLA-DR3
  presence: Positive
  evidence:
  - reference: PMID:17910142
    reference_title: "Antinuclear antibodies and HLA class II alleles in Jamaican patients with systemic lupus erythematosus."
    supports: SUPPORT
    snippet: A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01).
    explanation: The study finds a significant association between HLA-DR3 and the presence of anti-Ro/La antibodies in SLE patients, though it does not establish that HLA-DR3 alone is a genetic risk factor for SLE.
  - reference: PMID:6103441
    reference_title: "Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility."
    supports: NO_EVIDENCE
    snippet: It was also noted that the distribution of DR antigens in the hydralazine-SLE patients was significantly different from that in the group with idiopathic SLE.
    explanation: This study highlights differences in HLA-DR distribution between drug-induced SLE and idiopathic SLE, but it does not specifically address the genetic contribution of HLA-DR3 to idiopathic SLE.
- name: PTPN22
  gene_term:
    preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  association: Associated
  evidence:
  - reference: PMID:31232672
    reference_title: "PTPN22 Gene Polymorphisms in Pediatric Systemic Lupus Erythematosus."
    supports: SUPPORT
    snippet: We found that the PTPN22 polymorphisms rs1310182 A allele (p = 0.01, OR = 1.92 95% CI = 1.16-3.18), and rs1310182 AA genotype with (p < 0.001) and rs12760457 TT (p = 0.046) were associated with PSLE.
    explanation: The study indicates that certain polymorphisms in the PTPN22 gene are associated with pediatric systemic lupus erythematosus (PSLE), supporting the genetic association between PTPN22 and SLE.
- name: STAT4
  gene_term:
    preferred_term: STAT4
    term:
      id: hgnc:11365
      label: STAT4
  association: Associated
  evidence:
  - reference: PMID:23912645
    reference_title: "Association of STAT4 rs7574865 with susceptibility to systemic lupus erythematosus in Iranian population."
    supports: SUPPORT
    snippet: Our results showed a significant association between rs7574865 T allele (odds ratio (OR) = 1.50, 95 % CI = 1.18-1.92, P = 0.002) and susceptibility to SLE.
    explanation: The study found a significant association between the STAT4 gene (specifically rs7574865) and susceptibility to SLE.
  - reference: PMID:31082500
    reference_title: "Investigation of systemic lupus erythematosus (SLE) with integrating transcriptomics and genome wide association information."
    supports: SUPPORT
    snippet: Analysis of existing transcriptomes and GWAS data identified eight up-regulated candidate genes with more than four relationships among the different pathways associated with SNPs to pinpoint the relevant loci linked to SLE... STAT4...
    explanation: This study identified STAT4 as one of the candidate genes associated with SLE through transcriptomic data analysis and pathway analysis of GWAS data.
  - reference: PMID:34525002
    reference_title: "Genetic Polymorphisms in Patients With Systemic Lupus Erythematosus and Jaccoud Arthropathy: A Pilot Study."
    supports: NO_EVIDENCE
    snippet: 'The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. METHODS: Patients were selected from a cohort of individuals with SLE followed at 2 rheumatology reference centers in Salvador, Bahia, Brazil.'
    explanation: The study aimed to evaluate the association between STAT4 polymorphisms and the presence of Jaccoud Arthropathy in individuals with SLE, implying an association between STAT4 and SLE.
- name: IRF5
  gene_term:
    preferred_term: IRF5
    term:
      id: hgnc:6120
      label: IRF5
  association: Associated
  notes: Interferon regulatory factor 5; transcription factor driving type I interferon pathway activation
  evidence:
  - reference: PMID:20962850
    reference_title: "A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles."
    supports: SUPPORT
    snippet: Our results replicate previously reported associations to alleles of interferon regulatory factor 5 (IRF5)... This study confirms the existence of multiple genetic risk factors for SLE...
    explanation: The study clearly identifies IRF5 as one of the genetic risk factors associated with SLE.
  - reference: PMID:26233721
    reference_title: "Association of the IRF5 rs2070197 polymorphism with systemic lupus erythematosus: a meta-analysis."
    supports: SUPPORT
    snippet: This meta-analysis demonstrated the IRF5 rs2070197 polymorphism conferred susceptibility to SLE in all subjects... The IRF5 rs2070197 polymorphism was identified as risk factors for SLE...
    explanation: The meta-analysis confirms the association of IRF5 polymorphism with SLE in multiple populations.
  - reference: PMID:23251221
    reference_title: "Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Interferon regulatory factor 5 (IRF5) is a transcription factor which... genetic variants of IRF5 have been strongly linked to SLE pathogenesis.
    explanation: The paper discusses the role of IRF5 in SLE pathogenesis and confirms its genetic association with the disease.
  - reference: PMID:20453440
    reference_title: "Association of IRF5, STAT4 and BLK with systemic lupus erythematosus and other rheumatic diseases."
    supports: SUPPORT
    snippet: Recent large-scale studies in the Caucasian populations identified many new susceptibility genes to systemic lupus erythematosus (SLE)... In IRF5, the risk haplotype in Caucasians was not present in Japanese... All of these genes were associated with SLE...
    explanation: The study confirms that IRF5 is associated with SLE in both Caucasian and Japanese populations.
  - reference: PMID:36245280
    reference_title: "Integrative Functional Genomics Identifies Systemic Lupus Erythematosus Causal Genetic Variant in the IRF5 Risk Locus."
    supports: SUPPORT
    snippet: IRF5 plays a crucial role in the development of lupus... Genome-wide association studies have identified several systemic lupus erythematosus (SLE) risk single-nucleotide polymorphisms (SNPs) enriched in the IRF5 locus.
    explanation: The study identifies IRF5 as playing a key role in SLE development with confirmed risk SNPs.
- name: TLR7
  gene_term:
    preferred_term: TLR7
    term:
      id: hgnc:15631
      label: TLR7
  association: Associated
  notes: Toll-like receptor 7; B cell-intrinsic driver promoting RNA-associated autoantibodies and disease activity
- name: TLR9
  gene_term:
    preferred_term: TLR9
    term:
      id: hgnc:15633
      label: TLR9
  association: Associated
  notes: Toll-like receptor 9; can exert counter-regulatory effects, restraining age-associated B cell differentiation
- name: MYD88
  gene_term:
    preferred_term: MYD88
    term:
      id: hgnc:7562
      label: MYD88
  association: Associated
  notes: Myeloid differentiation primary response 88; adaptor protein downstream of TLR7/9 required for autoantibody production
- name: CYBB
  gene_term:
    preferred_term: CYBB
    term:
      id: hgnc:2578
      label: CYBB
  association: Associated
  notes: Cytochrome b-245 beta chain (NOX2); NOX2-generated ROS negatively regulate TLR7 signaling; loss exacerbates disease
- name: TNFSF13B
  gene_term:
    preferred_term: TNFSF13B
    term:
      id: hgnc:11929
      label: TNFSF13B
  association: Associated
  notes: TNF superfamily member 13b (BAFF); supports B cell survival and extrafollicular responses integrated with IFN/Tfh circuits
- name: IL21
  gene_term:
    preferred_term: IL21
    term:
      id: hgnc:6005
      label: IL21
  association: Associated
  notes: Interleukin 21; Tfh-derived cytokine driving B cell differentiation to plasma cells
- name: BACH2
  gene_term:
    preferred_term: BACH2
    term:
      id: hgnc:14078
      label: BACH2
  association: GWAS
  notes: Transcription factor regulating Treg/effector T cell balance and B cell class switching
- name: TNFAIP3
  gene_term:
    preferred_term: TNFAIP3
    term:
      id: hgnc:11896
      label: TNFAIP3
  association: GWAS
  notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB signaling
- name: STAT3
  gene_term:
    preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  association: GWAS
  notes: Signal transducer mediating Th17 differentiation via JAK-STAT pathway
- name: IL10
  gene_term:
    preferred_term: IL10
    term:
      id: hgnc:5962
      label: IL10
  association: GWAS
  notes: Anti-inflammatory cytokine critical for immune tolerance
- name: EGR2
  gene_term:
    preferred_term: EGR2
    term:
      id: hgnc:3239
      label: EGR2
  association: GWAS
  notes: Transcription factor involved in T cell anergy and peripheral tolerance
- name: ETS1
  gene_term:
    preferred_term: ETS1
    term:
      id: hgnc:3488
      label: ETS1
  association: GWAS
  notes: Transcription factor regulating T and B cell development and immune cell differentiation
- name: IRF4
  gene_term:
    preferred_term: IRF4
    term:
      id: hgnc:6119
      label: IRF4
  association: GWAS
  notes: Transcription factor essential for Th17 and Th2 cell differentiation and plasma cell development
- name: IRF8
  gene_term:
    preferred_term: IRF8
    term:
      id: hgnc:5358
      label: IRF8
  association: GWAS
  notes: Interferon regulatory factor controlling myeloid cell development and type I interferon response
- name: IKZF1
  gene_term:
    preferred_term: IKZF1
    term:
      id: hgnc:13176
      label: IKZF1
  association: GWAS
  notes: Ikaros transcription factor essential for lymphocyte development and differentiation
- name: SMAD3
  gene_term:
    preferred_term: SMAD3
    term:
      id: hgnc:6769
      label: SMAD3
  association: GWAS
  notes: TGF-beta signaling mediator regulating T cell differentiation and immune tolerance
- name: REL
  gene_term:
    preferred_term: REL
    term:
      id: hgnc:9954
      label: REL
  association: GWAS
  notes: NF-kB subunit c-Rel controlling lymphocyte activation and survival
- name: PRDM1
  gene_term:
    preferred_term: PRDM1
    term:
      id: hgnc:9346
      label: PRDM1
  association: GWAS
  notes: Blimp-1 transcription factor regulating T cell and B cell terminal differentiation
- name: DNASE1
  gene_term:
    preferred_term: DNASE1
    term:
      id: hgnc:2956
      label: DNASE1
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_b71d9246-5a7e-4e81-8fc6-925181d124cd-2024-06-14T190000.000Z
    reference_title: "DNASE1 / systemic lupus erythematosus (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "DNASE1 | HGNC:2956 | systemic lupus erythematosus | MONDO:0007915 | AD | Limited"
    explanation: ClinGen classifies the DNASE1-systemic lupus erythematosus gene-disease relationship as limited with autosomal dominant inheritance.
- name: PRKCD
  gene_term:
    preferred_term: PRKCD
    term:
      id: hgnc:9399
      label: PRKCD
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_842fc2a6-9c37-47f1-8c38-bacb3880d31a-2024-10-11T190000.000Z
    reference_title: "PRKCD / systemic lupus erythematosus (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PRKCD | HGNC:9399 | systemic lupus erythematosus | MONDO:0007915 | AR | Definitive"
    explanation: ClinGen classifies the PRKCD-systemic lupus erythematosus gene-disease relationship as definitive with autosomal recessive inheritance.
- name: UNC93B1
  gene_term:
    preferred_term: UNC93B1
    term:
      id: hgnc:13481
      label: UNC93B1
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_5cd5e1c8-5047-4ea1-9045-cb5bf978613b-2025-04-09T190000.000Z
    reference_title: "UNC93B1 / systemic lupus erythematosus (Moderate)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UNC93B1 | HGNC:13481 | systemic lupus erythematosus | MONDO:0007915 | SD | Moderate"
    explanation: ClinGen classifies the UNC93B1-systemic lupus erythematosus gene-disease relationship as moderate with semidominant inheritance.
environmental:
- name: UV Exposure
  influences_mechanisms:
  - target: Flare-Ups
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The source is unusually explicit that these are two different claims:
      ultraviolet light worsens established disease, while whether it causes
      disease in the first place is unresolved. EXACERBATES records the
      supported half and declines the unsupported one.
    evidence:
    - reference: PMID:24763542
      reference_title: "Ultraviolet radiation and systemic lupus erythematosus."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE."
      explanation: >-
        States that ultraviolet exposure may exacerbate pre-existing lupus
        while noting it remains unclear whether it is a risk factor for
        developing the disease, which is exactly the distinction this effect
        value encodes.
  notes: Exacerbates disease activity.
  presence: Positive
  evidence:
  - reference: PMID:24763542
    reference_title: "Ultraviolet radiation and systemic lupus erythematosus."
    supports: SUPPORT
    snippet: While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE.
    explanation: The literature clearly states that UV radiation exposure may exacerbate pre-existing lupus, which supports the statement.
  - reference: PMID:22385883
    reference_title: "Seasonal variations of systemic lupus erythematosus flares in southern France."
    supports: SUPPORT
    snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
    explanation: The study investigates the seasonal variation in lupus flares and correlates increased flares with increased temperature and sunshine, supporting the statement that UV exposure exacerbates disease activity.
  exposure_term:
    preferred_term: UV light exposure
    term:
      id: ECTO:0000006
      label: exposure to ultraviolet radiation
- name: Infection
  influences_mechanisms:
  - target: Flare-Ups
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Graded alongside the stress link and below the existing ultraviolet one
      for the same reason: no cited sentence follows infection to a node. The
      onset arm of this exposure is deliberately not drawn separately, even
      though the entry models nucleic-acid sensing and interferon activation
      that a viral trigger would plausibly enter, because the one item that
      addresses the question says the mechanism remains to be elucidated. That
      item is carried here rather than left out, so the open question travels
      with the claim.
    evidence:
    - reference: PMID:25022358
      reference_title: "Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described."
      explanation: >-
        Reports that new mechanisms for autoimmunity triggered by Epstein-Barr
        virus and commensal microbiota have been described. It records that
        mechanisms exist without stating one.
    - reference: PMID:38146370
      reference_title: "Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated."
      explanation: >-
        States that the relationship has been suggested for decades but the
        underlying mechanism remains to be elucidated. Carried because it is
        the reason the intermediates here are recorded as unknown.
    - reference: PMID:36332998
      reference_title: "Systemic Lupus Erythematosus Risk: The Role of Environmental Factors."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "This review focuses on SLE risk potentially associated with environmental factors including infections."
      explanation: >-
        A review of environmental risk that names infections among the factors
        it covers. Category-level, and the weakest of the three.
  notes: Can trigger or worsen disease symptoms.
  presence: Positive
  evidence:
  - reference: PMID:36332998
    reference_title: "Systemic Lupus Erythematosus Risk: The Role of Environmental Factors."
    supports: SUPPORT
    snippet: This review focuses on SLE risk potentially associated with environmental factors including infections.
    explanation: The paper identifies infections as one of the environmental factors potentially associated with the risk of SLE, thereby supporting the statement that infections can trigger or worsen disease symptoms in SLE.
  - reference: PMID:25022358
    reference_title: "Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome."
    supports: SUPPORT
    snippet: New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described.
    explanation: This review mentions infections, specifically Epstein-Barr virus, as triggers for autoimmunity, which supports the notion that infections can influence SLE disease activity.
  - reference: PMID:38146370
    reference_title: "Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus."
    supports: SUPPORT
    snippet: The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated.
    explanation: This study supports the connection between infections (specifically EBV) and SLE, further establishing that infections can trigger or worsen SLE symptoms.
  exposure_term:
    preferred_term: Infectious agent exposure
    term:
      id: ECTO:3000000
      label: exposure to organism
- name: Stress
  influences_mechanisms:
  - target: Flare-Ups
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Points at the same flare node as this entry's existing ultraviolet link
      and is graded just below it: ultraviolet exposure is recorded with known
      intermediates because this entry models the apoptotic and
      nucleic-acid-sensing route it acts through, whereas nothing here follows
      psychological stress to any node. The evidence is nonetheless the
      strongest of the three items, because one is a longitudinal cohort
      measuring the outcome this node holds rather than asserting that
      environmental factors matter in general.
    evidence:
    - reference: PMID:36537191
      reference_title: "Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In a racially diverse sample of individuals with SLE, those who experienced an increase in stress had significantly worse disease activity and greater symptom burden at follow-up compared to those with stress levels that remained stable or declined."
      explanation: >-
        Cohort finding that patients whose stress increased had significantly
        worse disease activity and symptom burden at follow-up than those
        whose stress was stable or fell. Disease activity is this node.
    - reference: PMID:25216337
      reference_title: "Environmental factors, toxicants and systemic lupus erythematosus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individuals"
      explanation: >-
        States that onset and flares are triggered by various environmental
        factors in susceptible individuals. It supports the category and does
        not name this exposure.
    - reference: PMID:36535611
      reference_title: "The link between post-traumatic stress disorder and systemic lupus erythematosus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disorder characterized by unpredictable disease flares.... suggesting that stress-related disorders alter the susceptibility to SLE."
      explanation: >-
        Suggests that stress-related disorders alter susceptibility.
        Susceptibility to the disease rather than the flare this node holds.
  notes: Psychological stress can trigger flares.
  presence: Positive
  evidence:
  - reference: PMID:25216337
    reference_title: "Environmental factors, toxicants and systemic lupus erythematosus."
    supports: SUPPORT
    snippet: It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individuals
    explanation: This reference discusses various environmental factors that can trigger SLE flares, which supports the notion that stress, as an environmental factor, can do so as well.
  - reference: PMID:36537191
    reference_title: "Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort."
    supports: SUPPORT
    snippet: In a racially diverse sample of individuals with SLE, those who experienced an increase in stress had significantly worse disease activity and greater symptom burden at follow-up compared to those with stress levels that remained stable or declined.
    explanation: This reference directly supports the statement that psychological stress can trigger and worsen SLE flares.
  - reference: PMID:36535611
    reference_title: "The link between post-traumatic stress disorder and systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disorder characterized by unpredictable disease flares.... suggesting that stress-related disorders alter the susceptibility to SLE.
    explanation: This reference indicates a link between stress-related disorders and the development or worsening of SLE.
  exposure_term:
    preferred_term: Psychological stress exposure
    term:
      id: XCO:0001265
      label: stress
animal_models:
- name: MRL/lpr
  species: Mouse
  genes:
  - preferred_term: FAS
    term:
      id: hgnc:11920
      label: FAS
  genotype: MRL/lpr strain
  alleles:
  - FAS lpr
  description: genetically prone to develop lupus-like symptoms and APS
  evidence:
  - reference: PMID:25183233
    reference_title: "Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model."
    supports: SUPPORT
    snippet: Mouse models of autoimmunity, such as (NZB×NZW)F1, MRL/MpJ-Fas(lpr) (MRL-lpr) and BXSB mice, spontaneously develop systemic lupus erythematosus (SLE)-like syndromes with heterogeneity and complexity that characterize human SLE
    explanation: This excerpt supports the statement by confirming that MRL/MpJ-Fas(lpr) (MRL-lpr) mice develop SLE-like syndromes.
  - reference: PMID:38113962
    reference_title: "Fas(lpr) gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus."
    supports: SUPPORT
    snippet: Sle1 and Faslpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus
    explanation: The snippet confirms that Fas(lpr) is a lupus susceptibility locus leading to SLE manifestations.
  - reference: PMID:28078597
    reference_title: "CD95 and the MRL-lpr Mouse Model."
    supports: SUPPORT
    snippet: This is characterized by the development of arthritis and immune complex glomerulonephrosis making this strain a useful model for studying systemic lupus erythematosus.
    explanation: This excerpt supports the statement by describing the MRL-lpr strain as a useful model for studying SLE, noting the development of relevant symptoms.
  - reference: PMID:18325838
    reference_title: "Accelerated atherosclerosis in ApoE deficient lupus mouse models."
    supports: SUPPORT
    snippet: breeding the ApoE(-/-) defect onto MRL/lpr mice all caused a modest increase of atherosclerosis...
    explanation: This excerpt partially supports the statement, indicating that breeding the ApoE(-/-) defect into MRL/lpr mice results in an increase in atherosclerosis (related to APS). However, it does not explicitly conclude a genetic predisposition to APS.
- name: NZB/W F1
  species: Mouse
  background: (NZB/BlNJ x NZW/LacJ)F1/J
  evidence:
  - reference: PMID:36211391
    reference_title: "(NZW × BXSB) F1 male mice: An unusual, severe and fatal mouse model of lupus erythematosus."
    supports: SUPPORT
    snippet: The (NZW×BXSB) F1 lupus-prone male mouse model of this disease is potentially useful to study mechanism and treatment modalities, but there is a lack of information about this model's characterization and disease progression
    explanation: The reference discusses the (NZWxBXSB) F1 model rather than the (NZB/BlNJ x NZW/LacJ) F1/J model.
  - reference: PMID:31943822
    reference_title: "DNA Vaccination With Hsp70 Protects Against Systemic Lupus Erythematosus in (NZB × NZW)F1 Mice."
    supports: SUPPORT
    snippet: 'METHODS: Lupus-prone (NZB × NZW)F1 mice that had been DNA-vaccinated with plasmids encoding Hsp70 and controls were monitored for lupus disease parameters including anti-double stranded DNA (anti-dsDNA) autoantibodies and cytokines using enzyme-linked immunosorbent assay, and for kidney function and pathology'
    explanation: This reference supports the use of (NZB x NZW)F1 mice as a model for SLE.
discussions:
- discussion_id: gap_sle_interferon_trigger_persistence_tissue_specificity
  prompt: >-
    Which upstream nucleic-acid trigger first ignites type I interferon in SLE,
    which immune-complex, pDC, B-cell, NET, cGAS-STING, and complement loops
    maintain it, and which tissue-local variables determine nephritis versus
    cutaneous, CNS, hematologic, vascular, or serosal injury?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#nucleic_acid_immune_complex_interferon_tissue_injury_model
  - pathophysiology#Type I Interferon Pathway Activation
  - pathophysiology#TLR7/TLR9-Mediated Nucleic Acid Sensing
  - pathophysiology#Nucleic Acid Immune Complex-pDC Endosomal Loop
  - pathophysiology#Cytosolic cGAS-STING DNA Sensing
  - pathophysiology#NETosis and Neutrophil Extracellular Trap Formation
  - pathophysiology#Complement Pathway Dysregulation
  - pathophysiology#Glomerular Immune Complex Deposition
  - phenotypes#Lupus Nephritis
  rationale: >-
    The entry now models a canonical loop in which nucleic-acid immune complexes,
    NET-derived self-antigens, plasmacytoid dendritic-cell TLR signaling, B-cell
    autoantibody production, and complement handling converge on sustained type I
    interferon and immune-complex inflammation. The unresolved curation problem
    is not whether this loop exists, but how to assign patient- and organ-specific
    causal priority: high IFN can precede disease and associate with nephritis,
    pDC endosomal sensing and cytosolic cGAS-STING sensing can both produce
    interferon, but immune-complex deposition alone is insufficient for
    proliferative renal disease, and the same systemic autoantibody/IFN
    background can present as skin, CNS, hematologic, vascular, serosal, or
    kidney-predominant SLE.
  evidence:
  - reference: PMID:33246136
    reference_title: "Type I interferon in the pathogenesis of systemic lupus erythematosus."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the specific triggers of type I IFN production, the mechanisms by which IFNs help perpetuate the cycle of autoreactive cells and autoantibody production are not completely clear."
    explanation: This directly supports the trigger and persistence portion of the SLE interferon knowledge gap.
  - reference: PMID:22192660
    reference_title: "Mechanisms of tissue injury in lupus nephritis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Deposition of ICs, however, is not sufficient for disease expression"
    explanation: This supports keeping organ-specific downstream injury as an open modeling problem rather than a simple immune-complex-deposition edge.
  - reference: PMID:35872103
    reference_title: "Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the underlying mechanisms of autoantibody-induced tissue damage and systemic inflammation are still not fully understood."
    explanation: This supports the broader unresolved mechanism of autoantibody-linked systemic and tissue damage.
  proposed_experiments:
  - experiment_id: exp_sle_longitudinal_flare_paired_tissue_ifn_loop
    name: Longitudinal flare and paired-tissue interferon-loop cohort
    description: >-
      Enroll autoantibody-positive at-risk individuals and established SLE
      patients before, during, and after flares, with oversampling of nephritis,
      cutaneous, CNS, hematologic, and serosal presentations. Combine serial
      serum immune-complex/NET/complement measurements, pDC and B-cell single-cell
      profiles, IFN-stimulated gene scores, autoantibody repertoires, and paired
      renal, skin, blood, urine, and CSF readouts where clinically available.
      The design should test whether the first measurable IFN rise follows a
      specific nucleic-acid source, whether B-cell and complement states maintain
      the loop after onset, and whether tissue-local programs explain organ
      selection.
    experiment_type:
      preferred_term: longitudinal multimodal cohort study
    assays:
    - preferred_term: peripheral blood single-cell RNA sequencing
    - preferred_term: interferon-stimulated gene expression profiling
    - preferred_term: autoantibody repertoire profiling
    - preferred_term: serum complement biomarker profiling
    - preferred_term: neutrophil extracellular trap quantification
    - preferred_term: cGAS-STING pathway activation profiling
    - preferred_term: paired kidney and skin biopsy transcriptomics
    readouts:
    - name: Interferon ignition temporal precedence
      target: pathophysiology#Type I Interferon Pathway Activation
      description: >-
        Time-resolved IFN-stimulated gene scores, serum IFN-alpha/protein
        markers, pDC activation state, and preceding infection, UV, NET, apoptotic
        debris, or immune-complex measurements.
      direction: POSITIVE
      interpretation: >-
        IFN elevation after a specific nucleic-acid or immune-complex signal would
        support that trigger as upstream; IFN elevation before measurable
        immune-complex/NET changes would require a separate initiating mechanism.
    - name: Autoreactive B-cell and immune-complex persistence
      target: pathophysiology#Formation of Immune Complexes
      description: >-
        Longitudinal autoreactive B-cell clones, plasma-cell signatures,
        autoantibody titers, immune-complex burden, and complement consumption
        modeled relative to IFN activity and flare resolution.
      direction: POSITIVE
      interpretation: >-
        Persistent B-cell/immune-complex activity after IFN normalization would
        support a self-maintaining adaptive loop; collapse after IFNAR blockade
        or IFN-score decline would support IFN-dependent maintenance.
    - name: Organ-specific injury selection
      target: phenotypes#Lupus Nephritis
      description: >-
        Tissue and biofluid readouts comparing nephritis with skin, CNS,
        hematologic, vascular, and serosal-predominant disease for local
        complement activation, Fc receptor/TLR signaling, endothelial injury,
        resident-cell IFN response, chemokine recruitment, and repair/fibrosis
        programs.
      direction: POSITIVE
      interpretation: >-
        Organ-restricted signatures that predict nephritis independently of
        systemic IFN and autoantibody burden would support separate downstream
        tissue-injury modules.
    controls:
    - name: Autoantibody-positive non-SLE controls
      description: Individuals with antinuclear or anti-Ro/La antibodies but no classified SLE.
    - name: IFN-low SLE controls
      description: Established SLE patients without a high interferon-stimulated gene signature.
    decision_criterion: >-
      Revise the pathophysiology graph according to which signal reproducibly
      precedes IFN onset, which loop persists after clinical flare resolution,
      and which tissue-local readouts predict nephritis or other organ injury
      after controlling for systemic IFN score and autoantibody burden.
- discussion_id: gap_sle_cuproptosis_evidence_hierarchy
  prompt: >-
    Is canonical cuproptosis - copper-dependent, FDX1-lipoylation-driven
    regulated cell death - an actual causal mechanism in lupus lesions and lupus
    immune cells, or is the reported copper signal only a correlative
    transcriptomic and metabolic-stress marker that should stay out of the SLE
    pathograph until the canonical criteria are demonstrated in vivo?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Epigenetic Dysregulation and T Cell Metabolic Reprogramming
  - pathophysiology#Impaired Apoptotic Cell Clearance
  rationale: >-
    SLE is one of the two systemic autoimmune diseases named in the
    cuproptosis-in-autoimmunity literature, and copper dysregulation,
    mitochondrial stress, and immunometabolic remodeling are all reported in
    lupus. This entry deliberately does NOT model cuproptosis as a mechanism
    node, because the published SLE evidence is transcriptomic association and
    public-dataset mining rather than demonstration of the canonical criteria
    (copper dependence, FDX1-lipoylation involvement, lipoylated-protein
    aggregation, Fe-S cluster destabilization, and functional rescue). The gap
    matters for two existing nodes: T cell metabolic reprogramming already
    carries an immunometabolic claim that a copper-dependent mitochondrial
    mechanism would either extend or compete with, and impaired apoptotic-cell
    clearance is the entry's autoantigen-supply node, which a distinct
    copper-dependent regulated-cell-death route would add to rather than
    replace. The entry's other regulated-cell-death node, NETosis and
    neutrophil extracellular trap formation, is the closest structural analog
    for a cuproptosis claim but is deliberately NOT attached: the source's
    immune-cell analysis covers macrophages, dendritic cells and T cells and
    does not extend to neutrophils, so attaching the gap there would assert a
    cell-type scope the evidence does not carry. Recording this as an open gap
    keeps the mechanism visible to curators without asserting a cell-death
    pathway the source itself declines to confirm.
  evidence:
  - reference: PMID:42435071
    reference_title: "From copper imbalance to immunometabolic remodeling: cuproptosis-related vulnerability and therapeutic hypotheses in autoimmune diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      direct in vivo evidence of canonical cuproptosis in autoimmune lesions
      remains scarce, and most relevant studies rely on transcriptomic
      associations, public dataset mining, or model-dependent experiments
    explanation: >-
      States the evidence-hierarchy gap directly - the reason this entry records
      cuproptosis as an open question rather than as a pathophysiology node.
  - reference: PMID:42435071
    reference_title: "From copper imbalance to immunometabolic remodeling: cuproptosis-related vulnerability and therapeutic hypotheses in autoimmune diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      systemic AIDs (e.g., systemic lupus erythematosus, rheumatoid arthritis)
      and organ-specific AIDs (e.g., inflammatory bowel disease, ankylosing
      spondylitis) were summarized. Findings mostly reflected copper-associated
      metabolic stress or susceptibility markers rather than definitive
      functional activation.
    explanation: >-
      Names systemic lupus erythematosus specifically, and characterizes what the
      lupus-relevant findings actually show - metabolic stress or susceptibility
      markers, not demonstrated functional activation.
  - reference: PMID:42435071
    reference_title: "From copper imbalance to immunometabolic remodeling: cuproptosis-related vulnerability and therapeutic hypotheses in autoimmune diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      immunometabolic regulatory roles of cuproptosis in immune cells-including
      macrophages, dendritic cells, and T cells-were analyzed, highlighting that
      their effects are cell-type and context dependent
    explanation: >-
      Supports attaching the gap to the T cell metabolic reprogramming node while
      warning that any resolution will be cell-type specific rather than a single
      disease-level edge.
  - reference: PMID:42435071
    reference_title: "From copper imbalance to immunometabolic remodeling: cuproptosis-related vulnerability and therapeutic hypotheses in autoimmune diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Current research on cuproptosis in AIDs is largely correlative,
      bioinformatic, or model dependent, and is insufficient to confirm canonical
      cuproptosis as a primary pathogenic mechanism in AIDs
    explanation: >-
      The review's own conclusion, and the explicit justification for leaving
      this out of the causal graph.
  proposed_experiments:
  - experiment_id: exp_sle_canonical_cuproptosis_criteria_in_lesional_tissue
    name: Canonical-cuproptosis criteria applied to lupus nephritis biopsies and matched immune cells
    description: >-
      Apply the five canonical cuproptosis criteria directly to
      disease-relevant human lupus material rather than to transcriptomic
      surrogates: measure tissue and intracellular copper in lupus nephritis
      biopsies and matched peripheral immune subsets, assay FDX1 protein and
      lipoylated DLAT/DLST aggregation in situ, quantify Fe-S cluster protein
      destabilization, and test copper-chelation and copper-ionophore rescue in
      a lupus-prone mouse model with the same biochemical panel read out in
      kidney. Stratify by interferon score and disease activity so that any
      copper signal can be separated from a generic inflammatory or
      metabolic-stress correlate.
    experiment_type:
      preferred_term: mechanism validation study with biochemical and in vivo arms
    assays:
    - preferred_term: tissue and intracellular copper quantification
    - preferred_term: FDX1 immunoblot and in situ protein detection
    - preferred_term: lipoylated protein aggregation assay
    - preferred_term: Fe-S cluster protein stability assay
    - preferred_term: copper chelator and ionophore rescue in lupus-prone mice
    readouts:
    - name: Copper dependence of lesional cell death
      target: pathophysiology#Impaired Apoptotic Cell Clearance
      description: >-
        Copper content in lesional kidney and immune subsets paired with
        cell-death burden, and the change in that burden under chelation.
      direction: INCREASED
      interpretation: >-
        A copper burden that tracks lesional cell death and falls with chelation
        would satisfy the copper-dependence criterion; an unchanged death burden
        would place the copper signal downstream or incidental.
    - name: FDX1-lipoylation axis engagement in situ
      target: pathophysiology#Epigenetic Dysregulation and T Cell Metabolic Reprogramming
      description: >-
        FDX1 protein level, lipoylated DLAT/DLST aggregate formation, and Fe-S
        cluster protein destabilization measured in the same lesional and
        immune-cell material.
      direction: ALTERED
      interpretation: >-
        Concordant FDX1-dependent lipoylated-protein aggregation with Fe-S
        destabilization would support canonical cuproptosis; transcript-level
        change without protein aggregation would confirm the correlative reading
        and close the gap negatively.
    controls:
    - name: Non-lupus inflammatory nephropathy controls
      description: >-
        Biopsy-proven inflammatory kidney disease without SLE, to test whether any
        copper signal is lupus-specific or a generic inflammation correlate.
    - name: Interferon-high SLE without nephritis
      description: >-
        Systemically active SLE lacking renal involvement, separating tissue-local
        copper biology from systemic disease activity.
    decision_criterion: >-
      Add a cuproptosis pathophysiology node to this entry only if copper
      dependence, FDX1-lipoylation axis involvement, lipoylated-protein
      aggregation, Fe-S cluster destabilization, and functional rescue are all
      demonstrated in lupus-relevant tissue; otherwise record the copper signal as
      a susceptibility or metabolic-stress marker and leave the graph unchanged.
    would_support:
    - pathophysiology#Impaired Apoptotic Cell Clearance
    - pathophysiology#Epigenetic Dysregulation and T Cell Metabolic Reprogramming
  posed_date: "2026-08-11T00:00:00Z"
  notes: >-
    Filed from monarch-initiative/dismech#6381. The parallel gap is recorded on
    Rheumatoid_Arthritis and Ankylosing_Spondylitis, the other dismech entries
    named in the source review.
treatments:
- name: Type I Interferon Receptor Antagonist
  description: Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: anifrolumab
      term:
        id: NCIT:C166658
        label: Anifrolumab
  notes: Anifrolumab approved for moderate-to-severe SLE; biomarker-guided therapy
  evidence:
  - reference: PMID:28130918
    reference_title: "Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus."
    supports: SUPPORT
    snippet: Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE
    explanation: This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures.
- name: B Cell Depletion Therapy
  description: Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  notes: CAR-T cell therapy has induced drug-free remissions in early clinical experiences
- name: BAFF Pathway Inhibition
  description: Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: belimumab
      term:
        id: NCIT:C91385
        label: Belimumab
  notes: Integrates BAFF/IFN biomarkers with therapeutic selection
  evidence:
  - reference: PMID:22127708
    reference_title: "A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus."
    supports: SUPPORT
    snippet: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE
    explanation: This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo.
- name: Immunosuppressive Therapy
  description: Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.
  treatment_term:
    preferred_term: immunosuppressive therapy
    term:
      id: NCIT:C15261
      label: Immunosuppressive Therapy
  notes: Standard immunosuppressive agents for disease control
  evidence:
  - reference: PMID:37827694
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus: 2023 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation."
    explanation: The 2023 EULAR recommendations advise prompt use of immunosuppressive drugs (methotrexate, azathioprine, mycophenolate) and biologics to control disease and enable glucocorticoid tapering.
  - reference: PMID:37827694
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus: 2023 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered."
    explanation: The 2023 EULAR recommendations name glucocorticoids plus mycophenolate or low-dose cyclophosphamide as anchor drugs for active lupus nephritis, with belimumab or a calcineurin inhibitor as add-on therapy.
- name: Supportive Care
  description: Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  notes: Organ-specific symptomatic management
review_notes: "SLE is a complex autoimmune disorder that can affect multiple organ systems.\nThe hallmark is production of autoantibodies. Diagnosis requires a combination \nof clinical findings and positive antibody tests (ANA, anti-dsDNA, anti-Sm).\nFrequency of involvement of each organ system is variable. Renal and CNS involvement\nare major sources of morbidity. Disease course is characterized by periods of \nflare and remission."
disease_term:
  preferred_term: systemic lupus erythematosus
  term:
    id: MONDO:0007915
    label: systemic lupus erythematosus
gene_sets:
- gene_set: MYGENESET:KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG systemic lupus erythematosus pathway. Base entry; CNS-specific aspects belong on Neuropsychiatric_SLE.
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
datasets:
- accession: geo:GSE334206
  title: STK25 m6A modification regulates CD4+ T cell glycolysis mediated immune imbalance in systemic lupus erythematosus
  description: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with an incompletely understood pathogenesis. N6-methyladenosine (m6A) has been implicated in immune regulation and disease progression, yet its role in disrupting immune homeostasis in SLE, particularly in CD4+ T-cell differentiation, remains poorly understood. In the present study, m6A-modified RNA immunoprecipitation sequencing (m6A-seq) and RNA sequencing (RNA-seq) of peripheral blood mononuclear cells from patients with SLE identified serine/threonine protein kinase 25 (STK25) as a candidate gene exhibiting abnormal m6A modification, and its expression was subsequently validated using reverse transcription-quantitative (...
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 20
  notes: Identified by GEO DataSets index search for Systemic Lupus Erythematosus (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE298542
  title: Profiling and Functional Analysis of Urinary Exosomal MicroRNAs in Pregnant Women with Systemic Lupus Erythematosus
  description: 'Background: Pregnancy in Systemic Lupus Erythematosus (pSLE) is high-risk, necessitating non-invasive biomarkers for monitoring and predicting complications. Urinary exosomes, containing miRNAs, offer a promising source reflecting systemic and renal states, yet their profile in late gestation pSLE is less studied. Objective: This study aimed to investigate the profile of urinary exosomal miRNAs in pregnant women with SLE during late gestation compared to healthy pregnant controls and to explore their potential biological roles and pathways. Methods: Urinary exosomes were isolated from 6 pSLE patients and 5 controls. Exosomes were characterized, and miRNAs were sequenced.'
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 11
  notes: Identified by GEO DataSets index search for Systemic Lupus Erythematosus (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001000962
  title: Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing
  description: We performed a high-resolution analysis of the biological characteristics of plasma DNA in systemic lupus erythematosus (SLE) patients using massively parallel genomic and methylomic sequencing. A number of plasma DNA abnormalities were found. First, aberrations in measured genomic representations (MGRs) were identified in the plasma DNA of SLE patients. The extent of the aberrations in MGRs correlated with anti-double–stranded DNA (anti-dsDNA) antibody level. Second, the plasma DNA of active SLE patients exhibited skewed molecular size-distribution profiles with a significantly increased proportion of short DNA fragments.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:25427797
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Systemic Lupus Erythematosus"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001003662
  title: Combined genetic and transcriptome analysis of patients with Systemic Lupus Erythematosus (SLE)
  description: A comprehensive profiling of the genomic architecture of Systemic Lupus Erythematosus (SLE) by combining genetic and transscriptomic analysis by RNA-seq.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Systemic Lupus Erythematosus"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001006798
  title: Single-cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus
  description: Rituximab, a CD20+ B cell depletion therapy, is frequently used in the treatment of systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation. In this study, we conducted longitudinal single-cell profiling of nine SLE patients treated with rituximab from pretreatment to up to 15 months post-treatment. These were compared to eight healthy controls. We profiled PBMCs via 10X Genomics single-cell RNA, surface protein (CITE-seq), B cell receptor (BCR), and T cell receptor (TCR) sequencing and sequenced bulk BCR repertoires in parallel.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Systemic Lupus Erythematosus"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: dbgap:phs001850
  title: Systemic Lupus Erythematosus Subtypes in a Multi-Ethnic Cohort
  description:  Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple organ systems and varies in severity across different populations. To examine the clinical heterogeneity of SLE, we sought to identify different lupus subtypes within our multi-ethnic cohort using a clustering approach. Additionally, with genome-wide methylation and genotype data generated for our cohort, we applied integrative methods to investigate genetic and epigenetic risk factors. This integrative and computational approach revealed molecular differences associated with phenotypic clusters.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Systemic Lupus Erythematosus"). Retrieved 2026-08-02.

📚

References & Deep Research

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Cyberian ▸

Systemic Lupus Erythematosus Pathophysiology Report

deep-research 57 citations 2026-02-01T14:47:49.161854

Systemic Lupus Erythematosus Pathophysiology Report

Introduction

Systemic lupus erythematosus (SLE; MONDO:0007915) is a systemic autoimmune disorder with heterogeneous organ involvement and a core immunologic theme of loss of tolerance to ubiquitous nuclear antigens.[medgen-6146-sle][crispin-2010-pathogenesis-human-sle] As summarized in a mechanistic review, "SLE is a systemic autoimmune disorder driven by an immune response directed against ubiquitous, mostly intranuclear, self-antigens," and patients can manifest "skin rash, photosensitivity" and other systemic features.[crispin-2010-pathogenesis-human-sle] The disease course is shaped by autoantibodies, immune complex formation, innate immune activation, and tissue-damaging inflammatory cascades that link molecular triggers to clinical phenotypes.[obermoser-2010-interferon-alpha-signature][crispin-2010-pathogenesis-human-sle]

Core Pathophysiology

A recurring early step is defective handling of self-antigens derived from dying cells. In SLE, "apoptotic material and production of autoantibodies have long been recognized as major pathogenic events in this disease," emphasizing the connection between self-antigen exposure and autoimmunity.[obermoser-2010-interferon-alpha-signature] Consistent with this, disturbances in cell death and clearance are mechanistically important; one review notes that "Disturbances in apoptosis and/or clearance of apoptotic cells can play an important role in the pathogenesis of SLE."[crispin-2010-pathogenesis-human-sle]

Type I interferon (IFN) pathways form a central amplification loop. Plasmacytoid dendritic cells are highlighted as critical innate sensors because "pDCs ... are the main source of type I interferon (IFN) cytokines, which contribute to the immunopathogenesis of SLE."[kim-2015-pdc-ifn-axis-sle] This fits with the broader observation that "the type I interferon cytokine family has been postulated to play a central role in SLE pathogenesis," linking nucleic acid recognition to systemic immune activation.[obermoser-2010-interferon-alpha-signature]

Transcriptomic studies in blood reinforce the centrality of interferon programs and myeloid signatures. One study reported that the IFN gene expression "signature" served as a marker for more severe disease involving the kidneys, hematopoetic cells, and/or the central nervous system.[baechler-2003-interferon-signature-severe-sle] Another found that active SLE shows overexpression of granulopoiesis-related and IFN-induced genes and that immature neutrophils are present in many patients, indicating a granulopoiesis signature linked to disease activity.[bennett-2003-interferon-granulopoiesis-signature]

Complement biology adds an additional axis of susceptibility and tissue injury. Classical pathway deficiency is strongly associated with disease, with a review noting that "deficiency of early complement proteins from the classical pathway ... is strongly associated with development of systemic lupus erythematosus (SLE)."[macedo-2016-complement-classical] Complement and Fc receptor-mediated handling of immune complexes thereby influences both tolerance and end-organ inflammation.[macedo-2016-complement-classical]

Neutrophil extracellular traps (NETs) are another source of nuclear autoantigens and inflammatory signals. NETs are described as "web-like structures composed of chromatin backbones and granular molecules," and "an imbalance between NET formation and clearance in SLE patients may play a prominent role in the perpetuation of autoimmunity and the exacerbation of disease."[kaplan-2013-nets-sle] This integrates neutrophil biology into the self-amplifying cycles of autoantigen exposure and interferon-driven activation.

Neutrophil heterogeneity further refines this axis. A systems analysis notes that "SLE is characterized by elevated levels of a pathogenic neutrophil subset known as low-density granulocytes (LDGs)" and highlights functional diversity among neutrophil subsets.[li-2019-neutrophil-diversity-sle] A comprehensive review adds that "LDNs in SLE can secrete increased levels of type I interferon (IFN)" and readily form NETs, linking neutrophil subsets to IFN amplification and tissue damage.[carriere-2020-low-density-neutrophils-sle]

Endosomal nucleic-acid sensing via TLR7 and TLR9 is differentially regulated in SLE. In pDCs, TLR7-mediated IFN-alpha production is up-regulated and correlates with disease activity, whereas TLR9-mediated IFN-alpha production is down-regulated, indicating asymmetric tuning of these pathways.[takeda-2018-tlr7-ifn-pdc-sle] In B cells, TLR9 responses are impaired, with defective upregulation of activation molecules and diminished cytokine production, and this defect is restricted to B cells rather than pDCs, suggesting loss of TLR9 tolerogenic function contributes to the break of B cell tolerance.[mahdavi-2018-tlr9-bcells-sle]

Mitochondrial stress and oxidized mitochondrial DNA (mtDNA) provide an additional source of interferogenic nucleic acids. In a primary study of NETosis, "release of oxidized mitochondrial DNA is proinflammatory in vitro" and "stimulates type-I interferon (IFN) signaling through a pathway dependent on the DNA sensor, STING."[campbell-2016-oxidized-mtdna-nets-sle] Complementary evidence shows that "Mitochondrial stress releases mitochondrial DNA (mtDNA) into the cytosol and triggers the type-I interferon (IFN) response" and that mtDNA fragments are released "via pores formed by the voltage-dependent anion channel (VDAC) oligomers" in the mitochondrial outer membrane.[liu-2019-vdac-mtdna-lupus]

Defective extracellular DNA degradation can further fuel autoreactivity. In a primary study, "SLE patients with nephritis manifested reduced DNASE1L3 activity in circulation, which was associated with neutralizing autoantibodies to DNASE1L3," directly linking nuclease impairment to lupus nephritis and immune activation.[hartl-2021-dnase1l3-autoantibodies]

Key Molecular Players and Ontology Annotations

Genetic susceptibility spans immune recognition, signaling, and clearance pathways. A genomic-era review reports "more than 30 robust genetic associations with SLE including genetic variants of HLA and Fc gamma receptor genes, IRF5, STAT4, PTPN22, TNFAIP3, BLK, BANK1, TNFSF4 and ITGAM."[deng-2011-genetic-susceptibility-sle] These translate into key gene annotations such as IRF5 (HGNC:6120), STAT4 (HGNC:11365), PTPN22 (HGNC:9652), TNFAIP3 (HGNC:11896), BLK (HGNC:1057), BANK1 (HGNC:18233), TNFSF4 (HGNC:11934), ITGAM (HGNC:6149), and Fc gamma receptor genes FCGR2A (HGNC:3616) and FCGR2B (HGNC:3618), all implicated in immune signaling and tolerance in SLE.[deng-2011-genetic-susceptibility-sle]

Complement-associated genes are also central, reflecting the strong disease association of classical pathway deficiency: C1QA (HGNC:1241), C1QB (HGNC:1242), C1QC (HGNC:1245), C2 (HGNC:1248), and C4A/C4B (HGNC:1323/1324) underpin immune complex clearance and tolerance.[macedo-2016-complement-classical] Nuclease-mediated clearance of extracellular DNA involves DNASE1L3 (HGNC:2959), which is functionally impaired in a substantial subset of patients with nephritis.[hartl-2021-dnase1l3-autoantibodies] Innate nucleic-acid sensing by endosomal receptors contributes to the interferon program; pDCs recognize nucleic acids through TLR7 (HGNC:15631) and TLR9 (HGNC:15633), which links nucleic acid exposure to IFN production in SLE.[kim-2015-pdc-ifn-axis-sle]

BAFF signaling provides a bridge between T cell activation and autoreactive B cell expansion. In active SLE, CD4+ and CD8+ T cells express BAFF (TNFSF13B; HGNC:11929), and the authors conclude that "BAFF may play a pathogenic role in SLE by stimulating T cell-dependent B cell autoantibodies production."[zhang-2007-baff-tcells-sle] BAFF receptors including TACI (TNFRSF13B; HGNC:18153) and BAFF-R (TNFRSF13C; HGNC:17755) are expressed on B cells, and blockade with TACI-Ig suppresses spontaneous anti-dsDNA production in active SLE with kidney involvement, linking BAFF to pathogenic autoantibody generation.[zhang-2007-baff-tcells-sle] Altered B cell signaling components also emerge in TLR9-defective B cells, including decreased expression of the CD19/CD21 complex (CD19 HGNC:1633; CR2 HGNC:2336), underscoring disrupted B cell regulatory circuits.[mahdavi-2018-tlr9-bcells-sle]

Mitochondrial pathways implicated in lupus include VDAC1 (HGNC:12669), where VDAC oligomerization controls mtDNA release and downstream IFN signaling in lupus-like disease models.[liu-2019-vdac-mtdna-lupus]

Relevant chemical entities include nucleic acids that act as autoantigens and innate immune ligands: deoxyribonucleic acid (DNA; CHEBI:16991) and ribonucleic acid (RNA; CHEBI:33697) as well as the cGAS-STING second messenger 2'-3'-cGAMP (CHEBI:75947) implicated in DNA-sensing pathways.[kim-2015-pdc-ifn-axis-sle][thim-2020-sting-lupus] The antimalarial immunomodulator hydroxychloroquine (CHEBI:5801) is relevant in SLE studies of TLR9 function, where defective responses were reported in B cells from patients without hydroxychloroquine treatment.[mahdavi-2018-tlr9-bcells-sle]

Evidence items with PMIDs anchoring these mechanistic claims include 20138006 (apoptotic clearance and lupus pathogenesis), 20693194 (type I IFN signature), 26110387 (pDC-IFN axis), 26941740 (complement deficiency), 24244889 (NETs), 33783474 (DNASE1L3 autoantibodies), 21060334 (genetic susceptibility), 23929771 and 25014039 (lupus nephritis), 12604793 and 12642603 (interferon and granulopoiesis signatures), 30210502 and 29515028 (TLR7/9 dysregulation), 17500077 (BAFF in T cells), 26779811 (oxidized mtDNA NETs), 31857488 (VDAC-mediated mtDNA release), 31754025 (neutrophil diversity and LDGs), 32524751 (LDNs in SLE), and 33083760 (STING-mediated lupus in vivo).[crispin-2010-pathogenesis-human-sle][obermoser-2010-interferon-alpha-signature][kim-2015-pdc-ifn-axis-sle][macedo-2016-complement-classical][kaplan-2013-nets-sle][hartl-2021-dnase1l3-autoantibodies][deng-2011-genetic-susceptibility-sle][lech-2013-lupus-nephritis][schwartz-2014-lupus-nephritis-pathogenesis][baechler-2003-interferon-signature-severe-sle][bennett-2003-interferon-granulopoiesis-signature][takeda-2018-tlr7-ifn-pdc-sle][mahdavi-2018-tlr9-bcells-sle][zhang-2007-baff-tcells-sle][campbell-2016-oxidized-mtdna-nets-sle][liu-2019-vdac-mtdna-lupus][li-2019-neutrophil-diversity-sle][carriere-2020-low-density-neutrophils-sle][thim-2020-sting-lupus]

Cellular Components and Dysregulated Processes

Core dysregulated biological processes include type I interferon-mediated signaling (GO:0060337), B cell activation (GO:0042113), T cell activation (GO:0042110), classical pathway complement activation (GO:0006958), apoptotic cell clearance (GO:0043277), neutrophil extracellular trap formation (GO:0140645), toll-like receptor 7 signaling pathway (GO:0034154), toll-like receptor 9 signaling pathway (GO:0034162), and myeloid cell differentiation (GO:0030099), all of which are repeatedly implicated across mechanistic studies and reviews.[obermoser-2010-interferon-alpha-signature][kim-2015-pdc-ifn-axis-sle][macedo-2016-complement-classical][crispin-2010-pathogenesis-human-sle][kaplan-2013-nets-sle][takeda-2018-tlr7-ifn-pdc-sle][mahdavi-2018-tlr9-bcells-sle][bennett-2003-interferon-granulopoiesis-signature]

The principal cellular participants include plasmacytoid dendritic cells (CL:0000784), B cells (CL:0000236), CD4-positive helper T cells (CL:0000492), neutrophils (CL:0000775), monocytes (CL:0000576), macrophages (CL:0000235), and plasma cells (CL:0000786), which together integrate innate sensing with adaptive autoantibody production.[kim-2015-pdc-ifn-axis-sle][crispin-2010-pathogenesis-human-sle][kaplan-2013-nets-sle] Key cellular components and compartments include endosomes (GO:0005768) for TLR7/9 sensing, cytosolic DNA-sensing pathways involving cGAS-STING, nuclear reservoirs of autoantigens, mitochondria (GO:0005739) including the mitochondrial outer membrane (GO:0005741) where VDAC oligomers release mtDNA, and extracellular space (GO:0005615) where immune complexes and NETs accumulate and trigger complement activation.[kim-2015-pdc-ifn-axis-sle][thim-2020-sting-lupus][kaplan-2013-nets-sle][macedo-2016-complement-classical][liu-2019-vdac-mtdna-lupus] The granulopoiesis signature in active SLE also points to altered myeloid development in bone marrow (UBERON:0002371), consistent with the presence of immature neutrophils in peripheral blood.[bennett-2003-interferon-granulopoiesis-signature]

Disease Progression Model

A plausible mechanistic sequence begins with genetic susceptibility to immune dysregulation and clearance defects.[deng-2011-genetic-susceptibility-sle] Environmental or endogenous triggers increase cell death and the release of nuclear antigens, while defective apoptotic and extracellular DNA clearance allows these ligands to persist.[crispin-2010-pathogenesis-human-sle][hartl-2021-dnase1l3-autoantibodies] Nucleic acid-rich material and immune complexes stimulate pDCs and endosomal TLR7/9, promoting a sustained type I IFN program that is skewed toward enhanced TLR7 and reduced TLR9 responses.[kim-2015-pdc-ifn-axis-sle][obermoser-2010-interferon-alpha-signature][takeda-2018-tlr7-ifn-pdc-sle][mahdavi-2018-tlr9-bcells-sle] Mitochondrial stress and VDAC-dependent mtDNA release further amplify cytosolic DNA sensing and type I IFN signaling.[campbell-2016-oxidized-mtdna-nets-sle][liu-2019-vdac-mtdna-lupus] IFN-driven activation of B and T cells feeds autoantibody production, which is further supported by BAFF signaling and leads to immune complex formation and complement activation, culminating in tissue deposition and inflammation.[obermoser-2010-interferon-alpha-signature][macedo-2016-complement-classical][zhang-2007-baff-tcells-sle] NETosis provides an additional source of extracellular chromatin that sustains this loop, particularly in LDG/LDN subsets.[kaplan-2013-nets-sle][li-2019-neutrophil-diversity-sle][carriere-2020-low-density-neutrophils-sle] In parallel, cGAS-STING signaling can promote dendritic cell activation and lupus-like disease in vivo, indicating a cytosolic DNA-sensing axis that may reinforce the interferon circuit.[thim-2020-sting-lupus]

Phenotypic Manifestations and Mechanistic Links

The systemic autoimmune phenotype (HP:0002725) manifests across multiple tissues, consistent with widespread exposure to nuclear autoantigens and immune complex-mediated inflammation.[crispin-2010-pathogenesis-human-sle][obermoser-2010-interferon-alpha-signature] Gene-expression data indicate that the IFN signature is associated with severe disease involving kidneys, hematopoetic cells, and the central nervous system (UBERON:0001017), providing a molecular link between interferon biology and organ involvement.[baechler-2003-interferon-signature-severe-sle] Cutaneous involvement is common in skin (UBERON:0002097), and SLE patients can exhibit skin rash, cutaneous photosensitivity (HP:0000992), and malar rash (HP:0025300).[crispin-2010-pathogenesis-human-sle] Musculoskeletal involvement includes arthritis (HP:0001369), reflecting immune activation and inflammatory cascades.[crispin-2010-pathogenesis-human-sle] Hematologic manifestations include hemolytic anemia (HP:0001878), thrombocytopenia (HP:0001873), and decreased total leukocyte count (HP:0001882), consistent with systemic immune activation and granulopoiesis signatures.[crispin-2010-pathogenesis-human-sle][bennett-2003-interferon-granulopoiesis-signature] Neurologic involvement can include seizures (HP:0001250), aligning with central nervous system involvement in severe disease.[crispin-2010-pathogenesis-human-sle][baechler-2003-interferon-signature-severe-sle]

Renal disease is a central end-organ manifestation. Lupus nephritis occurs in kidney (UBERON:0002113), particularly in the renal glomerulus (UBERON:0000074), and is characterized clinically by nephritis (HP:0000123) and proteinuria (HP:0000093).[lech-2013-lupus-nephritis][schwartz-2014-lupus-nephritis-pathogenesis] Mechanistically, "Lupus nephritis is an immune complex GN that develops as a frequent complication of SLE," linking autoantibody-immune complex formation to glomerular injury.[lech-2013-lupus-nephritis] Impaired DNA clearance (e.g., DNASE1L3 neutralization) is enriched in patients with nephritis, providing a mechanistic bridge between nucleic acid-driven autoimmunity and renal damage.[hartl-2021-dnase1l3-autoantibodies]

Open Questions

A major open question is how distinct sources of self-nucleic acids (apoptotic debris versus NET-derived chromatin versus microparticle-associated DNA) differentially drive interferon programs and organ tropism in human SLE.[crispin-2010-pathogenesis-human-sle][kaplan-2013-nets-sle][hartl-2021-dnase1l3-autoantibodies] Another unresolved issue is the hierarchy of innate sensors in patient subsets, whether endosomal TLR7/9 or cytosolic cGAS-STING pathways dominate in specific clinical phenotypes and how this relates to genetic background or treatment response.[kim-2015-pdc-ifn-axis-sle][thim-2020-sting-lupus] Finally, the precise mechanisms by which classical pathway complement deficiencies and Fc receptor variants skew tolerance and immune complex handling in vivo remain incompletely mapped, particularly in the transition from systemic autoimmunity to organ-specific injury.[macedo-2016-complement-classical][deng-2011-genetic-susceptibility-sle]

References

crispin-2010-pathogenesis-human-sle: Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in Molecular Medicine. 2010;16(2):47-57. PMID:20138006. PMCID:PMC2823952. DOI:10.1016/j.molmed.2009.12.005. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2823952/
obermoser-2010-interferon-alpha-signature: Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus. 2010;19(9):1012-1019. PMID:20693194. PMCID:PMC3658279. DOI:10.1177/0961203310371161. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3658279/
kim-2015-pdc-ifn-axis-sle: Kim JM, Park SH, Kim HY, Kwok SK. A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus. International Journal of Molecular Sciences. 2015;16(6):14158-14170. PMID:26110387. PMCID:PMC4490545. DOI:10.3390/ijms160614158. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4490545/
macedo-2016-complement-classical: Macedo AC, Isaac L. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Frontiers in Immunology. 2016;7:55. PMID:26941740. PMCID:PMC4764694. DOI:10.3389/fimmu.2016.00055. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4764694/
kaplan-2013-nets-sle: Yu Y, Su K. Neutrophil Extracellular Traps and Systemic Lupus Erythematosus. Journal of Clinical & Cellular Immunology. 2013;4:139. PMID:24244889. PMCID:PMC3826916. DOI:10.4172/2155-9899.1000139. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3826916/
lech-2013-lupus-nephritis: Lech M, Anders HJ. The pathogenesis of lupus nephritis. Journal of the American Society of Nephrology. 2013;24(9):1357-1366. PMID:23929771. PMCID:PMC3752952. DOI:10.1681/ASN.2013010026. URL: https://pubmed.ncbi.nlm.nih.gov/23929771/
schwartz-2014-lupus-nephritis-pathogenesis: Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Current Opinion in Rheumatology. 2014;26(5):502-509. PMID:25014039. PMCID:PMC4221732. DOI:10.1097/BOR.0000000000000089. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4221732/
hartl-2021-dnase1l3-autoantibodies: Hartl J, Serpas L, Wang Y, et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. Journal of Experimental Medicine. 2021;218(5):e20201138. PMID:33783474. PMCID:PMC8020718. DOI:10.1084/jem.20201138. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8020718/
deng-2011-genetic-susceptibility-sle: Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nature Reviews Rheumatology. 2010;6(12):683-692. PMID:21060334. PMCID:PMC3135416. DOI:10.1038/nrrheum.2010.176. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3135416/
thim-2020-sting-lupus: Thim-uam A, Prabakaran T, Tansakul M, et al. STING Mediates Lupus via the Activation of Conventional Dendritic Cell Maturation and Plasmacytoid Dendritic Cell Differentiation. iScience. 2020;23(9):101530. PMID:33083760. PMCID:PMC7502826. DOI:10.1016/j.isci.2020.101530. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7502826/
baechler-2003-interferon-signature-severe-sle: Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(5):2610-5. PMID:12604793. DOI:10.1073/pnas.0337679100. URL: https://pubmed.ncbi.nlm.nih.gov/12604793/
bennett-2003-interferon-granulopoiesis-signature: Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. The Journal of Experimental Medicine. 2003;197(6):711-23. PMID:12642603. DOI:10.1084/jem.20021553. URL: https://pubmed.ncbi.nlm.nih.gov/12642603/
takeda-2018-tlr7-ifn-pdc-sle: Sakata K, Nakayamada S, Miyazaki Y, et al. Up-Regulation of TLR7-Mediated IFN-alpha Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology. 2018;9:1957. PMID:30210502. PMCID:PMC6121190. DOI:10.3389/fimmu.2018.01957. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6121190/
zhang-2007-baff-tcells-sle: Morimoto S, Nakano S, Watanabe T, et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford). 2007;46(7):1083-6. PMID:17500077. DOI:10.1093/rheumatology/kem097. URL: https://pubmed.ncbi.nlm.nih.gov/17500077/
mahdavi-2018-tlr9-bcells-sle: Gies V, Schickel JN, Jung S, et al. Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. JCI Insight. 2018;3(5). PMID:29515028. PMCID:PMC5922279. DOI:10.1172/jci.insight.96795. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5922279/
campbell-2016-oxidized-mtdna-nets-sle: Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nature Medicine. 2016;22(2):146-153. PMID:26779811. PMCID:PMC4742415. DOI:10.1038/nm.4027. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4742415/
liu-2019-vdac-mtdna-lupus: Kim J, Gupta R, Blanco LP, et al. VDAC oligomers form mitochondrial pores that release mtDNA fragments and promote lupus-like disease. Science. 2019;366(6472):1531-1536. PMID:31857488. PMCID:PMC8325171. DOI:10.1126/science.aav4011. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8325171/
li-2019-neutrophil-diversity-sle: Mistry P, Nakabo S, O'Neil L, et al. Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(50):25222-25228. PMID:31754025. PMCID:PMC6911190. DOI:10.1073/pnas.1908576116. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6911190/
carriere-2020-low-density-neutrophils-sle: Tay SH, Celhar T, Fairhurst AM. Low-Density Neutrophils in Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2020;72(10):1587-1595. PMID:32524751. PMCID:PMC7590095. DOI:10.1002/art.41395. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7590095/
medgen-6146-sle: NCBI MedGen. Systemic lupus erythematosus (C0024141) with MONDO:0007915 mapping. URL: https://www.ncbi.nlm.nih.gov/medgen/6146

Falcon ▸

Pathophysiology description (current understanding)

Edison Scientific Literature 24 citations 2025-12-15T09:54:15.090699

Pathophysiology description (current understanding) Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease driven by breakdown of immune tolerance, chronic activation of innate nucleic acid–sensing pathways (especially the type I interferon axis), aberrant B- and T-cell help, impaired clearance of apoptotic and NETotic debris, and complement pathway perturbations leading to immune complex deposition and organ inflammation (kidney, skin, CNS, vasculature). Contemporary reviews highlight a unifying framework that integrates type I IFN signaling, TLR7/9-driven autoreactivity, neutrophil extracellular traps (NETs) and oxidative stress, B cell extrafollicular and germinal-center responses (including age-associated B cells, ABCs), and tissue injury mediated by immune complexes and complement activation (Oct 2024; https://doi.org/10.3390/ijms252010905) (moysidou2024lymphocyteschangetheir pages 18-20). NETs are now recognized as amplifiers of the pDC–TLR9–IFN-α loop and as sources of modified autoantigens; “impaired NET catabolism due to deficient serum DNase1 is associated with renal involvement,” while NET DNA–peptide complexes can protect nucleic acids from degradation and activate pDCs to produce IFN-α (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (yuan2024globalresearchtrends pages 10-10).

Key mechanistic axes - Type I interferon signature: An IFN-I–inflamed milieu is present in a majority of patients and shapes dysregulation across immune cell lineages. Stratified analyses link elevated IFN gene signatures and chemokines (e.g., CXCL10/CXCL13) to clinical phenotypes and therapy responses; notably, “High IFN gene signature [is associated with] favorable response to anifrolumab therapy” (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - Nucleic-acid sensing via endosomal TLRs: B cell–intrinsic TLR7 signaling is a central driver of lupus pathology, whereas TLR9 can exert counter-regulatory effects; genetic and mechanistic data show that when TLR9 is absent, unrestrained TLR7 signaling worsens disease (2024; dissertation/manuscript synthesis) (cosgrove2024tolllikereceptor7 pages 160-164). As one concise conclusion from this body of work: “B cell–intrinsic TLR7 drives severe lupus,” and NOX2 (CYBB)–dependent ROS can negatively regulate TLR7–NF-κB signaling (cosgrove2024tolllikereceptor7 pages 160-164). - Impaired clearance and complement: Defective apoptotic cell clearance and complement deficiencies increase exposure to nuclear antigens, propagate immune complex formation, and correlate with lupus nephritis; early-component complement defects (e.g., C1q) and impaired NET degradation are linked to renal injury and complement activation (Oct 2024; https://doi.org/10.3390/ijms252010905; Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - B–T collaboration and tolerance failure: Extrafollicular and GC pathways are both implicated. T follicular helper–like cells (ICOS+, PD-1+, IL-21+) expand and drive autoreactive B-cell differentiation; murine and human data show that blocking Tfh development ameliorates disease (Jul 2025; https://doi.org/10.3390/cells14141080) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). Age-associated B cells (ABCs; CD11c+, T-bet+) are enriched in SLE and correlate with IFN signatures and disease activity, linking IFN-BAFF-IL-21 circuits to persistent autoantibody production (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z; 2024 mechanistic synthesis) (wu2025immunecellaberrations pages 29-30, cosgrove2024tolllikereceptor7 pages 160-164). - NETosis and oxidative stress: NETs fuel IFN-α production, directly activate autoreactive B cells, and trigger complement; oxidative stress and defective NET clearance amplify this loop (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350; Oct 2024; https://doi.org/10.3390/ijms252010905) (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Neurovascular and CNS injury: Neuropsychiatric SLE reflects composite mechanisms (vasculopathy, microthrombi, inflammatory mediators) superimposed on systemic autoimmunity; “no single laboratory test is currently available to definitively confirm the diagnosis of NPSLE,” emphasizing mechanistic heterogeneity (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).

Direct supporting statements (selected quotes) - “Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis… NETs… protect DNA from degradation, enabling activation of plasmacytoid dendritic cells (pDCs) through TLR9 and driving IFN-α production.” (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (yuan2024globalresearchtrends pages 10-10). - “High IFN gene signature [→] favorable response to anifrolumab therapy,” underscoring mechanism-based stratification (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - “B cell–intrinsic TLR7 drives severe lupus… [and] TLR9 can restrain differentiation of age/autoimmune-associated B cells and plasmablasts,” highlighting TLR7/9 counterpoints (2024; mechanistic synthesis) (cosgrove2024tolllikereceptor7 pages 160-164). - “No single laboratory test is currently available to definitively confirm the diagnosis of NPSLE,” reflecting complex pathophysiology (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).

Key molecular players - Genes (HGNC): - TLR7 (HGNC:15631) – B cell–intrinsic driver; promotes RNA-associated autoantibodies and disease; counterbalanced by TLR9 (cosgrove2024tolllikereceptor7 pages 160-164). - MYD88 (HGNC:7562) – adaptor downstream of TLR7/9, required in B cells for autoantibody production and glomerulonephritis in models (conceptual synthesis) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - CYBB (NOX2; HGNC:2553) – NOX2-generated ROS negatively regulate TLR7 NF-κB signaling; loss exaggerates disease (cosgrove2024tolllikereceptor7 pages 160-164). - Cytokines/ligands (UniProt/protein classes): - IFN-α (type I interferon) – signature pathway with clinical and therapeutic implications (wu2025immunecellaberrations pages 29-30). - BAFF (TNFSF13B) – supports B-cell survival and extrafollicular responses; integrated with IFN/Tfh circuits (wu2025immunecellaberrations pages 29-30, zhou2024cartcelltherapy pages 4-4). - IL-21 – Tfh-derived; drives B-cell differentiation to plasma cells; Tfh IL-21 blockade ameliorates disease in models (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, zhou2024cartcelltherapy pages 4-4). - Autoantibodies: ANA, anti-dsDNA, anti-Sm; anti-C1q associated with nephritis activity; immune complexes underlie type III injury and complement consumption (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4, moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - Complement (components/regulators): C1q/C3/C4 perturbations and complement activation/consumption integrate with immune complexes and NET persistence (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10).

Cell types (CL ontology exemplars) - Plasmacytoid dendritic cells (pDCs; CL:0000784) – principal IFN-α producers downstream of NET DNA/RNA and TLR9/TLR7 ligation (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - B cells (CL:0000236); age-associated B cells (ABCs; CL subclass) – enriched, T-bet/CD11c+ phenotypes; extrafollicular activation; autoantibody production (wu2025immunecellaberrations pages 29-30, cosgrove2024tolllikereceptor7 pages 160-164). - T follicular helper cells (Tfh; CL:0002038) and T peripheral helper cells (Tph) – IL-21/ICOS/PD-1+ subsets that support autoreactive B cells (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, zhou2024cartcelltherapy pages 4-4). - Neutrophils and low-density granulocytes (LDGs; CL:0000096 variant) – heightened NETosis and oxidant stress; impaired NET clearance (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - Cytotoxic/effector T cells – contribute to tissue injury and, in NPSLE, inflammatory milieu and vascular injury (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4, moysidou2024lymphocyteschangetheir pages 18-20).

Anatomical locations/organs (UBERON) - Kidney/glomerulus (UBERON:0002113/0000071) – immune complex GN, NET/complement interplay (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Skin (UBERON:0002097) – cutaneous lupus; Tfh/Tph and local immune complexes (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, moysidou2024lymphocyteschangetheir pages 18-20). - CNS (UBERON:0000955) – neuropsychiatric SLE with vasculopathy/microthrombi/inflammation (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4). - Vasculature (UBERON:0001981) – accelerated vascular damage and atherogenesis in SLE inflammatory milieu (moysidou2024lymphocyteschangetheir pages 18-20).

Chemical entities (CHEBI) and biomarkers - DNA/RNA in NETs (CHEBI:16991; CHEBI:33697) – ligands for TLR9/TLR7; NET remnants (e.g., MPO-DNA, CitH3) as activity biomarkers in LN (yuan2024globalresearchtrends pages 10-10). - Cytokines/chemokines: IFN-α, IL-21, CXCL10/CXCL13 as mechanistic biomarkers and stratifiers (wu2025immunecellaberrations pages 29-30). - Complement split products (e.g., C3/C4 consumption) as activity markers linked to immune complex burden (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4, moysidou2024lymphocyteschangetheir pages 18-20).

GO biological processes (disrupted) - Type I interferon signaling pathway (GO:0060337): chronic activation across cell types (wu2025immunecellaberrations pages 29-30). - Toll-like receptor signaling (GO:0002224/GO:0035663): TLR7/9 in B cells/pDCs; MyD88–NF-κB axis (cosgrove2024tolllikereceptor7 pages 160-164, moysidou2024lymphocyteschangetheir pages 18-20). - B cell activation and differentiation (GO:0042113; GO:0030183): IL-21 and BAFF-driven plasma cell formation; ABC expansion (wu2025immunecellaberrations pages 29-30, shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Neutrophil degranulation and NET formation (GO:0043312; GO:0036349): NETs driving IFN/complement loops (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Complement activation, classical pathway (GO:0006958): immune complex–triggered activation; links to LN (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10). - Apoptotic cell clearance/efferocytosis (GO:0043277): defects expose nuclear antigens (moysidou2024lymphocyteschangetheir pages 18-20).

Cellular components (where processes occur) - Endosome/lysosome (GO:0005768/GO:0005764): TLR7/9 nucleic-acid sensing (cosgrove2024tolllikereceptor7 pages 160-164). - Extracellular region (GO:0005576): NET scaffolds (DNA, histones, granule proteins) and immune complexes (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Plasma membrane/immune synapse (GO:0005886; GO:0001772): Tfh–B cell interactions (ICOS, PD-1) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3).

Disease progression (sequence of events) - Initiation/triggers: genetic predisposition and environmental insults (infections; repeated innate triggers) lower activation thresholds; repeated infections can “break T cell anergy,” driving autoreactive Tfh development (Jul 2025; https://doi.org/10.3390/cells14141080) (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Amplification: impaired apoptotic/NET debris clearance and early complement pathway insufficiency promote endogenous nucleic-acid presentation to TLR7/9 (B cells, pDCs) → IFN-α programs and BAFF elevation → ABC and Tfh/Tph expansion → extrafollicular and GC autoantibody responses (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10, wu2025immunecellaberrations pages 29-30, shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Tissue injury: immune complex deposition and complement activation; leukocyte infiltration; NET-associated oxidant injury; organ-specific patterns (glomerulonephritis; cutaneous lesions; neurovascular injury) (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10, justizvaillant2024neuropsychiatricsystemiclupus pages 2-4). - Chronicity and flares: self-sustaining IFN–TLR–B/T feedback loops; persistence of long-lived plasma cells and NET–IFN circuits; fluctuating complement consumption and autoantibody titers (wu2025immunecellaberrations pages 29-30, moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10).

Phenotypic manifestations (HP terms) and mechanistic links - Lupus nephritis (HP:0000127): immune complexes, complement, NETs (yuan2024globalresearchtrends pages 10-10, moysidou2024lymphocyteschangetheir pages 18-20). - Cutaneous photosensitive rash (HP:0000988/HP:0000684): immune complex vasculitis in skin; Tfh/Tph involvement (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3, moysidou2024lymphocyteschangetheir pages 18-20). - Neuropsychiatric features (HP:0100022; HP:0000716): vasculopathy, microthrombi, inflammatory mediators; diagnostic complexity (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4). - Cytopenias (HP:0001873/HP:0001876/HP:0001877): immune-mediated cytopenias consonant with systemic immune complex/complement activation (moysidou2024lymphocyteschangetheir pages 18-20, justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).

Current applications and real-world implementations - IFN-I pathway therapeutics: Anifrolumab (anti–IFNAR1) efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based stratification (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - B-cell–directed strategies: BAFF pathway modulation (belimumab) fits B-cell survival/tolerance failure paradigm summarized here; reviews underscore integrating BAFF/IFN biomarkers with therapeutic selection (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - Cellular therapy: Anti-CD19 CAR-T has induced drug-free remissions in early experiences and is rationalized by B-cell centrality in SLE pathogenesis (Dec 2024; https://doi.org/10.3389/fimmu.2024.1476859) (zhou2024cartcelltherapy pages 4-4). - Biomarkers: NET remnants (e.g., MPO-DNA/CitH3), IFN gene signatures, and chemokines (CXCL10/CXCL13) are candidate activity/response biomarkers tied to the mechanisms above (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350; Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (yuan2024globalresearchtrends pages 10-10, wu2025immunecellaberrations pages 29-30).

Expert opinions and analysis - Reviews integrating immune cell perturbations argue for moving “from single-target blockade to reconstruction of immune network homeostasis,” cautioning against compensatory remodeling and advocating dynamic immunomonitoring (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - Mechanistic syntheses emphasize the TLR7–driven, B cell–intrinsic nature of disease with regulatory inputs from TLR9 and redox signaling (NOX2), suggesting strategies that antagonize TLR7 while preserving/leveraging TLR9’s counter-regulation (2024 synthesis) (cosgrove2024tolllikereceptor7 pages 160-164).

Relevant statistics and data (recent) - NETs: impaired degradation associates with LN; mechanistically, LL37/HNP–DNA complexes resist nucleases and activate pDC TLR9 to induce IFN-α (Jul 2024; https://doi.org/10.1016/j.heliyon.2024.e33350) (yuan2024globalresearchtrends pages 10-10). - IFN biomarker–therapy link: high IFN gene signature correlates with better response to anifrolumab (precise wording per review figure/text) (Jun 2025; https://doi.org/10.1186/s11658-025-00749-z) (wu2025immunecellaberrations pages 29-30). - B cell–intrinsic TLR7: genetic deletion of Tlr7 in B cells rescues severe disease in specific lupus-prone backgrounds; NOX2 deficiency augments TLR7–NF-κB signaling (experimental findings synthesized in 2024 work) (cosgrove2024tolllikereceptor7 pages 160-164). - NPSLE: clinicopathologic heterogeneity and absence of a single confirmatory laboratory test underscore the need for multimodal biomarkers (Feb 2024; https://doi.org/10.3390/molecules29040747) (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).

Gene/protein annotations and ontology mappings - HGNC: TLR7 (HGNC:15631); MYD88 (HGNC:7562); CYBB/NOX2 (HGNC:2553); TNFSF13B/BAFF (HGNC:11929); IL21 (HGNC:6008); IFNA1 family (HGNC:5399). - GO processes: GO:0060337 (type I IFN signaling); GO:0002224/GO:0035663 (TLR signaling); GO:0030183 (B cell differentiation); GO:0036349 (NET formation); GO:0006958 (complement activation, classical pathway); GO:0043277 (apoptotic cell clearance). - CL: pDCs (CL:0000784); B cells (CL:0000236) including ABCs; Tfh (CL:0002038); neutrophils (CL:0000096); Tph-like cells. - UBERON: kidney (UBERON:0002113), glomerulus (UBERON:0000071); skin (UBERON:0002097); brain (UBERON:0000955); vasculature (UBERON:0001981). - CHEBI: nucleic acids (DNA, CHEBI:16991; RNA, CHEBI:33697); chemokines/cytokines as applicable. - HP: lupus nephritis (HP:0000127); malar/photosensitive rash (HP:0000988); neuropsychiatric features (HP:0100022); leukopenia/thrombocytopenia/anemia (HP:0001882/HP:0001873/HP:0001876).

Evidence items (PMIDs/DOIs/URLs and dates) - Moysidou E, et al. Lymphocytes change their phenotype and function in SLE and LN. Int J Mol Sci. Oct 2024. URL: https://doi.org/10.3390/ijms252010905 (moysidou2024lymphocyteschangetheir pages 18-20). - Yuan Z, et al. Global precision-targeted therapies in SLE; NETs–IFN loop and biomarkers. Heliyon. Jul 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e33350 (yuan2024globalresearchtrends pages 10-10). - Wu YX, et al. Immune cell aberrations and precision management in SLE; IFN signature–anifrolumab link. Cell Mol Biol Lett. Jun 2025. URL: https://doi.org/10.1186/s11658-025-00749-z (wu2025immunecellaberrations pages 29-30). - Zhou J, et al. CAR T-cell therapy for SLE: current status and perspectives. Front Immunol. Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1476859 (zhou2024cartcelltherapy pages 4-4). - Cosgrove HA. TLR7 in SLE: B cell–intrinsic roles and NOX2 regulation. 2024 research synthesis (cosgrove2024tolllikereceptor7 pages 160-164). - Shiozawa S. Tfh and infection-triggered models; ICOS/IL-21 involvement. Cells. Jul 2025. URL: https://doi.org/10.3390/cells14141080 (shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - Justiz-Vaillant AA, et al. NPSLE: molecules, features, treatment; diagnostic caveats. Molecules. Feb 2024. URL: https://doi.org/10.3390/molecules29040747 (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).

Limitations and open questions - While IFN-I and TLR7/9 biology are strongly implicated, the relative contributions of endosomal sensing versus cytosolic nucleic-acid–sensing (e.g., cGAS–STING) pathways in human SLE subsets remain active areas. Mechanism-guided stratification (IFN gene signatures; NET biomarkers) shows promise but requires prospective standardization (wu2025immunecellaberrations pages 29-30, yuan2024globalresearchtrends pages 10-10). - The protective–pathogenic duality of TLR9 and context-dependent roles of redox signaling (NOX2) suggest that pathway-selective modulation, not blanket inhibition, may be necessary (cosgrove2024tolllikereceptor7 pages 160-164).

Citations (support for major claims) - Core mechanisms (IFN axis, TLR7/9, impaired clearance, NETosis/complement, B/T help): (moysidou2024lymphocyteschangetheir pages 18-20, yuan2024globalresearchtrends pages 10-10, cosgrove2024tolllikereceptor7 pages 160-164, shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3). - IFN signature and therapy response (anifrolumab): (wu2025immunecellaberrations pages 29-30). - NETs as mechanistic drivers and LN biomarkers: (yuan2024globalresearchtrends pages 10-10). - CAR-T and B-cell centrality: (zhou2024cartcelltherapy pages 4-4). - NPSLE pathogenesis complexity and diagnostics: (justizvaillant2024neuropsychiatricsystemiclupus pages 2-4).

References

(moysidou2024lymphocyteschangetheir pages 18-20): Eleni Moysidou, Michalis Christodoulou, Georgios Lioulios, Stamatia Stai, Theodoros Karamitsos, Theodoros Dimitroulas, Asimina Fylaktou, and Maria Stangou. Lymphocytes change their phenotype and function in systemic lupus erythematosus and lupus nephritis. International Journal of Molecular Sciences, 25:10905, Oct 2024. URL: https://doi.org/10.3390/ijms252010905, doi:10.3390/ijms252010905. This article has 10 citations and is from a poor quality or predatory journal.
(yuan2024globalresearchtrends pages 10-10): Zengze Yuan, Weiqing Zhang, Zhaokai Jin, Yihan Wang, Zhiting Lin, Zhimin Xie, and Xinchang Wang. Global research trends in precision-targeted therapies for systemic lupus erythematosus (2003–2023): a bibliographic study. Heliyon, 10:e33350, Jul 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e33350, doi:10.1016/j.heliyon.2024.e33350. This article has 2 citations and is from a peer-reviewed journal.
(wu2025immunecellaberrations pages 29-30): YuXian Wu, Wangzheqi Zhang, Yan Liao, Ting Sun, Yang Liu, and Yaoyang Liu. Immune cell aberrations in systemic lupus erythematosus: navigating the targeted therapies toward precision management. Cellular & Molecular Biology Letters, Jun 2025. URL: https://doi.org/10.1186/s11658-025-00749-z, doi:10.1186/s11658-025-00749-z. This article has 6 citations and is from a peer-reviewed journal.
(cosgrove2024tolllikereceptor7 pages 160-164): HA Cosgrove. Toll-like receptor 7 in systemic lupus erythematosus: characterization of cell-intrinsic roles and regulation by nadph oxidase. Unknown journal, 2024.
(shiozawa2025pathogenesisofautoimmunitysystemic pages 1-3): Shunichi Shiozawa. Pathogenesis of autoimmunity/systemic lupus erythematosus (sle). Cells, 14:1080, Jul 2025. URL: https://doi.org/10.3390/cells14141080, doi:10.3390/cells14141080. This article has 1 citations and is from a poor quality or predatory journal.
(justizvaillant2024neuropsychiatricsystemiclupus pages 2-4): Angel A. Justiz-Vaillant, Darren Gopaul, Sachin Soodeen, Rodolfo Arozarena-Fundora, Odette Arozarena Barbosa, Chandrashehkar Unakal, Reinand Thompson, Bijay Pandit, Srikanth Umakanthan, and Patrick E. Akpaka. Neuropsychiatric systemic lupus erythematosus: molecules involved in its imunopathogenesis, clinical features, and treatment. Molecules, 29:747, Feb 2024. URL: https://doi.org/10.3390/molecules29040747, doi:10.3390/molecules29040747. This article has 58 citations and is from a poor quality or predatory journal.
(zhou2024cartcelltherapy pages 4-4): Jincai Zhou, Bixia Lei, Feifei Shi, Xinran Luo, Kai Wu, Yanhong Xu, Yuting Zhang, Rongjiao Liu, Huajing Wang, Joy Zhou, and Xiaowen He. Car t-cell therapy for systemic lupus erythematosus: current status and future perspectives. Frontiers in Immunology, Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1476859, doi:10.3389/fimmu.2024.1476859. This article has 22 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Progression

Prevalence

Related Datasets

Animal Models

Source YAML

References & Deep Research

Deep Research

Systemic Lupus Erythematosus Pathophysiology Report

Introduction

Core Pathophysiology

Key Molecular Players and Ontology Annotations

Cellular Components and Dysregulated Processes

Disease Progression Model

Phenotypic Manifestations and Mechanistic Links

Open Questions

References